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IntroductIon
Preeclampsia (PE) is a pregnancy-related cardiovascular hypertensive disorder, compli-
cating 3-5% of all pregnancies1, 2. Clinically, it is diagnosed as new-onset hypertension 
after 20 weeks of gestational age along with de novo proteinuria (0.3g/day)3, although 
currently hypertension along with growth restriction or HELLP (hemolysis, elevated liver 
enzymes and low platelets) syndrome are also viewed upon as preeclampsia4. Preeclamp-
sia has on the one hand major short time implications as it is one of the primary causes of 
fetal and maternal morbidity and mortality5, 6. On the other hand, PE has important long 
term sequela as it increases the risk for premature cardiovascular disease (CVD) later 
in life7, 8. Women with a history of PE have an about two – to sevenfold increased risk 
of developing ischemic cardiac disease compared with healthy controls within 15 years 
after pregnancy, with the highest risk accounting for early-onset PE7. Moreover, former 
preeclamptic women have a four-fold risk of developing chronic hypertension within 15 
years after pregnancy7.
Pregnancy is a women sensitive cardiovascular stress test that can, if valued appropri-
ately, substantially change the remote cardiovascular health prognosis of women in the 
near future (Figure 1). Recent studies indicate that at least 1 in 4 former preeclamptic 
women have structural cardiac alterations, mostly concentric, consistent with heart 
failure stage B (HF-B) at least one year after delivery8. It is unknown whether or not 
these women are at one year postpartum still in their recovering phase from hypertensive 
complicated pregnancy or that this unfavorable state persists and preludes imminent 
cardiac dysfunction and disease.
age
subclinical vascular disfunction
clinical vascular disfunction
pregnancies
Figure 1: Pregnancy as cardiovascular risk test.
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Despite the recognition by the American Heart Association of PE being an indepen-
dent gender-specific CVD risk factor, no standardized follow-up screening or preventive 
programs are yet implemented in clinical care9. Several initiatives have emerged develop-
ing very divers and unstandardized CVD assessments programs at divergent intervals 
after PE.
cVd In women
Cardiovascular disease is the number one cause of death in women10, 11. CVD include 
coronary heart disease, cerebrovascular disease, peripheral arterial disease, rheumatic 
heart disease, congenital heart disease, deep vein thrombosis and pulmonary embolism12. 
Although more men than women are affected by CVD, more women than men die of 
it. In the Netherlands, each day, 53 women and 50 men die each day due to CVD13. The 
number of patients worldwide affected by heart failure (HF) are over 23 million14. The 
prevalence is rising due to increased cardiovascular riskfactor comorbidities and higher 
life expectancy, thus the target group that is expected to benefit from therapy is growing14. 
HF is a major public health issue, associated with significant morbidity, mortality, and 
healthcare expenditures and costs in the past decade over $39 billion annually in the 
USA alone14, 15. The lifetime risk of developing HF is one in five with a 5-year mortality 
that corresponds to those of many cancers14. Instead of being a single entity, HF is a 
deadly clinical syndrome with possible different characteristics depending on age, sex, 
race or ethnicity, systolic and diastolic function and the underlying risk etiology. Once 
clinical, most of these HF entities (especially with preserved ejection fraction (EF)) do 
not respond to pharmacotherapy.
The American College of Cardiology Foundation/American Heart Association (ACCF/
AHA) Task Force developed a new classification system of heart failure16. These stages 
represent the development and progression of the disease, from risk factors, to struc-
tural cardiac changes in absence of clinical complaint to clinical overt disease (Figure 
2). Figure 2 is showing a simplistic reproduction of the four stages, using guidelines of 
the World Health Organization and the ACCF/AHA to determine the cut-off values of 
the different entities16-18. Using the term heart failure stage A and B is subject of discus-
sion, because these are clearly not heart failure16. However, when viewed upon as tool to 
identify young women at risk for developing heart failure, this chronology may be helpful 
in timely detection of those at risk16. In the suggested chronology, heart failure progresses 
through four stages; the subclinical stages A and B and the clinical stages C and D16. The 
progression of the subclinical heart failure stage B to the clinical heart failure stage C is 
associated with a five-fold increased risk of death19.
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There are risk models to calculate this person-specific CVD risk score, like the Fram-
ingham risk score, SCORE, CUORE and the Reynolds risk score20, 21. The Framingham 
risk score is the most widely used risk scoring calculator in North American Countries20. 
However, there are also a few disadvantages using this risk score. If preeclampsia is viewed 
upon as a cardiovascular incident, the Framingham risk score, originally developed in a 
population with elder men and women, may underestimate CVD risk in these relative 
young women22, 23. None of the other risk scores has been validated in a younger cohort.
conVentIonal and women sPecIFIc cV rIsk Factors
PE and CVD share similar risk factors including hypertension, insulin resistance, obesity, 
lipid abnormalities and endothelial dysfunction24-26. With timely detection, these factors 
may be modifiable by lifestyle or pharmacological intervention9, 27, emphasizing the im-
portance of cardiovascular follow-up in these patients. Quantifying the person-specific 
CVD risk could be useful in counseling these patients.
The prevalence of hypertension after PE is 25% in the 4-10 years after delivery28. Prior 
to overt disease, elevated blood pressure preludes to left ventricular (LV) hypertrophy 
which can lead to ventricular diastolic dysfunction and is also a risk factor for myocardial 
infarction, which causes left ventricular systolic function29. As such, elevated blood pres-
sure forms a major risk factor in the development of HF with clinical symptoms, both 
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Figure 2: Heart failure stages16-18.
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with preserved ejection fraction (HFpEF) and reduced ejection fraction (HFrEF)29-31. 
Hypertension relates more to congestive HF in women than in men30.
The prevalence of obesity in former preeclamptic women is 13% after their compli-
cated pregnancy, in the first months postpartum32. Obesity is a major independent risk 
factor for CVD, particularly amongst women33. As excessive adipose tissue increases 
a variety of adaptations, alterations in cardiac structure will occur, even in absence of 
comorbidities34, 35. In women with a history of PE, dyslipidemia (impaired HDL and 
impaired triglycerides) occurred in approximately 18% of the women in the first years 
postpartum36. Dyslipidemia is a strong risk factor for CVD, by facilitating the forma-
tion of atherosclerotic soft plaques25, 37. The prevalence of insulin resistance after PE is 
42%-53% in the first years postpartum36. Insulin resistance stimulates atherogenesis and 
plaque progression, the mechanisms which are likely to be involved in these processes 
include systemic factors (like dyslipidemia, hypertension, pro-inflammatory state) and 
a disturbed insulin signaling38. Moreover, insulin resistance drives the development of 
atherogenic dyslipidemia, creates a low-grade inflammatory state and rises the release 
of inflammatory markers39. Furthermore, insulin resistance also associates to increased 
blood pressure and intrinsic endothelial cell dysfunction39. Besides the influence of 
insulin resistance on the endothelium, all the above cardiovascular risk factors also 
extrinsically affect endothelial function40. Endothelial function seems to be significantly 
lower in preeclamptic women compared with women with uncomplicated pregnancies41. 
The endothelium, a monolayer of endothelial cells, functions as a protective barrier be-
tween the circulating blood and all tissues42. Preeclampsia is thought to be jeopardizing 
both placental and endothelial function, by an interaction between different mechanical 
and biochemical underlying disorders43-46. The flow-mediated dilation (FMD) is a well-
established and non-invasive technique to assess part of the endothelial function by 
measuring the change in artery diameter in response to reactive hyperaemia, a function 
test indicative for cardiovascular health and disease41, 47.
cardIac remodelIng durIng Pregnancy
Cardiac remodeling is determined as change in size, shape and/or structure of the 
heart2, 48. To maintain adequate pumping capacity, in response to either volume or pressure 
overload, the heart uses cardiac remodeling as an important compensatory mechanism2. 
Cardiac remodeling can be divided in either eccentric or concentric remodeling2, 49. This 
division is based on the left ventricular mass (LVM) and the ratio of LV wall thickness to 
end-diastolic volume, the so-called relative wall thickness (RWT)2, 18.
A first detectable systemic change during pregnancy is systemic arterial vasodilata-
tion, leading to decreased vascular resistance and with it a decreased afterload, initiating 
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renin-angiotensin-aldosterone orchestrated plasma volume expansion50-53. The reduced 
afterload also stimulates baroreceptor activity, rising heart rate and cardiac contractility 
and with it stroke volume and cardiac output53.
Elevated plasma volume during pregnancy increases venous return resulting in a 
higher preload, which is also reflected in elevated left atrial volumes54, 55. This high preload 
along with the vasoactive (neuro)hormonal environment, initiates a volume dependent 
remodeling response of the heart characterized by LV geometric changes and spherical 
dilatation along the LV short axis49, 54, 56, 57. At term, due to the persistent volume overload, 
the ventricle compensates this by enlargement to preserve stroke volume at the expense 
of a higher end systolic wall stress54. This results in an increase in the left ventricular 
mass by 35%54. This remodeling process is also called eccentric hypertrophy, which is an 
increase in cardiac mass with increased chamber volume58.
Pregnancy complicated by preeclampsia is often paralleled by suboptimal plasma 
volume expansion, which could be inhibited in the absence of a concomitant increase in 
capacity of the venous storage due to an adverse response of the autonomic control of the 
cardiovascular system and or of a lack of rice in vascular compliance, which suggest that 
the adaptive capacity of the venous system is limited in these women53, 59. These women 
also have higher sympathetic activity to preserve the venous return at the expense of car-
diovascular reserves60, 61. Women with preterm PE show a higher total vascular resistance 
index and a lower cardiac index in the phase prior to overt disease62.
In women destined to develop preterm PE, this low cardiac output/ high total vascular 
resistance hemodynamic state suggests that there is even at mid-gestation, an elevated 
LV afterload and contracted circulating volume, which triggers also a cardiac remodeling 
process characterized by LV concentric remodeling or total altered geometry62. This pro-
cess is needed to minimize the higher wall stress that occurs with the elevated afterload62.
cardIac remodelIng aFter Pregnancy
During a normal pregnancy, the physiologic LV remodeling resolves in the first weeks 
postpartum63. In contrast, the cardiovascular implications of PE do not end with deliv-
ery8. The additional increase in LVM in women with PE does not always resolve after 
delivery8, 63. It was observed that four-in-ten former preterm PE women still present ab-
normal LV geometry 1 year after their complicated pregnancy8. Certain antihypertensive 
medication (mainly angiotensin-converting enzyme inhibitors and angiotensin receptor 
blockers) have a protective and inhibitory effect on adverse cardiac remodeling16, 64.
Our group studied the relationship of PE and conventional modifiable cardiovas-
cular risk factors that are related with asymptomatic structural and functional cardiac 
abnormalities postpartum28. After adjusting for conventional risk factors, preeclampsia 
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remained independently associated with a four-fold increased risk of having subclinical 
HF-B28. Currently, it is still unknown whether these women already had cardiovascular 
abnormalities prior to their pregnancy and that preeclampsia reveals this condition 
or that healthy women develop preeclampsia and that preeclampsia itself damages the 
cardiovascular system.
Currently, we suppose that hemodynamic assessments of both the vasculature and the 
heart is essential in the understanding, prediction and possible therapies of cardiovascu-
lar disease in this specific population2.
aIm oF tHIs tHesIs
Although studies have indicated that preeclampsia increases the cardiovascular disease 
risk, the pathologic process and cardiovascular determinants of this increased risk 
remains unclear. We first assessed meta-analytically in a systematic review, the natural 
course of systolic function during normal pregnancy and during preeclamptic pregnancy 
(CHAPTER 2). In order to improve follow-up in former preeclamptic women it is of 
importance to gain more knowledge on factors that increase CV risk in these women. 
At present there is no tailored risk score available to predict cardiovascular disease in 
young, seemingly healthy former preeclamptic women. Therefore, we estimated the 
predicted risk of cardiovascular disease in the next 10 and 30 years as computed with 
the Framingham risk score calculator in former preeclamptic women and women with 
an uncomplicated pregnancy. Moreover, we compared subgroups based on onset of 
preeclampsia and/or whether hypertension was developed (CHAPTER 3). Thereafter, we 
studied the development and recovery of subclinical heart failure in former preeclamptic 
women between 1 and 4 years postpartum (CHAPTER 4). To obtain further insight in 
the relation between subclinical heart failure and impaired endothelial function after PE, 
we assessed flow mediated dilation and echocardiography in women with and without 
subclinical heart failure and a control group of healthy parous women (CHAPTER 5). 
Finally, we assessed whether cardiac preload, as indicated by low plasma volume mea-
sured in former preeclamptic women is related to concentric remodeling 4 years later 
(CHAPTER 6).
The main findings of this thesis are discussed in the context of each other in the last 
chapter (CHAPTER 7)
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AbstrAct
Objective
To analyse the predicted 10- and 30-year risk scores for cardiovascular disease (CVD) 
in patients who experienced preeclampsia (PE) 5–10 years previously compared with 
healthy parous controls.
Design
Observational study.
setting
Tertiary referral hospital in the Netherlands.
Population
One hundred and fifteen patients with a history of PE and 50 controls. PE patients were 
categorised into two groups, hypertensive (n = 21) and normotensive (n = 94), based on 
use of antihypertensive medication, and next categorised into subgroups based on the 
onset of PE: early-onset PE (n = 39) and late-onset PE (n = 76).
Methods
All participants underwent cardiovascular risk screening 5–10 years after index preg-
nancy. We measured body mass, height and blood pressure. Blood was analysed for fast-
ing glucose, insulin and lipid levels. All participants completed a validated questionnaire. 
The 10- and 30-year Framingham risk scores were calculated and compared.
Main outcome measures
Estimated Framingham 10- and 30-year risk scores for CVD.
results
The overall 10- and 30-year CVD median risks weighing subjects’ lipids were comparable 
between formerly PE women and controls; 1.6 versus 1.5% (P = 0.22) and 9.0 versus 9.0% 
(P = 0.49), respectively. However, hypertensive formerly PE women have twice the CVD 
risk as normotensive formerly PE women: 10- and 30-year CVD median risks were 3.1 
versus 1.5% (P < 0.01) and 19.0% versus 8.0% (P < 0.01), respectively. Risk estimates 
based on BMI rather than lipid profile show comparable results. Early-onset PE clustered 
more often in the hypertensive formerly PE group and showed significantly higher 10- 
and 30 year CVD risk estimates based on lipids compared with the late-onset PE group: 
1.7 versus 1.3% (P < 0.05) and 10.0 versus 7.0% (P < 0.05), respectively.
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conclusions
Women who are hypertensive after preeclampsia, have a twofold risk of developing 
CVD in the next 10–30 years. Formerly PE women who are normotensive in the first 10 
years after their preeclamptic pregnancy have a comparable future cardiovascular risk to 
healthy controls.
Keywords
Cardiovascular risk, Framingham risk score, hypertension, metabolic syndrome, pre-
eclampsia.
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IntrODuctIOn
Preeclampsia (PE), a vascular pregnancy-related disorder complicating 5–8% of all 
pregnancies1 is not only a major cause of fetal and maternal morbidity and mortality2,3 
but also increases the risk for premature cardiovascular disease (CVD) later in life4,5. PE 
is diagnosed as new-onset hypertension after 20 weeks gestational age with proteinuria 
(0.3 g/day)6. Depending on gestational age at delivery, patients with a history of PE have 
about a two- to – sevenfold risk of developing ischaemic cardiac disease compared with 
healthy controls and an approximately four-fold risk of developing chronic hypertension 
within 15 years after pregnancy4. Cardiovascular disease is the number one cause of death 
in women7. It is not known whether PE itself, as a gender-specific disorder, increases this 
risk independently or through risk factors known to be associated with both PE and CVD. 
Patients with a history of PE exhibit more often constituents of the metabolic syndrome, 
e.g. insulin resistance, dyslipidaemia, hypertension, micro-albuminuria and obesity 
compared with patients with a history of uncomplicated pregnancies8–11. When detected 
in time, these factors may be modifiable12, emphasising the importance of cardiovascular 
follow-up in these patients. Quantifying the person-specific CVD risk could be useful in 
counselling these patients.
At present, there is no tailored risk score available to predict cardiovascular disease 
in this specific population (women with a history of PE). Several risk scores have been 
proven to be of predictive value in other different risk populations. The Framingham 
risk score calculator is the most widely used and a well validated strategy to estimate 
personalised risk13–15. Although a few studies have analysed the Framingham risk score 
in a population of former PE women, these studies did not differentiate between the 
risk calculator modelled on lipids or on BMI16–18. Moreover, these studies did not dif-
ferentiate between the subgroups of former PE patients, either by onset of disease or 
later postgestation chronic hypertension16–18. The aim of this study was to compare the 
predicted risk of cardiovascular disease in the next 10 and 30 years as computed with 
the Framingham risk score calculator, between patients with a history of PE and women 
who had a normotensive pregnancy in the past (5–10 years after index pregnancy) and 
subsequently compare subgroups within the former PE group based on onset of disease 
and/or whether hypertension has developed. We hypothesise that (1) patients with a his-
tory of PE have higher predicted Framingham CVD risk scores compared with patients 
with a history of only uncomplicated pregnancies and that (2) the risk estimates vary 
among the different subgroups of former PE patients.
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MethODs
The study protocol of this observational study was approved by the Medical Ethics 
Committee of the Radboud University Medical Centre (CMO: 2010/245). For this study, 
women were included between 2010 and 2012.
study population
Formerly preeclamptic women were recruited from a database of women who had pre-
eclampsia and volunteered to participate in a cardiovascular follow-up study program. PE 
in index-pregnancy was diagnosed according to criteria set the International Society of 
Hypertension in Pregnancy: new-onset hypertension, systolic blood pressure (SBP) ≥ 140 
mmHg and/or diastolic blood pressure (DBP)  ≥ 90 mmHg, after 20 weeks’ gestation and 
proteinuria exceeding 0.3 g/day6,19. Early-onset PE was defined as PE developing before 
34 weeks’ gestation. [Correction added on 5 December 2014, after first online publica-
tion: the number of weeks of gestation has been changed from ‘35 weeks’ to ‘34 weeks’ 
in the preceding sentence.] Women who had completed the 5- to 10-year postpartum 
cardiovascular risk screening were eligible for analysis in the current study. Formerly 
preeclamptic women who participated in a previous study were invited to participate in 
this study by mail. Initially, former PE women were recruited at the 6 week postpartum 
screening by a clinician, and were seen at 1 year postpartum, and invited to participate in 
this study approximately 5 years later. The catchment area of this study population was in 
the east side of the Netherlands in which the socioeconomic status is reported to be aver-
age with a low prevalence of immigrants. Controls were recruited by advertisement in 
local newspapers, schools and childcare centres in the same area. Women in the control 
group had to be between 25 and 45 years old, and to have had their first pregnancy 5–10 
years earlier.
Pregnancy charts were checked to ensure an uncomplicated pregnancy. Uncomplicated 
pregnancies were defined as pregnancies not complicated by gestational hypertension, 
PE, HELLP syndrome or fetal growth restriction, placental abruption or intrauterine fetal 
demise. Patients and controls underwent the same cardiovascular risk screening accord-
ing to standardised protocol. At the time of cardiovascular risk screening, all women were 
nonpregnant and had stopped breastfeeding, women who had pregnancies after the index 
pregnancy had to be at least 6 months postpartum.
Exclusion criteria used in this study were known diabetes mellitus, auto-immune 
diseases and pre-existent hypertension prior to index-pregnancy, as these diseases could 
lead to bias. Finally, participants who did not wish to be informed about the outcome of 
the screening were excluded.
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Measurements
The cardiovascular risk screening started at 08:00 hours in a temperature-controlled room 
(22°C), after an overnight fast. Body weight (kg, Seca 888 scale, Hamburg, Germany) and 
height (m) were measured. After 15 minutes’ rest, blood pressure (BP) was determined 
for 30 minutes (at a 3-minute interval) in upright sitting position, using a semiautomatic 
oscillometric device (Dinamap Vital Signs Monitor 1846; Critikon, Tampa, FL, USA) with 
a cuff-size appropriate for arm circumference. Participants were instructed not to talk 
during measurements. The median blood pressure was used for analysis. As the Fram-
ingham risk model both weighs the use of antihypertensive medication and actual blood 
pressure, women were assigned to the hypertensive group when using anti-hypertensive 
medication. A venous blood sample was taken at the level of the antecubital vein and 
analysed for fasting glucose (mmol/l), insulin (mmol/l) and lipids (mg/dl): low-density 
lipoprotein (LDL), high density lipoprotein (HDL), triglycerides and total cholesterol. 
Body mass index (BMI) was calculated by dividing body weight (kg) by squared height 
(m). Participants filled out a questionnaire regarding general history, current medication 
intake, intoxications, lifestyle factors and family history for CVD (in first line relatives < 
60 years old). The cardiovascular risk screening was performed following a standardised 
study protocol by one experienced physician.
Framingham risk scores
Framingham risk scores were calculated with a gender-specific multivariable risk fac-
tor algorithm20. Variables included sex, age, systolic blood pressure (SBP), hypertension 
treatment, current smoking and de novo diabetes mellitus plus lipid spectrum (HDL and 
total cholesterol) or body mass index (BMI)20–23. The 10-year risk for CVD was calculated 
with the ‘Cardiovascular disease (10-year risk)’ calculator using BMI or lipids in the 
age range of 30– 74 years21. Due to the young age of a few participants, the risk score 
for 10 years could not be estimated for nine participants. The 30-year risk for CVD was 
calculated with the ‘Cardiovascular disease (30-year risk)’ calculator using BMI or lipids 
in the age range of 20–59 years22. Likewise, for the 30-year risk, the ‘full CVD’ risk score 
was used which included coronary death, myocardial infarction, fatal or non-fatal stroke, 
coronary insufficiency, angina pectoris, transient ischaemic attack, intermittent claudica-
tion or congestive heart failure22.
Data analysis
We performed all statistical analyses using SPSS version 20.0 (version 20, IBM SPSS Statis-
tics, Armonk, NY, USA). We reported normally distributed continuous variables as mean 
(standard deviation) and otherwise as median (range). Binary variables were reported as 
absolute value (percentage). Formerly preeclamptic patients were subdivided into two 
groups: a group with hypertension (HTPE) at the time of the cardiovascular evaluation 
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and women without hypertension (NTPE). In addition, we subdivided the PE group into 
a group with a history of early-onset of PE and a group with a history of late PE. We used 
the independent t-test for evaluating differences between groups in continuous variables 
that were normally distributed. Dichotomous data were analysed using the chi-square 
test. Differences between variables that were not normally distributed were analysed 
using the nonparametric Kruskal–Wallis test or the nonparametric Mann–Whitney U-
test where appropriate. Differences between the Framingham risk score based on BMI 
versus lipids were analysed with the Wilcoxon Signed Rank test. A two-sided P-value of < 
0.05 was considered statistically significant. We used the difference in risk of developing 
CVD within 30 years after gestation between the PE and control group to estimate the 
sample size needed. We determined this sample size on the basis of a clinically relevant 
proportional difference of 25% in an average 30-year Framingham Risk score (in healthy 
women estimated to be 10–3.5%) between the PE and the control group. A minimum of 
42 patients per group was needed for power of 80%, using an alpha of 5% for determin-
ing statistical significance. To compensate for possible heterogeneity among formerly PE 
patients, we included at least two formerly PE patients for each included control.
results
In this observational study we included 115 patients with a history of PE and 50 controls 
with an uncomplicated pregnancy. The characteristics of patients and controls are shown 
in Table 1. Most women belonged to the European continental ancestry group, two 
women were of Turkish origin, and one was of Moroccan origin. Patients with previous 
PE, were on average, 3 years younger, had higher weight and BMI and were using less 
alcohol compared with controls. The interval between delivery at index pregnancy and 
cardiovascular risk screening was approximately 2 years longer (P < 0.01) and gestational 
age at delivery was approximately 6 weeks shorter in the PE group compared with con-
trols (P < 0.01).
In the former PE group, 21 women had been diagnosed with hypertension and 94 
women had not been. In the control group, none of the women was diagnosed with 
chronic hypertension. The variables of the Framingham risk calculator are presented in 
Table 2. Patients in the hypertensive formerly PE group have a higher age, SBP and BMI 
(P < 0.01). Moreover, early-onset PE clustered more often in the hypertensive former PE 
group than in the normotensive former PE group, 90 and 61%, respectively (P < 0.01). 
The results of the 10- and 30-year Framingham risk scores are presented in Table 3. The 
10-year predicted risk score weighing subjects’ lipids did not differ between formerly PE 
patients and controls (1.6 and 1.5%, respectively; P = 0.22), nor did the 30-year predicted 
risk score using lipids (9.0 and 9.0%, respectively; P = 0.49). The 10-year predicted risk 
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table 1. characteristics of Pe and cO group.
controls
(n = 50)
Formerly Pe
(n = 115) P-value
Patient characteristics
Age, years 39 ± 4.0 36 ± 4.0 <0.01
Height, m 1.71 ± 0.1 1.69 ± 0.1 0.09
Weight, kg 69 ± 12 74 ± 18 <0.05
BMI, kg/m2 23.3 ± 3.0 25.6 ± 6.2 <0.01
Obesity, (BMI>30kg/m2), n (%) 2/50 (4) 21/115 (18) <0.05
Smoking, n (%) 5/50 (10) 9/115 (8) 0.76
Alcohol, n (%) 36/50 (72) 26/115 (23) <0.01
Family history of CVD, n (%) 22/50 (44) 49/115 (43) 0.87
Obstetric variables
Primiparous, n (%) 5/50 (10) 41/115 (36) <0.01
Postpartum, years 8.0 ± 2.7 5.4 ± 2.6 <0.01
Recurrent PE, n (%) - 27/82 (33) -
Index pregnancy
GA at birth, weeks 39.6 ± 2.3 33.3 ± 4.3 <0.01
Birth weight, g 3367 ± 574 1800 ± 939 <0.01
SGA, n (%) - 61/115 (53) -
IUFD, n (%) - 8/115 (7) -
Early-onset PE, n (%) - 76/115 (66) -
biochemical markers
Triglycerides, mmol/l 0.9 ± 0.4 1.0 ± 0.5 0.15
Total cholesterol, mg/dl 187.0 ± 29.7 180.1 ± 28.6 0.16
LDL, mg/dl 110.6 ± 25.9 112.7 ± 24.5 0.62
HDL, mg/dl 61.6 ± 13.0 51.8 ± 9.9 <0.01
Glucose, mmol/l 4.7 ± 0.4 4.8 ± 0.6 0.27
Insulin, mmol/l 6.3 ± 3.6 8.8 ± 4.7 <0.01
HOMA, IR 1.3 ± 0.8 1.9 ± 1.1 <0.01
blood pressure
Systolic blood pressure, mmHg 110 ± 10 117 ± 13 <0.01
Diastolic blood pressure, mmHg 71 ± 7 74 ± 10 0.07
Mean arterial pressure, mmHg 82 ± 8 86 ± 11 <0.01
Significant values are written in bold.
BMI, body mass index; CVD, cardiovascular disease; GA, gestational age; HDL, high density lipoprotein; 
HOMA, homeostatic model assessment; IUFD, intrauterine fetal death; LDL, low density lipoprotein; PE, 
preeclampsia; SGA, small for gestational age.
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score for the hypertensive formerly PE was higher than in normotensive formerly PE 
women and controls (respectively, 3.1, 1.5 and 1.5%; P < 0.01). The 30-year predicted risk 
was also higher in the hypertensive formerly PE than in the other groups (respectively, 
19.0, 8.0 and 9.0%; P < 0.01). The 10-year predicted risk score using BMI instead of lipid 
profile did not differ between formerly PE patients and controls (1.5 and 1.5% respec-
tively; P = 0.60), nor did the 30-year predicted risk score (9.0 and 9.0% respectively; P = 
0.86). In contrast, the 10-year predicted risk score for the hypertensive formerly PE was 
higher than that in normotensive formerly PE and controls (respectively, 3.4, 1.5 and 
1.5%; P < 0.01). Also, the 30-year predicted risk was higher in the hypertensive formerly 
PE compared with the other groups (respectively, 19.0, 8.0 and 9.0%; P < 0.01). The dif-
ferences we observed were irrespective of the model used, either with or without the use 
of observed lipid profile (Table 3). Despite comparable estimated median risk, comparing 
both risk models, the 10-year risk weighing BMI or lipid profile, we observed significant 
table 2. Demographic characteristics of cO, ntPe and htPe groups.
cO
 (n = 50)
ntPe
(n = 94)
htPe
(n = 21) P-value
Age, years 39 ± 4.0 35 ± 3.9 37 ± 3.8 <0.01
Early-onset PE, n (%) 0 (0) 57/94 (61) 19/21 (90) <0.01
Systolic blood pressure, mmHg 110 ± 10 115 ± 12 125 ± 12 <0.01
Antihypertensive treatment, n (%) 0 (0) 0 (0) 21/21 (100%) <0.01
Smoking, n (%) 5/50 (10) 8/94 (9) 1/21 (5) 0.85
Diabetes, n (%) 0 (0) 0 (0) 1/21 (5) 0.13
BMI, kg/m2 23.3 ± 3.0 25.1 ± 6.2 28.0 ± 5.9 <0.01
HDL, mg/dl 61.6 ± 13.0 52.2 ± 10.3 50.0 ± 7.8 <0.01
Total cholesterol, mg/dl 187.0 ± 29.7 178.0 ± 28.8 189.9 ± 26.5 0.11
table 3. Predicted Framingham cVD risk scores based on lipids or bMI in formerly Pe women and 
healthy parous controls.
cO
(n = 50)
Pe
(n = 115)
ntPe
(n = 94)
htPe
(n = 21)
10 year cVD risk
Lipids 1.5 (1.0;1.9) 1.6 (1.1;2.4) 1.5 (1.1;2.0) 3.1 (2.2;4.3)*,**
BMI 1.5 (1.2;2.3) *** 1.7 (1.2;2.4) *** 1.5 (1.1;2.0) 3.4 (2.2;5.0) *,**
30 year cVD risk
Lipids 9.0 (7.0;12.0) 9.0 (7.0;14.0) 8.0 (6.0;11.0) 19.0 (15.0;26.0) *,**
BMI 9.0 (8.0;14.0) *** 9.0 (7.0;14.0) 8.0 (6.8;11.0) 19.0 (14.0;28.5) *,**
*P < 0.01 relative to CO.
**P < 0.01 relative to NTPE.
***Significantly higher than the calculator using lipids.
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differences for the CO group and PE group. The 30-year risk models using BMI versus 
lipid profile indicated significant differences for the CO group, but comparable results for 
PE, NTPE and HTPE.
Table 4 present the results of the analysis after subdividing the PE group into a sub-
group consisting of women who had early-onset PE and a group of women who had 
late-onset PE. The 10- and 30-year predicted risk score weighing subjects’ lipids or BMI 
did not differ between late-onset PE and controls. However, the 10- and 30-year predicted 
risk score for early-onset PE based on lipids was higher than in the late-onset PE group 
(respectively, 1.7 versus 1.3%; P < 0.05 and 10.0 versus 7.0%; P < 0.05). The 10-year pre-
dicted risk score based on the lipids was higher in the early-onset PE than the controls 
(1.7 and 1.5%, respectively; P < 0.05) but only differed from the CO. When weighing 
BMI, the 10-year predicted risk score did not differ between early-onset PE and both 
other groups. However, the 30-year predicted risk score for early-onset PE was higher 
than in the late-onset PE group (10.0 and 8.0%, respectively P < 0.05) but did not differ 
from the control group.
When comparing both risk models (Table 4) we observed a significantly higher score 
for the risk model weighing BMI compared with the model weighing lipids in the 10-year 
risk assessment for the late-onset PE group and the CO group and for the 30-year risk 
assessment in the CO group.
Next, we subdivided the former PE group into four subgroups based on onset and 
whether they had hypertension. In the late-onset PE group, 37/39 (95%) were normoten-
sive and 2/39 (5%) were HT. In the early-onset PE group, 57/76 (75%) were NT and 19/76 
(25%) were hypertensive. The 10- and 30-year predicted risk score based on the lipids was 
higher in the early PE-HT compared with the early PE-NT and controls (3.0 versus 1.6 
versus 1.5%, P < 0.01; 17 versus 9 versus 9%, P < 0.01, respectively). The 10- and 30-year 
table 4. Predicted Framingham cVD risk scores based on early- and late-onset Pe in formerly Pe 
women and healthy parous controls.
cO
(n = 50)
late-onset Pe
(n = 39)
early-onset Pe
(n = 76)
10 year cVD risk
Lipids 1.5 (1.0;1.9) 1.3 (0.9;2.2) 1.7 (1.3;2.5) *,**
BMI 1.5 (1.2;2.3) *** 1.5 (1.1;2.2) *** 1.7 (1.3;2.6)
30 year cVD risk
Lipids 9.0 (7.0;12.0) 7.0 (6.0;12.0) 10.0 (7.0;14.8)**
BMI 9.0 (8.0;14.0)*** 8.0 (6.0;11.0) 10.0 (8.0;14.8) **
*P < 0.05 relative to CO.
**P < 0.05 relative to late-onset PE.
***Significantly higher than the calculator using lipids.
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predicted risk score based on the BMI was also higher in early PE-HT compared to early 
PE-NT and controls (3.1% versus 1.5% versus 1.5% P < 0.01; 19% versus 8% versus 9% P 
< 0.01, respectively). However, the modelled cardiovascular disease risk of early PE-NT 
did not differ in any way from that observed in controls.
DIscussIOn
Main findings
Despite the fact that formerly PE patients have elevated risk of CVD and death compared 
to healthy parous controls, still the largest fraction will not suffer from these remote 
vascular complications. In order to differentiate between those with low and elevated 
risk, we modelled remote cardiovascular risk using Framingham risk scores in formerly 
PE patients and controls 5 to 10 years after birth, and analysed the predicted 10- and 
30-year risk scores. In contrast to our expectations, as group, formerly PE patients had 
comparable risk estimates compared to healthy parous controls. In contrast to hyperten-
sion, other risk factors that are known to be increased after PE (e.g. cholesterol, BMI) 
did not contribute substantially to the modelled increased risk for CVD in our studied 
population. Nonetheless, treated hypertensive formerly PE patients had twofold risk on 
CVD—compared to both normotensive formerly PE patients and controls. The increased 
risk of CVD after PE appears to be primarily related to blood pressure control and not 
subclinical biochemical classical cardiovascular risk factors. This study is a translation of 
the increased risk after PE to a predicting risk score to the patient.
strengths and limitations
This study compares both formerly PE patients and healthy parous controls at a time 
interval after birth sufficient to be fully recovered. As such, both the effect of pregnancy 
course and underlying risk factors could be weighted reliably. Until now, studies that 
analysed the Framingham risk score in a population did not make a distinction between 
hypertensive and normotensive former preeclamptic women16–18. In fact, normotensive 
former PE women and women with a history of late-onset PE had comparable modelled 
cardiovascular event risk with that observed in controls. Women on antihypertensive 
medication showed a significant increased risk score. This study has some limitations 
that need to be addressed. First, most women that participated in this study belonged 
to the European continental ancestry group. Therefore our findings may not fully be 
translational to other populations. Second, on average, healthy parous controls were 
older than formerly PE. This difference might have affected calculated risk scores, but 
can be expected in higher rather than lower risk estimates. Third, the control group was 
recruited by advertisement in contrast to the former PE group which was a hospital 
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based recruitment. The women responding to advertisement on cardiovascular check, 
may somehow have a predisposition for CVD or may have subtle signs making them 
question their CV risk. If the latest is true, the scores of the control group may give an 
overestimation of the CV risk. Fourth, it would be an interesting analysis to study in the 
control group a normotensive and hypertensive group. Unfortunately, our set of included 
controls does not give us the opportunity to answer this. However, the prevalence of 
chronic hypertension amongst young women with a history of normotensive pregnancies 
is extremely low and underscores the suggestion that the increased risk of cardiovascular 
disease in formerly preeclamptic women primarily originates from high blood pressure. 
Fifth, the Framingham risk score has not been validated in former PE patients. It may 
be that the Framingham risk score is not fully applicable for patients with previous PE. 
Even though we were unable to substantiate an intrinsic detrimental effect of PE itself on 
remote cardiovascular health, we cannot completely rule out PE to be an independent 
risk factor for CVD that should be included in the risk prediction independent of other 
conventional risk factors.
The Framingham risk CV scoring system is originally developed using older popula-
tions of men and women20, and may not be directly applicable in our study population 
with an average age of 37 years. Thus the scorings system may underestimate the risk 
score in our population. It would require a very long-term follow-up of a large cohort 
of postpartum women to determine alternate cut-offs for the 10-year and 30-year risk 
estimates for cardiovascular events. Further, by weighing traditional cardiovascular 
risk factors in patients without vascular gestational problems, differences in risk scores 
primarily seem to originate from chronic hypertension despite treatment, unless BP 
is really substantially lowered. As the prevalence chronic hypertension rises up to ap-
proximately fourfold within 15 years after giving birth4, our data suggest that the excess 
in CVD confines to those developing chronic hypertension.
Interpretation
The Framingham risk score is the most compared risk calculator and widely used in North 
American countries16. Other risk models for ischaemic heart disease (IHD) and stroke 
are SCORE, CUORE and the Reynolds risk score16,24. In comparison, the Framingham 
risk score is the only model which is able to model both 10- and 30-year risk23. Despite 
similarities in estimated outcome, results are conflicting in precision and accuracy. Al-
though some claim the Framingham 10-year risk calculator to estimate close to the actual 
observed risk25, others state that the Framingham risk model overestimates the risk of 
CVD26,27, or underestimate it in young women. Previous studies claimed the calculated 
10- and 30-years CV risk, based on the Framingham risk calculator to be raised in former 
PE patients compared to controls16–18. However, these studies did not report on the differ-
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ences between BMI and lipid risk model calculators. In our study, the BMI based model 
seems to present higher risk estimates on the CVD risk in the next 10–30 years.
Nowadays it is not known which postpartum interval needs to be taken into account 
to rule out the pregnancy induced alterations in the CV system. It is important to wait 
a certain period to assure that most PE changes have returned to a steady state. When 
it is likely that this state is reached, the Framingham risk calculator may be applicable 
to calculate patients individual risk score. The outcome of the risk calculator may be 
considered a surrogate marker for CV outcome. We expected, considering the reported 
elevated chance on cardiovascular disease in these women, a higher cardiovascular risk 
in formerly preeclamptic women as a whole, especially when also taking lipid profile 
into account. To our surprise, we did not see this. Only after taking hypertension into 
account did a higher risk estimate become visible. Therefore we think that, even though 
we detailed group differences, our analysis underscores the use of the risk calculator in 
individual care. Follow-up of this population is necessary to validate expectation with 
observation.
Hypertension strongly affects CVD risk28. Moreover, hypertension relates to significant 
chronic disability29 and increases the risk of progression to chronic kidney disease and 
obvious cardiovascular morbidity and mortality30,31. Coronary heart disease is three times 
more frequent in hypertensive than in normotensive individuals29 and even an SBP ≥ 115 
mmHg accounts for two-thirds of cerebrovascular diseases and almost half of ischaemic 
heart disease cases32. As such, there is no single factor except elevated BP that plays a more 
important role in increasing cardiovascular morbidity, mortality and overall mortality29.
Functionally, antihypertensive medication has the ability to reverse or correct high 
blood pressure-induced structural and functional alterations in large and small arter-
ies33. Clinically, the detrimental effects on cardiovascular health can be reversed by 
antihypertensives34. In young patients (30–54 years), hypertension treatment resulted in 
a 41% reduction of cerebrovascular events and 27% risk reduction of fatal and non-fatal 
cardiovascular events35. Meta-analysis of 1 million participants demonstrated a linear as-
sociation between SBP and DBP and the risk of CVD mortality (down to 115 mmHg and 
75 mmHg)36. Every 10 mmHg and 5 mmHg decrease of the usual (long-term average) 
SBP and DBP, respectively, results in a 40% reduction of risk of death from stroke and a 
30% reduction in the risk of IHD36. Even a small reduction of 2 mmHg from the usual 
SBP results in a 10% lower stroke mortality and about a 7% lower mortality from IHD 
or other vascular causes throughout middle age36. Consequently, antihypertensives are 
one of the more cost-effective methods of reducing premature cardiovascular morbidity 
and mortality37. It should be noted that lifestyle interventions could already be sufficient 
in patients with mildly elevated BP, and should always be suggested when patients re-
ceive medication, as these may lower the necessary dosage38. However, compliance with 
long-term healthy lifestyle adjustments is extremely low34. Based on average achieved 
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reduction in traditional cardiovascular risk factors imputed in the several cardiovascular 
risk models, lifestyle adjustment may lead to a 4–13% reduction in CVD in patients with 
a history of PE24.
We found in our study the highest prevalence of hypertension after early-onset PE, 
which is in line with previous findings39,40. The different subclassifications in our study 
allowed us to conclude that chronic hypertension is a key factor in predicting CVD risk 
later in life, even in the highest risk subgroup of women with early-onset PE. Moreover, 
those women with a history of early-onset PE who were normotensive, had comparable 
risk estimates as controls. Nevertheless, our results suggest that early-onset PE is also 
associated with the highest risk for hypertension, in contrast to late-onset PE, and there 
should be greater awareness of the necessity of cardiovascular follow-up.
In contrast to hypertension, other risk factors that are known to be increased after PE 
(e.g. cholesterol, BMI) did not contribute substantially to the modelled increased risk 
for CVD in our studied population, either after early-onset or after late-onset disease. 
Therefore, the observations in this study, together with the available reported evidence, 
indicate that the PE-related increased risk for CVD is probably increased by chronic 
hypertension. Nevertheless, it is still unclear whether (1) PE in the absence of other risk 
factors also predisposes independently to chronic HT and CVD and (2) PE magnifies the 
negative effects of other subclinical risk factors on cardiovascular health, thus expediting 
the development of premature CVD. Preventive strategies, early detection and correc-
tive BP treatment towards healthy reference values reduces the risk of coronary heart 
failure (CHF)41 and may prevent or delay the onset of costly CVD or renal disease37. It is 
important to manage a careful follow-up, as more than half of known and treated hyper-
tensive subjects still end up with uncontrolled BP despite antihypertensive medicines42. 
The follow-up of former PE patients is also incomplete, as more than one-third of these 
women do not have their blood pressure followed-up after gestation or opportunistic 
blood pressure measurements taken when a former PE patient visits the GP for other 
reasons43. Apparently, pregnancies complicated by a vascular disorder are still not being 
fully recognised as a potential risk factor for developing chronic hypertension and CVD. 
Besides, there is as yet no tailored risk score model available to assess a patient’s indi-
vidual risk for CVD after PE. Clinicians often perform CV risk assessment on different 
ways. Most studies have shown group differences for CV risk with an increased risk in 
former PE women compared with controls. In our study, we used the Framingham risk 
assessment to calculate the individual CV risk of patients. It is possible to communicate 
the increased risk to the patient, and make them more aware of the importance of blood 
pressure measurements and control during follow-up. More importantly, the cardiovas-
cular risk assessment does not stop after one follow-up screening. A woman with no 
current hypertension has an increased risk of becoming hypertensive in the following 
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years. We stress the importance of ongoing surveillance which at present we do not think 
is practised consistently.
cOnclusIOns
In this study, patients with a history of PE without chronic hypertension have a com-
parable estimated future risk to develop CVD events compared with patients with 
uncomplicated pregnancies. In contrast, patients with previous PE who develop chronic 
hypertension in the first decade after pregnancy have an approximately twofold higher 
risk of developing CVD in the next 10–30 years. One of five former PE patients who 
are currently hypertensive seem to be destined for a cardiovascular event. Only former 
PE women with chronic hypertension and/or early-onset PE have an increased risk 
score. Apparently, hypertension is a very important and useful risk factor in this specific 
population. Our findings stress again the importance of CVD screening and follow-up in 
former PE patients with a special focus on blood pressure measurement and treatment.
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AbstrAct
Objectives
After pre-eclampsia (PE), the prevalence of structural heart disease without symptoms, 
i.e. heart failure Stage B (HF-B), may be as high as one in four women in the first year 
postpartum. We hypothesize that a significant number of formerly pre-eclamptic women 
with HF-B postpartum are still in their resolving period and will not have HF-B during 
follow-up.
Methods
In this prospective longitudinal cohort study, we included 69 formerly pre-eclamptic 
women who underwent serial echocardiographic measurements at 1 and 4 years post-
partum. HF-B was diagnosed as left ventricular hypertrophy (left ventricular mass index 
(LVMi) > 95g/m2), concentric remodeling (relative wall thickness > 0.42 and LVMi ≤ 
95g/m2), mild systolic dysfunction (left ventricular ejection fraction > 40% and < 55%) 
or asymptomatic valvular disease. Women were subdivided and analyzed according to 
HF-B outcome: no HF-B at either visit; HF-B at first visit only; HF-B at second visit only; 
HF-B at both visits.
results
The prevalence of HF-B in formerly pre-eclamptic women was 23% in the first year post-
partum and 23% after 4 years. At the second visit, HF-B had resolved in 62.5% of affected 
women but was newly developed in 19% of initially unaffected women. At the first visit, 
56% of women diagnosed with HF-B had reduced systolic function whereas at the second 
visit 69% of women with HF-B had concentric remodeling with mostly normal ejection 
fraction, consistent with diastolic dysfunction.
conclusions
The prevalence of HF-B can be considered consistently high (1 in 4) amongst formerly 
pre-eclamptic women at follow-up. Nonetheless, at an individual level, more than 60% of 
women found initially to be affected by HF-B will recover, whilst about 20% of formerly 
pre-eclamptic women with normal echocardiography in the first year postpartum will 
develop HF-B over the following years.
Keywords
Cardiovascular disease, echocardiography, heart failure, HFpEF, pre-eclampsia.
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IntrOductIOn
Cardiovascular disease (CVD) is the leading cause of death worldwide 1–3. Although 
more men are affected by CVD than women, more women die of the disease4. Aside 
from the classical risk factors that contribute to the development of CVD2, women also 
have gender-specific risk factors such as pre-eclampsia (PE), a hypertensive pregnancy 
syndrome5, which increases the risk for CVD developing within 15 years after pregnancy 
by two- to seven-fold6. In contrast to healthy pregnancies in which left ventricular (LV) 
eccentric hypertrophy occurs, during a pre-eclamptic pregnancy the left ventricle un-
dergoes remodeling and concentric hypertrophy occurs, resembling that seen in heart 
failure (HF)7,8. The additional PE-induced increase in left ventricular mass (LVM) does 
not always resolve completely postpartum9. In fact, the incidence of preclinical HF Stage 
B (HF-B) is 24% at 1 year postpartum in formerly pre-eclamptic patients9.
HF is becoming a major health problem as life expectancy and prevalence of risk 
factors rise globally, leading to high healthcare costs, exceeding even those of cancer10. 
The progression of preclinical HF-B to the clinical stage C is associated with a five-fold 
increase in cardiovascular-related morbidity, mortality and decrease in quality of life11,12. 
This highlights the importance of identifying patients early in Stage B, which is potentially 
reversible when treated appropriately.
More women are affected by HF than are men4, and therefore sex differences in this 
condition should be evaluated. Currently, it is not known whether HF-B persists in 
formerly pre-eclamptic women. On the one hand, if HF-B persists, secondary prevention 
programs could be implemented. On the other hand, if HF-B resolves spontaneously over 
time, expectant management seems a reasonable option. In our study, we hypothesize 
that a significant number of women with HF-B at 1 year postpartum are still in their 
resolving period and will no longer have HF-B 4 years later. To this end, we performed 
serial cardiac ultrasound examinations in women with a history of PE at 1 and 4 years 
postpartum.
MethOds
This longitudinal cohort study was approved by the medical ethics committee of the 
Radboud University Medical Center (NL32718.091.10) before patient enrollment and 
all subjects provided written informed consent before participation. The procedures we 
followed conformed with institutional guidelines and adhered to the principles of the 
Declaration of Helsinki and Title 45, U.S. Code of Federal Regulation, Part 46, Protec-
tion of Human Subjects, Revised 13 November 2001, effective 13 December 2001. We 
included women who had a 1-year postpartum clinical cardiovascular risk assessment 
Prevalence of asymptomatic heart failure in formerly pre-eclamptic women: a cohort study | 3
following a pregnancy complicated by PE and invited them for a second postpartum 
follow-up screening between 2009 and 2011.
study Population
Formerly pre-eclamptic women were recruited by an obstetric clinician at the 6-week-
postpartum visit to participate in a 1-year postpartum cardiovascular screening 
assessment. At 4 years postpartum, women were invited by mail to participate in the 
cardiovascular follow-up study. The catchment area of this study population was in the 
east side of the Netherlands in which the socioeconomic status is reported to be average, 
with a low prevalence of immigrants. For the second visit, we included 69 women without 
any pre-existing comorbidity (diabetes mellitus, autoimmune disease, or pre-existing 
hypertension) and with a complete workup at both visits that allowed us to diagnose 
HF-B at two separate time points following a pregnancy complicated by PE.
PE in the index pregnancy was diagnosed according to the criteria set by the Inter-
national Society of Hypertension in Pregnancy: new-onset hypertension, systolic blood 
pressure (SBP) ≥ 140mmHg and/or diastolic blood pressure (DBP) ≥ 90mmHg, after 
20 weeks’ gestation and proteinuria exceeding 0.3g/day13. Early-onset PE was diagnosed 
as PE developing before 34 weeks’ gestation. Preterm PE was defined as PE requiring 
delivery before 37 weeks’ gestation. Four women in the study population gave birth to 
twins. All birth weights were included in our analysis. A birth weight ≤ 10th percentile 
was defined as small-for-gestational age. Patients underwent cardiovascular screening 
and echocardiographic measurements according to a standardized protocol at both 
postpartum intervals. Most women were of continental European ancestry; two women 
were of Turkish descent and one was of Moroccan descent. At the time of the first set of 
measurements, no woman was pregnant, all had stopped breastfeeding and none was 
using oral contraceptives. Women who had become pregnant again after their index 
pregnancy had to be at least 6 months postpartum for their second measurement.
cardiovascular screening
Each cardiovascular screening examination started at 8:00am in a temperature-controlled 
room (22 °C), after an overnight fast and was performed following a standardized study 
protocol by an experienced physician. The cardiovascular screening consisted of determi-
nation of body mass index (BMI) by measuring body weight (Seca 888 scale, Hamburg, 
Germany) and height. After 15min of rest, SBP, DBP and mean arterial pressure (MAP) 
were measured for 30min (at 3-min intervals) with the patient in an upright sitting posi-
tion, using a semi-automatic oscillometric device (Dinamap Vital Signs Monitor 1846; 
Critikon, Tampa, FL, USA) with a cuff size appropriate for arm circumference. We used 
the median of each patient’s measurements for statistical analysis. During the measure-
ments, the participants were not allowed to talk and external disturbances were kept to 
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a minimum. Hypertension was defined as SBP ≥ 140mmHg and/or DBP ≥ 90mmHg 
and/or if taking antihypertensive medication. Prehypertension was defined as SBP of 
120–139mmHg and/or DBP of 80–89mmHg. Blood samples were taken by venepuncture 
at the level of the antecubital vein and analyzed for fasting glucose (mmol/L), fasting insu-
lin (mU/L) and lipids (mmol/L; low-density lipoprotein (LDL), high density lipoprotein 
(HDL), total cholesterol and triglycerides). The homeostasis model assessment index for 
insulin resistance (HOMAIR) was calculated by insulin (mU/L)×glucose (mmol/L)/22.514. 
All participants collected their urine 24h preceding the measurements. The 24-h urine 
sample was assayed for albumin and creatinine to determine the (micro)albuminuria 
corrected for creatinine output (g/mol creatinine) (Aeroset, Abbot Laboratories, Chicago, 
IL, USA). Participants completed a questionnaire consisting of general history, current 
medication intake, intoxications (smoking was defined as ≥ one cigarette per day), lifestyle 
factors and family history of CVD (in first-degree relatives < 60 years old), occurrence of 
PE in first-degree relatives and gestational age at which participants themselves were born 
and their birth weight. Preterm birth was defined as a birth before 37 weeks’ gestation.
echocardiographic measurements
Echocardiographic measurements were performed with a phased-array echocardio-
graphic Doppler system. We performed two-dimensional, M-mode and Doppler echo-
cardiography according to the guidelines of the American Society of Echocardiography 
(ASE)15. We measured LV end-diastolic (LVEDd) and LV end-systolic (LVESd) diameters 
as well as end-diastolic interventricular septum thickness (IVST) and posterior wall 
thickness (PWT) using M-mode in the parasternal long-axis view. LVM was calculated 
using the formula 0.8× (1.04 ((LVEDd+PWT+IVST)3 −LVEDd3)) + 0.6 and indexed for 
body surface area (BSA; Dubois formula), as recommended by the ASE16. The relative wall 
thickness (RWT) was calculated using the formula (2×PWT)/LVEDd16. LV end-diastolic 
volume (LVEDV) and LV end-systolic volume (LVESV) were estimated using the Teich-
holz formula16. Left ventricular ejection fraction (LVEF) was calculated by [(LVEDV – 
LVESV)/LVEDV]×100. In all cardiac assessments, heart rate (HR) was obtained by taking 
the reciprocal of the mean of five consecutive R–R intervals on the electrocardiogram 
multiplied by 60. Stroke volume and cardiac output were indexed for BSA.
definition of heart failure stage b
HF was diagnosed according to the guidelines of the American Heart Association12. 
HF-B was defined as the presence of previous myocardial infarction, LV hypertrophy 
(left ventricular mass index (LVMi) > 95g/m2), concentric remodeling (RWT > 0.42 and 
LVMi ≤ 95g/m2), mildly impaired LVEF (> 40% and < 55%) or asymptomatic valvular 
disease16. We defined asymptomatic valvular disease as mild aortic valve insufficiency or 
central aortic valve insufficiency. HF with preserved ejection fraction (HFpEF) in this 
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subclinical stage was defined as LVEF ≥ 55% but with the occurrence of one of the other 
criteria for HF-B16.
statistical analysis
We performed all statistical analyses using SPSS Statistics version 21.0 (IBM Corp., Ar-
monk, NY, USA). We subdivided the PE group into four subgroups based on the HF-B 
outcome: (1) formerly pre-eclamptic women with no HF-B at either visit were categorized 
as HF-B−/−; (2) formerly pre-eclamptic women with HF-B at both visits were categorized 
as HF-B+/+; (3) formerly pre-eclamptic women with HF-B at the first visit but no HF-B 
at the second visit were categorized as HF-B+/−; (4) formerly pre-eclamptic women who 
developed de-novo HF-B between the two visits were categorized as HF-B−/+. We ana-
lyzed our data non-parametrically and reported continuous data as median (interquartile 
range) due to the modest sample size after subdividing the study population. We analyzed 
the continuous data with Wilcoxon’s signed-rank test for intragroup differences and the 
Mann–Whitney U-test for intergroup differences. Dichotomous data were analyzed 
using McNemar’s test for intragroup differences and Fisher’s exact test for intergroup dif-
ferences and were reported as number (percentage). A P-value of < 0.05 was considered 
statistically significant. We determined the sample size needed for our study based on 
previous findings by Melchiorre et al. on the prevalence of altered geometry at 1 year 
postpartum in formerly preterm and term pre-eclamptic women (30%) compared with 
controls (6%)9. The required sample size was calculated with a desired power of 0.95 and 
a two-sided α of 0.05. A minimum of 64 patients at 1 year and at 4 years postpartum was 
necessary for determining statistical significance.
results
Of the 69 formerly pre-eclamptic women included, 16 (23%) had HF-B at the first visit, 1 
year postpartum, and 16 (23%) had HF-B at the second visit, 4 years postpartum (Figure 
1). Six (37.5%) of the 16 women with HF-B at the first visit sustained this condition, which 
was observed at the second visit (HF-B+/+), and in 10 (62.5%) of the 16 women HF-B 
resolved before the second visit (HF-B+/−). Of the 53 patients with no HF-B at the first 
visit, 43 (81%) preserved normal cardiac function and had a normal echocardiography 
scan at the second visit (HF-B−/−); however, 10 (19%) developed de-novo HF-B within the 
subsequent 4 years (HF-B−/+).
Characteristics of the formerly pre-eclamptic women are shown in Table 1. Body 
weight was comparable between the two visits. The index pregnancy was complicated by 
early-onset PE in 68% of cases and by preterm PE in 75%. Of the 69 women included, 44 
(64%) had a subsequent pregnancy at the time of the second visit of which nine (20%) 
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Pre-eclamptic pregnancy
(n = 69)
HF-B at 1 year
(n = 16; 23%)
No HF-B at 1 year
(n = 53; 77%)
HF-B at 4 years (HF-B+/+)
(n = 6; 37,5%)
No HF-B at 4 years (HF-B+/-)
(n = 10; 62,5%)
HF-B at 4 years (HF-B-/+)
(n = 10; 19%)
No HF-B at 4 years (HF-B-/-)
(n = 43; 81%)
Figure 1. Flowchart of formerly pre-eclamptic women who were screened for heart failure stage b 
(hF-b) at 1 year and 4 years postpartum. + and − indicate presence or absence, respectively, of hF-b 
at 1 year/4 years.
table 1. characteristics of 69 formerly pre-eclamptic women at 1 and 4 years postpartum.
characteristics
1 year
(n = 69)
4 years
(n = 69) P
Age (years) 32 (29-35) 35 (33-39) <0.01
Weight (kg) 66 (60-75) 67 (61-77) 0.07
BMI (kg/m2) 23.2 (21.3-27.2) 23.9 (21.3-26.3) 0.06
Obese (BMI ≥ 30 kg/m2) 9/69 (13) 11/69 (16) 0.63
Smoker 6/69 (9) 6/69 (9) 1.00
Family history of CVD 21/69 (30) 26/69 (38) 0.41
Family history of PE in first-degree relative 20/69 (29) - NA
Antihypertensive treatment 16/69 (23) 13/69 (19) 0.38
Number of years postpartum 0.6 (0.3-2.5) 4.4 (2.6-7.3) <0.01
Heart failure Stage B 16/69 (23) 16/69 (23) 1.00
Heart failure with preserved LVEF 7/69 (10) 12/69 (17) 0.30
Index pregnancy
    Early-onset PE* 46/68 (68) - NA
    Preterm PE 52/69 (75) - NA
    Primiparous, n (%) 57/69 (83) 18/69 (26) <0.01
    GA at birth (weeks) 33.4 (30.1-36.9) - NA
    Birth weight (g) 1572 (963-2573) - NA
    SGA neonate 28/69 (41) - NA
    IUFD 7/69 (10) - NA
    Subsequent pregnancy† - 44/69 (64) NA
        Recurrent PE - 9/44 (20) NA
Maternal offspring pregnancy‡
    GA at birth (weeks) 40 (37-40) - NA
    Preterm birth 10/52 (19) - NA
    Birth weight (g) 3050 (2500-3500) - NA
Data are given as median (interquartile range), median [range] or n/N (%).
*Time of onset of pre-eclampsia (PE) unknown in one case.
†Pregnancy between index pregnancy and second visit.
‡Pregnancy of which woman in this study was offspring.
BMI, body mass index; CVD, cardiovascular disease; GA, gestational age; IUFD, intrauterine fetal death; LVEF, 
left ventricular ejection fraction; NA, not applicable; SGA, small-for-gestational age.
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had recurrent PE. Of the study population, 29% had a first-degree relative who had a 
pregnancy complicated by PE. Characteristics of the cohort after excluding women with 
twin pregnancy are shown in Table S1.
Inter- and intragroup differences in hF-b vs no-hF-b
Table 2 shows the cardiac and metabolic characteristics in women with and without 
HF-B at each follow-up visit. Data excluding women with a twin pregnancy are shown 
in Table S2. The phenotype of the group of women with HF-B at the first visit differed 
in some aspects from the phenotype of the group of women with HF-B at the second 
table 2. cardiac and metabolic characteristics of heart failure stage b (hF-b) in 69 formerly pre-
eclamptic women categorized according to presence or absence of hF-b at 1 and 4 years postpartum.
Parameter
1 year 4 years
hF-b
(n = 16)
no-hF-b
(n = 53) P
hF-b
(n = 16)
no-hF-b
(n = 53) P
Myocardial infarction 0 (0) - NA 0 (0) - NA
LV hypertrophy 3 (19) - NA 1 (6) - NA
Concentric remodeling 5 (31) - NA 11 (69)* - NA
Mildly impaired LVEF 9 (56) - NA 4 (25) - NA
Asymptomatic valvular disease 1 (6) - NA 1 (6) - NA
Heart failure with preserved LVEF 7 (44) - NA 12 (75) - NA
Metabolic syndrome
    Fasting glucose (mmol/L) 4.9 (4.4-5.1) 4.8 (4.6-5.1) 0.54 4.8 (4.5-5.0) 4.7 (4.4-5.0) 0.37
    Fasting insulin (mU/L) 11.5 (8.3-14.0) 8.0 (6.0-10.0) <0.05 8.5 (6.3- 11.9) 7.7 (5.4-10.0) 0.22
    HOMA IR 2.5 (1.7-3.2) 1.9 (1.3-2.2) <0.05 1.8 (1.4-2.8) 1.5 (1.1-2.1) 0.22
    Triglyceride (mmol/L) 1.0 (0.7-1.5) 0.9 (0.7-1.1) 0.32 0.8 (0.7-1.2) 0.9 (0.7-1.1) 0.60
    Total cholesterol (mmol/L) 4.8 (4.3-5.3) 4.6 (4.1-5.2) 0.31 4.5 (4.1-5.1) 4.6 (4.2-5.0) 0.65
    LDL (mmol/L) 3.0 (2.6-3.6) 2.8 (2.4-3.4) 0.25 2.9 (2.4-3.5) 2.9 (2.5-3.2) 0.72
    HDL (mmol/L) 1.2 (1.1-1.3) 1.3 (1.2-1.5) 0.10 1.2 (1.1-1.4) 1.4 (1.1-1.5) 0.09
    Albumin/creatinine ratio (g/mol) 0.5 (0.1-1.9) 1.0 (0.3-2.1) 0.14 0.8 (0.6-1.2) 0.5 (0.2-1.6) 0.30
    SBP (mmHg) 124 (116-144) 115 (107-123) <0.01 116 (110-129) 115 (106-123) 0.37
    DBP (mmHg) 76 (68-83) 68 (64-73) <0.01 74 (71-82) 72 (66-77) 0.11
    MAP (mmHg) 91 (84-104) 82 (79-92) <0.01 86 (82-94) 83 (77-94) 0.20
    Heart rate (bpm) 70 (65-80) 66 (60-75) 0.13 69 (64-79) 62 (59-76) 0.08
    BMI (kg/m2) 27.8 (22.8-33.0) 22.8 (20.9-25.0) <0.01 25.2 (22.5-30.6) 23.6 (21.1-25.7) 0.17
    Antihypertensive treatment 5 (31) 11 (21) 0.50 4 (25) 9 (17) 0.48
Data are given as n (%) or median (interquartile range).
*P < 0.05 compared with HF-B at 1 year postpartum.
BMI, body mass index; DBP, diastolic blood pressure; HDL, high density lipoprotein; HOMAIR, homeostatic 
model assessment for insulin resistance; LDL, low density lipoprotein; LV, left ventricular; LVEF, left ventricu-
lar ejection fraction; MAP, mean arterial pressure; NA, not applicable; SBP, systolic blood pressure.
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visit. Concentric remodeling was present in 31% of women at visit 1 compared with 
69% at visit 2 (P < 0.05). On the other hand, systolic dysfunction, as indicated by mildly 
impaired LVEF, was present in 56% at visit 1 compared with 25% at visit 2 (P = 0.15). The 
prevalence of LV hypertrophy and asymptomatic valvular disease did not differ when 
comparing data from both visits.
At visit 1, the HF-B group had comparable fasting glucose, triglycerides, total choles-
terol, LDL, HDL and albumin/creatinine ratio levels compared with the no-HF-B group 
(Table 2). Fasting insulin and HOMA levels were higher in the HF-B group compared 
with the no-HF-B group, along with higher SBP, DBP, MAP and BMI. At visit 2, no 
significant differences were seen between the groups with and without HF-B.
Inter- and intragroup differences in hF-b−/− vs hF-b−/+
We first compared HF-B−/− and HF-B−/+ subgroups (Table 3; data excluding women with 
twin pregnancy are given in Table S3). Baseline characteristics, obstetric characteristics of 
index pregnancy complicated by PE and offspring pregnancy were comparable between 
the two groups except for a higher prevalence of primiparous women in the HF-B−/− group 
compared with the HF-B−/+ group at visit 1 (93% vs 60%). LVMi did not differ between 
subgroups at visit 1 or 2. RWT did not differ between subgroups at visit 1, but it was 
higher in the HF-B−/+ group compared with HF-B−/− at visit 2. LVEF did not differ between 
subgroups at visit 1 or 2. However, in the HF-B−/+ group, LVEF had decreased significantly 
at visit 2 when compared with visit 1. Stroke volume (SV) and SV index did not differ 
between groups at visit 1 or 2. However, in the HF-B−/− group, both SV and SV index had 
increased at visit 2 compared with visit 1, whereas they did not change over time in the 
HF-B−/+ group. The ratio of early to late ventricular filling velocity (EA ratio) did not differ 
between the two groups at visit 1 or 2, whereas cardiac output (CO) and CO index were 
higher in the HF-B−/+ group compared with the HF-B−/− group at visit 1, but this differ-
ence was no longer present at visit 2. Moreover, in the HF-B−/− group, CO and CO index 
had increased at visit 2 compared with visit 1, whereas they did not change over time in 
the HF-B−/+ group. HR was significantly higher in the HF-B−/+ group compared with the 
HF-B−/− group at visit 1, but this intergroup difference was not present at visit 2. LVEDV 
did not differ between groups at visit 1 or 2. However, in the HF-B−/− group, LVEDV was 
increased at visit 2 compared with visit 1, while in the HF-B−/+ it remained unchanged.
Table 4 presents the cardiometabolic variables at visits 1 and 2 in each subgroup 
of women (Table S4 shows data after excluding women with a twin pregnancy). No 
metabolic variable differed between the HF-B−/− and HF-B−/+ subgroups at either visit. 
Moreover, in the HF-B−/− group, fasting glucose had decreased between visits 1 and 2 
(4.8 vs 4.7mmol/L, P < 0.05), DBP had increased (68 vs 72mmHg, P < 0.05) and BMI 
had increased (22.5 vs 23.5kg/m2, P < 0.05). In the HF-B−/+ group, all metabolic variables 
remained unchanged over time.
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table 3. Pregnancy characteristics and cardiac indices in 69 formerly pre-eclamptic women, catego-
rized according to absence of heart failure stage b (hF-b) at 1 year and 4 years postpartum (hF-b−/−), 
absence of hF-b at 1 year but presence at 4 years (hF-b−/+), presence of hF-b at both 1 and 4 years 
(hF-b+/+) and presence of hF-b at 1 year but absence at 4 years (hF-b+/−).
characteristic
hF-b-/-
(n = 43)
hF-b-/+
(n = 10) P
hF-b+/+
(n = 6)
hF-b+/-
(n = 10) P
Postpartuminterval (years)
    1 year 0.6 (0.3-2.4) 0.6 (0.3-2.4) 0.91 0.9 (0.4-2.1) 0.6 (0.3-2.5) 0.64
    4 years 4.3 (2.7-7.3)* 4.3 (3.7-6.7)* 0.94 5.8 (2.6-6.8)† 4.7 (3.3-6.0)* 0.09
Index pregnancy
    Early-onset PE 26/43 (60) 8/10 (80) 0.30 4/5 (80) 8/10 (80) 1.00
    Preterm PE 32/43 (74) 8/10 (80) 1.00 4/6 (67) 8/10 (80) 0.60
    Primiparous at 1 year 40/43 (93) 6/10 (60) <0.05 3/6 (50) 8/10 (80) 0.30
    Primiparous at 4 years 14/43 (33)* 1/10 (10) 0.25 1/6 (17) 2/10 (20)† 1.00
    GA at birth (weeks) 34.9 (30.6-37.0) 32.6 (27.6-35.2) 0.26 30.2 (27.4-37.4) 31.8 (28.5-35.9) 0.64
    Birth weight (g) 1817 (1098-2695) 1350 (667-2013) 0.20 955 (480-2615) 1457 (941-2540) 0.48
    SGA neonate 16/43 (37) 7/10 (70) 0.08 2/6 (33) 3/10 (30) 1.00
    IUFD 3/43 (7) 2/10 (20) 0.24 2/6 (33) 0/10 (0) 0.13
    Subsequent pregnancy‡ 27/43 (63) 7/10 (70) 1.00 3/6 (50) 7/10 (70) 0.61
        Recurrent PE 3/27 (11) 0/7 (0) 1.00 3/3 (100) 3/7 (43) 0.20
Maternal offspring pregnancy
    GA at birth (weeks) 40.0 (37.3-40.0) 40.0 (33.5-40.5) 0.85 40.0 (37.0-40.0) 39.0 (34.3-41.3) 1.00
    Preterm birth 6/36 (17) 2/6 (33) 0.32 0/4 (0) 2/6 (33) 0.50
    Birth weight (g) 3200 (2550-3550) 2875 (2500-3500) 0.57 2000(1990-2000) 3000 (2500-3500) 0.07
    Family history of PE in first degree relative 12/43 (28) 3/10 (30) 1.00 4/6 (67) 1/10 (10) <0.05
cardiac measurements
LVM index (g/m2)
    1 year 63 (53-69) 60 (57-64) 0.62 76 (51-95) 65 (59-79) 0.79
    4 years 59 (51-64)† 63 (40-66) 0.98 58 (50-81) 62 (49-74) 0.79
RWT
    1 year 0.31 (0.26-0.35) 0.32 (0.29-0.35) 0.63 0.43 (0.37-0.47) 0.33 (0.30-0.42) 0.18
    4 years 0.33 (0.29-0.36) 0.44 (0.31- 0.46)† <0.05 0.44 (0.41-0.45) 0.32 (0.28-0.37) <0.01
LVEF (%)
    1 year 65 (61-69) 68 (61-72) 0.38 55 (51-63) 53 (50-59) 0.71
    4 years 64 (61-67) 62 (54-66) † 0.09 57 (55-59) 65 (61-67)* <0.01
SV (mL)
    1 year 73 (60-85) 83 (73-88) 0.11 62 (59-82) 78 (63-85) 0.43
    4 years 78 (72-89)* 85 (73-88) 0.65 74 (63-108) 83 (70-91) 0.69
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table 3. Pregnancy characteristics and cardiac indices in 69 formerly pre-eclamptic women, catego-
rized according to absence of heart failure stage b (hF-b) at 1 year and 4 years postpartum (hF-b−/−), 
absence of hF-b at 1 year but presence at 4 years (hF-b−/+), presence of hF-b at both 1 and 4 years 
(hF-b+/+) and presence of hF-b at 1 year but absence at 4 years (hF-b+/−). (continued)
characteristic
hF-b-/-
(n = 43)
hF-b-/+
(n = 10) P
hF-b+/+
(n = 6)
hF-b+/-
(n = 10) P
SV index (mL/m2)
    1 year 40 (35-49) 48 (40-53) 0.15 33 (29-47) 40 (32-46) 0.64
    4 years 45 (41-51)† 47 (42-51) 0.65 39 (37-52) 42 (37-48) 1.00
E/A ratio
    1 year 1.57 (1.31-2.04) 1.35 (1.19-1.68) 0.16 1.46 (1.24-1.68) 1.56 (1.16-1.91) 1.00
    4 years 1.61 (1.44-1.95) 1.66 (1.43-1.83) 0.85 1.58 (1.25-1.80) 1.60 (1.19-1.88) 0.79
CO (L/min)
    1 year 4.5 (3.8-5.2) 5.6 (5.3-6.3) <0.01 4.2 (4.0-6.2) 5.3 (4.1-5.6) 0.79
    4 years 4.8 (4.2-6.0)* 5.3 (4.8-6.2) 0.18 5.6 (4.4-7.7) 5.0 (4.5-5.4) 0.39
CO index (L/min/m2)
    1 year 2.5 (2.1-3.0) 3.2 (3.0-3.8) <0.01 2.3 (1.9-3.6) 2.8 (2.2-3.2) 0.88
    4 years 2.7 (2.4-3.2)† 2.9 (2.6-3.4) 0.25 3.0 (2.6-3.8) 2.6 (2.2-2.9) 0.15
Heart rate (bpm)
    1 year 60 (56-65) 73 (65-77) <0.01 70 (66-74) 69 (60-78) 0.79
    4 years 62 (57-69) 64 (58-74) 0.34 73 (61-78) 64 (59-70) 0.26
LVEDV (mL)
    1 year 81 (68-94) 90 (77-102) 0.12 85 (57-108) 95 (80-141) 0.26
    4 years 89 (76-103)* 90 (78-103) 0.93 88 (68-140) 101 (72-111) 0.79
Data are given as median [range], n/N (%) or median (interquartile range).
Comparison with 1 year postpartum: *P < 0.01; †P < 0.05.
‡Pregnancy between index pregnancy and second visit.
CO, cardiac output; EA ratio, ratio of early-to-late ventricular filling velocity; GA, gestational age; IUFD, in-
trauterine fetal death; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; 
LVMi, left ventricular mass index; PE, pre-eclampsia; RWT, relative wall thickness; SGA, small-for-gestational 
age; SV, stroke volume.
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table 4. Metabolic variables in 69 formerly pre-eclamptic women categorized according to absence 
of heart failure stage b (hF-b) at 1 year and 4 years postpartum (hF-b−/−), absence of hF-b at 1 year 
but presence at 4 years (hF-b−/+), presence of hF-b at both 1 and 4 years (hF-b+/+) and presence of 
hF-b at 1 year but absence at 4 years (hF-b+/−).
Variable
hF-b-/-
(n = 43)
hF-b-/+
(n = 10) P
hF-b+/+
(n = 6)
hF-b+/-
(n = 10) P
Fasting glucose (mmol/L)
    1 year 4.8 (4.5-5.1) 4.9 (4.7-5.4) 0.39 4.9 (4.6-5.0) 4.7 (4.2-5.2) 0.71
    4 years 4.7 (4.4-4.9)† 4.8 (4.4-5.0) 0.82 4.8 (4.7-5.3) 4.8 (4.3-5.4) 0.64
Fasting insulin (mU/L)
    1 year 8.0 (6.0-10.0) 9.0 (7.5-12.5) 0.36 13.0 (9.8-15.5) 10.0 (7.8-14.0) 0.49
    4 years 7.2 (5.4-10.0) 8.0 (6.6-11.9) 0.31 11.2 (4.5-12.8) 8.3 (4.3-13.6) 0.88
HOMAIR
    1 year 1.7 (1.3-2.2) 1.9 (1.6-3.0) 0.35 2.7 (2.1-3.5) 2.1 (1.6-3.1) 0.43
    4 years 1.5 (1.1-2.0) 1.7 (1.5-2.5) 0.31 2.6 (1.0-2.9) 1.7 (0.8-3.1) 0.88
Triglyceride (mmol/L)
    1 year 0.9 (0.7-1.0) 0.9 (0.6-1.3) 0.69 1.0 (0.8-1.3) 1.2 (0.5-1.7) 0.71
    4 years 0.9 (0.7-1.1) 0.8 (0.6-0.9) 0.23 1.2 (0.7-1.3) 0.9 (0.7-1.4) 0.88
Total cholesterol (mmol/L)
    1 year 4.6 (4.1-5.2) 4.5 (4.2-4.9) 0.84 4.8 (4.5-5.2) 4.7 (4.2-5.3) 0.56
    4 years 4.6 (4.2-4.9) 4.6 (4.2-5.1) 0.91 4.5 (4.1-5.5) 4.8 (4.3-5.5) 0.43
LDL (mmol/L)
    1 year 2.8 (2.4-3.4) 2.8 (2.4-3.3) 0.94 3.0 (2.8-3.6) 3.0 (2.6-3.4) 0.59
    4 years 2.8 (2.4-3.2) 3.0 (2.2-3.4) 0.51 2.7 (2.5-3.7) 2.9 (2.7-3.6) 0.37
HDL (mmol/L)
    1 year 1.3 (1.2-1.5) 1.3 (1.1-1.5) 0.45 1.2 (1.1-1.4) 1.2 (1.1-1.3) 1.00
    4 years 1.4 (1.1-1.5) 1.2 (1.1-1.4) 0.12 1.2 (1.1-1.5) 1.4 (1.1-1.5) 0.64
Albumin/creatinine ratio (g/mol)
    1 year 1.0 (0.3-2.1) 0.8 (0.3-1.7) 0.64 0.2 (0.0-0.7) 0.9 (0.3-2.3) 0.12
    4 years 0.5 (0.2-1.7) 0.6 (0.1-1.0) 0.96 1.1 (0.7-3.9) 0.5 (0.4-1.3) 0.07
SBP (mmHg)
    1 year 115 (107-123) 117 (105-122) 0.79 146 (116-155) 123 (114-126) 0.15
    4 years 114 (104-122) 112 (107-122) 0.80 129 (117-135) 119 (109-130) 0.18
DBP (mmHg)
    1 year 68 (63-74) 66 (64-71) 0.69 82 (77-89) 70 (68-78) <0.05
    4 years 72 (66-76)† 72 (69-75) 0.86 84 (78-91) 75 (66-78) <0.05
MAP (mmHg)
    1 year 83 (79-92) 82 (79-89) 0.72 104 (88-109) 87 (83-97) 0.07
    4 years 82 (77-93) 83 (80-86) 0.93 96 (89-105) 86 (80-95) 0.06
Heart rate (bpm)
    1 year 66 (60-74) 74 (62-76) 0.29 71 (66-80) 70 (63-82) 0.88
    4 years 62 (59-72) 69 (64-80) 0.17 70 (63-80) 62 (59-82) 0.37
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table 4. Metabolic variables in 69 formerly pre-eclamptic women categorized according to absence 
of heart failure stage b (hF-b) at 1 year and 4 years postpartum (hF-b−/−), absence of hF-b at 1 year 
but presence at 4 years (hF-b−/+), presence of hF-b at both 1 and 4 years (hF-b+/+) and presence of 
hF-b at 1 year but absence at 4 years (hF-b+/−). (continued)
Variable
hF-b-/-
(n = 43)
hF-b-/+
(n = 10) P
hF-b+/+
(n = 6)
hF-b+/-
(n = 10) P
BMI (kg/m2)
    1 year 22.5 (20.8-24.1) 24.3 (22.2-27.2) 0.15 28.3 (23.6-33.2) 27.6 (22.2-34.4) 0.79
    4 years 23.5 (20.8-25.0)† 24.4 (22.4-27.2) 0.30 29.9 (21.9-33.8) 25.2 (22.7-35.0) 0.88
    1 year 10/43 (23) 1/10 (10) 0.67 4/6 (67) 1/10 (10) <0.05
    4 years 7/43 (16) 1/10 (10) 1.00 3/6 (50) 2/10 (20) 0.30
Prehypertension
    1 year 7/43 (16) 4/10 (40) 0.19 0/6 (0) 4/10 (40) 0.23
    4 years 5/43 (12) 2/10 (20) 0.60 3/6 (50) 3/10 (30) 0.61
Hypertension
    1 year 10/43 (23) 1/10 (10) 0.67 5/6 (83) 2/10 (20) <0.05
    4 years 9/43 (21) 1/10 (10) 0.67 3/6 (50) 2/10 (20) 0.30
Data are given as median (interquartile range) or n/N (%).
Comparison with 1 year postpartum: *P < 0.01; †P < 0.05.
BMI, body mass index; DBP, diastolic blood pressure; HDL, high density lipoprotein; HOMA IR, homeostatic 
model assessment for insulin resistance; LDL, low density lipoprotein; MAP, mean arterial pressure; SBP, 
systolic blood pressure.
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Inter- and intragroup differences in hF-b+/+ vs hF-b+/−
We subsequently compared HF-B+/+ and HF-B+/− subgroups (Table 3; data excluding 
women with twin pregnancy are given in Table S3). Baseline characteristics, obstetric 
characteristics of index pregnancy and offspring pregnancy were comparable between 
the two groups. However, among the HF-B+/+ group there was a significantly greater pro-
portion of women with a family history of PE compared with the HF-B+/− group (67% vs 
10%). LVMi did not differ between subgroups at either visit. RWT did not differ between 
subgroups at visit 1 but was higher in the HF-B+/+ group compared with the HF-B+/− group 
at visit 2. LVEF did not differ between subgroups at visit 1. LVEF was significantly higher 
in the HF-B+/− group compared with the HF-B+/+ group at visit 2, and was increased in 
this subgroup compared to the first visit. SV, SV index, EA ratio, CO, CO index, HR and 
LVEDV did not differ between subgroups at visit 1 or 2. When analyzing metabolic risk 
factors (Table 4), no variable differed between the two subgroups at either visit (Table S4 
shows data after excluding women with a twin pregnancy). DBP was significantly higher 
in the HF-B+/+ group at visits 1 and 2 compared with the HF-B+/− group. Moreover, at 
visit 1, hypertension was significantly more prevalent in the HF-B+/+ group compared 
with the HF-B+/− group (83% vs 20%). However, at visit 2, this significant difference in 
hypertension prevalence was no longer present between the two subgroups.
dIscussIOn
To the best of our knowledge, this is the first presentation of a longitudinal cohort study 
on the prevalence of asymptomatic HF in formerly pre-eclamptic women. The prevalence 
of preclinical HF-B is similar at 1 and 4 years postpartum (23%) suggesting a persistent 
cardiac condition. However, HF-B resolved in two-thirds of originally affected women, 
and one in five initially unaffected women developed HF-B in the years thereafter.
The cardiovascular implications of PE do not end with delivery17. In fact, in contrast to 
the physiological LV remodeling in normal pregnancy, which resolves in the first weeks 
postpartum, the PE-induced cardiac adaptation may persist for at least several months 
postpartum8,18. To date, it is unknown whether (and when) PE-induced cardiac remodel-
ing resolves completely. Traditional cardiovascular risk factors may affect the resolving 
process after PE and could be responsible for the differences in postpartum recovery 
between healthy and PE pregnancies.
The observed 23% prevalence of HF-B in the first year postpartum is in line with 
previous findings9. Our data show that although the prevalence of HF-B at both visits 
is comparable, the underlying components are different. More than half of the women 
diagnosed with HF-B at visit 1 recovered, while about one in five formerly pre-eclamptic 
women without prior subclinical HF-B developed HF-B in the years thereafter, mostly as 
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a result of concentric remodeling. Considering diastolic dysfunction is the most preva-
lent form of cardiac dysfunction in women, it may be hypothesized that the development 
towards concentric remodeling could be a more persistent condition in these women 
than the initial HF-B variant with mostly reduced systolic function.
HF can occur with a reduced EF (HFrEF) or with a preserved EF (HFpEF), the lat-
ter occurring more often in women than in men with a noteworthy 2:1 ratio19. Despite 
significant uncertainty and conflicting results, the pathophysiological problem in patients 
with HFpEF has been related to impaired diastolic reserve20. HFpEF is thought to de-
velop from a ‘systemic pro-inflammatory state’ induced by comorbidities and with the 
involvement of microvascular endothelial inflammation21, all of which are thought to be 
involved in the etiology of PE22. Although this terminology is applied to symptomatic 
HF, specifying different subclinical phenotypes within the HF spectrum may theoreti-
cally allow stratification for potential early diagnosis and care to prevent progression. 
The prevalence of subclinical HFpEF in our population increased more than two-fold 
between both visits. Although borderline significant, in combination with the shift in 
concentric remodeling between both visits it is tempting to speculate that this shift may 
indicate a mechanistic response to the persistently high blood pressure that results in 
increased concentric remodeling23.
Recent evidence suggests that chronic volume and pressure overload determine the 
resulting phenotype of hypertrophic remodeling24. Untreated chronic high blood pres-
sure is a well-known cause of structural cardiovascular alterations25 and cardiovascular 
morbidity26. In the development of actual CVD, chronically elevated blood pressure is 
considered to be an important intermediate risk condition, which is easily identifiable 
and modifiable, enabling the timely institution of measures to prevent the premature 
development of a more debilitating CVD in women2,27. Besides the mechanical strain and 
risks, HF risk may also originate from all or a subset of biochemical stressors consistent 
with metabolic syndrome28. This is reflected in our findings, as some of the metabolic 
syndrome constituents seem to play a role in the prevalence of HF-B at visit 1. However, 
no association was found between the metabolic syndrome constituents and HF-B at 
visit 2, suggesting that different mechanisms contribute to the high prevalence at both 
time points. As most HF-B women have a phenotypical profile of consistent diastolic 
dysfunction, these findings may indicate a difference in either pressure or volume load, 
common in formerly pre-eclamptic women29,30.
In women, HF is often detected at a late and clinically overt stage. Formerly pre-
eclamptic women should be aware of the increased risk for potentially reversible HF-B 
before it develops to the much less reversible symptomatic Stages C and D. Therefore, 
patients and clinicians should be aware of the importance of regular postpartum car-
diovascular follow-up after a pre-eclamptic pregnancy. The patient may benefit from 
secondary prevention if CVD is diagnosed at an early stage. However, before specific 
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treatment can be implemented in daily clinical practice, intervention trials are necessary, 
in order to prevent CVD in formerly pre-eclamptic women. Follow-up studies with a 
longer postpartum interval are necessary to provide more information on the prevalence 
of HF-B. Whether PE induces HF or whether PE and HF are a common result of the same 
susceptibility is yet to be determined.
This prospective longitudinal cohort study has some limitations. First, most women 
had ancestry originating from Europe. Therefore, our results may not be fully applicable 
to women of other ethnic origins. Second, after subdividing the cohort according to HF 
outcome, the number of women per subgroup became modest thus increasing the risk 
of Type I error. However, we did detect clinically relevant significant differences between 
subgroups. Therefore, considering the sample size, prevalence of abnormalities, and 
potential importance of the observations, additional studies confirming our findings are 
required.
In conclusion, the prevalence of subclinical HF-B is persistently high in the years after 
a PE pregnancy. Nonetheless, there is a noteable shift in individuals and phenotypes 
contributing to HF-B in the years after PE. From a clinical perspective, these findings may 
imply that cardiovascular risk screening at approximately 1 year postpartum is important, 
and that an additional assessment a few years later is necessary. Whether lifestyle change 
and pharmacological therapy are effective at preventing progression or development 
towards clinical HF in these women needs to be investigated.
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suPPleMentAl InFOrMAtIOn
Pre-eclamptic pregnancy
(n = 65)
HF-B at 1 year
(n = 15; 23%)
No HF-B at 1 year
(n = 50; 77%)
HF-B at 4 years (HF-B+/+)
(n = 5; 33%)
No HF-B at 4 years (HF-B+/-)
(n = 10; 67%)
HF-B at 4 years (HF-B-/+)
(n = 10; 20%)
No HF-B at 4 years (HF-B-/-)
(n = 40; 80%)
supplemental Figure 1. Flowchart of formerly pre-eclamptic women who were screened for heart 
failure stage b (hF-b) at 1 year and 4 years postpartum. + and − indicate presence or absence, re-
spectively, of hF-b at 1 year/4 years, after excluding twin pregnancies.
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supplemental table 1. characteristics of 65 formerly pre-eclamptic women at 1 and 4 years postpar-
tum, after excluding those with twin pregnancy.
characteristic
1 year
(n = 65)
4 years
(n = 65) P
Age (years) 32 (29-35) 35 (33-39) < 0.01
Weight (kg) 66 (60-75) 67 (61-77) 0.09
BMI (kg/m2) 23.2 (21.3-27.2) 23.9 (21.3-26.3) 0.09
Obese (BMI ≥ 30 kg/m2) 8/65(12) 10/65 (15) 0.63
Smoker 5/65 (8) 6/65 (9) 1.00
Family history of CVD 20/65 (31) 24/65 (37) 0.52
Family history of PE in first-degree relative 19/65 (29) NA
Antihypertensive treatment 14/65 (22) 13/65 (20) 1.00
Number of years postpartum 0.6 [0.3-2.5] 4.5 [2.6–7.3] < 0.01
Heart failure Stage B 15/65 (23) 15/65 (23) 1.00
Heart failure with preserved LVEF 7/65 (11) 11/65 (17) 0.42
Index pregnancy
     Early-onset PE* 43/64 (67) NA
     Preterm PE 48/65 (74) NA
     Primiparous 54/65 (83) 15/65 (23) < 0.01
     GA at birth (weeks) 33.4 (30.1-37.0) NA
     Birth weight (g) 1603 (1006-2665) NA
     SGA neonate 27/65 (42) NA
     IUFD 7/65 (11) NA
     Subsequent pregnancy† — 44/65 (68) NA
         Recurrent PE — 9/44 (20) NA
 Maternal offspring pregnancy‡
     GA at birth (weeks) 40 (37-40) NA
     Preterm birth 10/48 (21) NA
     Birth weight (g) 3000 (2500-3500) NA
Data are given as median (interquartile range), median [range] or n/N (%). * Time of onset of pre-eclampsia 
(PE) unknown in one case.
† Pregnancy between index pregnancy and second visit.
‡ Pregnancy of which woman in this study was offspring.
BMI, body mass index; CVD, cardiovascular disease; GA, gestational age; IUFD, intrauterine fetal death; LVEF, 
left ventricular ejection fraction; NA, not applicable; PE, pre-eclampsia; SGA, small for gestational age.
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supplemental table 2. cardiac and metabolic characteristics of heart failure stage b (hF-b) in 65 
formerly pre-eclamptic women, excluding those with a twin pregnancy, categorized according to 
presence and absence of hF-b at 1 and 4 years postpartum.
Parameter
1 year 4 years
hF-b
(n = 15)
no-hF-b
(n = 50) P
hF-b
(n = 15)
no-hF-b
(n = 50) P
Myocardial infarction 0 (0) — NA 0 (0) — NA
LV hypertrophy 3 (20) — NA 0 (0) — NA
Concentric remodeling 5 (33) — NA 11 (73) — NA
Mildly impaired LVEF 8 (53) — NA 4 (27) — NA
Asymptomatic valve disease 1 (7) — NA 1 (7) — NA
Heart failure with preserved LVEF 7 (47) — NA 11 (73) — NA
Metabolic syndrome
    Fasting glucose (mmol/L) 4.8 (4.3-5.1) 4.8 (4.6-5.1) 0.42 4.8 (4.5-5.0) 4.7 (4.4-4.9) 0.41
   Fasting insulin (mU/L) 12.0 (8.0-14.0) 8.0 (6.0-10.0) < 0.05 8.0 (6.1-11.4) 7.8 (5.4-10.0) 0.34
    HOMAIR 2.5 (1.6-3.2) 1.9 (1.4-2.3) 0.07 1.8 (1.3-2.9) 1.6 (1.1-2.1) 0.34
    Triglyceride (mmol/L) 1.0 (0.6-1.6) 0.9 (0.7-1.0) 0.43 0.8 (0.7-1.2) 0.9 (0.7-1.1) 0.49
    Total cholesterol (mmol/L) 4.9 (4.2-5.3) 4.6 (4.1-5.1) 0.22 4.4 (4.1-5.1) 4.6 (4.2-5.0) 0.70
    LDL (mmol/L) 3.1(2.6-3.6) 2.8 (2.4-3.3) 0.17 2.9 (2.4-3.6) 2.8 (2.5-3.2) 0.64
    HDL (mmol/L) 1.2 (1.1-1.3) 1.3 (1.2-1.5) 0.13 1.2 (1.1-1.5) 1.4 (1.1-1.5) 0.11
    Albumin/creatinine ratio (g/mol) 0.7 (0.1-2.1) 1.0 (0.3-2.1) 0.18 0.8 (0.5-1.7) 0.5 (0.2-1.7) 0.42
    SBP (mmHg) 124 (117-144) 115 (107-123) < 0.01 118 (109-129) 116 (106-123) 0.41
    DBP (mmHg) 75 (68-83) 68 (64-74) < 0.05 74 (71-82) 72 (66-77) 0.21
    MAP (mmHg) 91 (84-104) 82 (79-92) < 0.01 85 (82-95) 84 (77-94) 0.33
    Heart rate (bpm) 70 (64-80) 67 (60-75) 0.14 68 (63-79) 62 (59-75) 0.09
    BMI (kg/m2) 27.3 (22.3-32.8) 22.9 (20.7-24.9) < 0.01 24.7 (22.4-30.4) 23.7 (21.1-25.8) 0.30
   Antihypertensive treatment 4 (27) 10 (20) 0.72 4 (27) 9 (18) 0.48
Data are given as n (%) or median (interquartile range).
*P < 0.05 compared to HF-B at 1 year postpartum.
BMI, body mass index; DBP, diastolic blood pressure; HDL, high density lipoprotein; HOMAIR, homeostatic 
model assessment for insulin resistance; LDL, low density lipoprotein; LV, left ventricular; LVEF, left ventricu-
lar ejection fraction; MAP, mean arterial pressure; NA, not applicable; SBP, systolic blood pressure.
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supplemental table 3. Pregnancy characteristics and cardiac indices in 65 formerly pre-eclamptic 
women, excluding those with twin pregnancy, categorized according to absence of heart failure 
stage b (hF-b) at 1 year and 4 years postpartum (hF-b–/–), absence of hF-b at 1 year but present at 
4 years (hF-b–/+), presence of hF-b at both 1 and 4 years (hF-b+/+) and presence of hF-b at 1 year but 
absence at 4 years (hF-b+/−). 
characteristic
hF-b–/–
(n = 40)
hF-b–/+
(n = 10) P
hF-b+/+
(n = 5)
hF-b+/–
(n = 10) P
Postpartum interval (years)
    1 year 0.6 [0.3-2.4] 0.6 [0.3-2.4] 0.77 0.5 [0.4-2.1] 0.6 (0.3-2.5) 0.86
    4 years 4.4 [2.7-7.3]* 4.3 [3.7-6.7]* 0.86 5.8 [2.6-6.8]† 4.7 (3.3-6.0)* 0.17
Index pregnancy
    Early-onset PE 24/40 (60) 8/10 (80) 0.30 3/4(75) 8/10 (80) 1.00
    Preterm PE 29/40 (73) 8/10 (80) 1.00 3/5 (60) 8/10 (80) 0.56
    Primiparous at 1 year 37/40 (93) 6/10 (60) < 0.05 3/5 (60) 8/10 (80) 0.56
    Primiparous at 4 years 11/40 (28)* 1/10 (10) 0.42 1/5 (20) 2/10 (20)† 1.00
    GA at birth (weeks) 34.9 (30.8–37.2) 32.6 (27.6-35.2) 0.22 31.9 (26.9-37.9) 31.8 (28.5-35.9) 0.86
    Birth weight (g) 1880 (1073-2770) 1350 (667-2013) 0.19 1603 (455-3018) 1457 (941-2540) 0.86
    SGA neonate 15/40 (38) 7/10 (70) 0.08 2/5 (40) 3/10 (30) 1.00
    IUFD 3/40 (8) 2/10 (20) 0.26 2/5 (40) 0/10 (0) 0.10
    Subsequent pregnancy‡ 27/40 (68) 7/10 (70) 1.00 3/5 (60) 7/10 (70) 1.00
        Recurrent PE 3/27 (11) 0/7 (0) 1.00 3/3 (100) 3/7 (43) 0.20
Maternal offspring pregnancy
    GA at birth (weeks) 39.0 (37.0-40.0) 40.0 (33.5-40.5) 0.78 40.0 (36.0-40.0) 39.0 (34.3-41.3) 1.00
    Preterm birth 6/33 (18) 2/6 (33) 0.58 0/3 (0) 2/6 (33) 0.50
    Birth weight (g) 3150 (2500-3525) 2875 (2500;3500) 0.65 2000 (1990-2000) 3000 (2500-3500) 0.07
     Family history of PE in first-degree 
relative
11/40 (28) 3/10 (30) 1.00 4/5 (80) 1/10 (10) <0.05
cardiac measurements
 LVMi (g/m2)
    1 year 62 (52-69) 60 (57-64) 0.69 70 (48-96) 65 (59-79) 1.00
    4 years 57 (49-64)† 63 (40-66) 0.80 53 (49-70) 62 (49-74) 0.86
 RWT
    1 year 0.31 (0.27;0.35) 0.32 (0.29-0.35) 0.61 0.43 (0.41-0.48) 0.33 (0.30-0.42) 0.05
    4 years 0.33 (0.29;0.36) 0.44 (0.31-0.46)† < 0.05 0.44 (0.38-0.45) 0.32 (0.28-0.37) <0.05
 LVEF (%)
    1 year 65 (61;68) 68 (61-72) 0.38 56 (53-65) 53 (50-59) 0.31
    4 years 65 (63;68) 62 (54-66)† 0.06 57 (55-59) 65 (61-67)* <0.01
 SV (mL)
    1 year 72 (60-84) 83 (73-88) 0.06 63 (58-88) 78 (63-85) 0.59
    4 years 77 (72-87)* 85 (73-88) 0.59 77 (62-121) 83 (70-91) 0.90
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supplemental table 3. Pregnancy characteristics and cardiac indices in 65 formerly pre-eclamptic 
women, excluding those with twin pregnancy, categorized according to absence of heart failure 
stage b (hF-b) at 1 year and 4 years postpartum (hF-b–/–), absence of hF-b at 1 year but present at 
4 years (hF-b–/+), presence of hF-b at both 1 and 4 years (hF-b+/+) and presence of hF-b at 1 year but 
absence at 4 years (hF-b+/−). (continued)
characteristic
hF-b–/–
(n = 40)
hF-b–/+
(n = 10) P
hF-b+/+
(n = 5)
hF-b+/–
(n = 10) P
 SV index (mL/m2)
    1 year 39 (34-48) 48 (40-53) 0.07 35 (28-51) 40 (32-46) 0.86
    4 years 44 (41-49)† 47 (42-51) 0.56 42 (37-58) 42 (37-48) 0.90
 E/A ratio
    1 year 1.62 (1.31-2.03) 1.35 (1.19-1.68) 0.15 1.42 (1.20-1.50) 1.56 (1.16-1.91) 0.52
    4 years 1.62 (1.44-1.94) 1.66 (1.43-1.83 0.84 1.39 (1.19-1.82) 1.60 (1.19;1.88) 0.68
 CO (L/min)
    1 year 4.4 (3.8-5.1) 5.6 (5.3-6.3) < 0.01 4.3 (4.0-6.4) 5.3 (4.1-5.6) 1.00
    4 years 4.8 (4.2-5.7)* 5.3 (4.8-6.2) 0.15 6.1 (4.3-8.2) 5.0 (4.5-5.4) 0.44
 CO index (L/min/m2)
    1 year 2.4 (2.1-3.0) 3.2 (3.0-3.8) < 0.01 2.5 (1.9-3.7) 2.8 (2.2-3.2) 0.95
    4 years 2.7 (2.4-3.0)† 2.9 (2.6-3.4) 0.22 3.2 (2.5-4.0) 2.6 (2.2-2.9) 0.11
 Heart rate (bpm)
    1 year 60 (55-66) 73 (65-77) < 0.01 71 (66-75) 69 (60-78) 0.68
    4 years 62 (57-68) 64 (58-74) 0.34 74 (61-78) 64 (59-70) 0.37
LVEDV (mL)
    1 year 80 (69-86) 90 (77-102) 0.10 74 (57-101) 95 (80-141) 0.13
    4 years 87 (76-101)* 90 (78-103) 0.77 94 (66-145) 101 (72-111) 1.00
Data are given as median [range], n/N (%) or median (interquartile range).
Comparison with 1 year postpartum: *P < 0.01; †P < 0.05.
‡Pregnancy between index pregnancy and second visit.
CO, cardiac output; EA ratio, ratio of early-to-late ventricular filling velocity; GA, gestational age; IUFD, in-
trauterine fetal death; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; 
LVMi, left ventricular mass index; PE, pre-eclampsia; RWT, relative wall thickness; SGA, small-for-gestational 
age; SV, stroke volume.
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supplemental table 4. Metabolic variables in 65 formerly pre-eclamptic women, excluding those 
with twin pregnancy, categorized according to absence of heart failure stage b (hF-b) at 1 year and 
4 years postpartum (hF-b–/–), absence of hF-b at 1 year but present at 4 years (hF-b–/+), presence of 
hF-b at both 1 and 4 years (hF-b+/+) and presence of hF-b at 1 year but absence at 4 years (hF-b+/−). 
Variable
hF-b–/–
(n = 40)
hF-b–/+
(n = 10) P
hF-b+/+
(n = 5)
hF-b+/–
(n = 10) P
Fasting glucose (mmol/L)
    1 year 4.8 (4.6-5.1) 4.9 (4.7-5.4) 0.46 4.8 (4.5-5.1) 4.7 (4.2-5.2) 0.86
    4 years 4.7 (4.4-4.9)† 4.8 (4.4-5.0) 0.86 4.8 (4.7-5.5) 4.8 (4.3-5.4) 0.59
Fasting insulin (mU/L)
    1 year 8.0 (6.0-10.0) 9.0 (7.5-12.5) 0.42 14.0 (9.0-17.0) 10.0 (7.8-14.0) 0.51
    4 years 7.5 (5.4-10.0) 8.0 (6.6-11.9) 0.34 11.0 (4.4-13.2) 8.3 (4.3-13.6) 0.95
HOMAIR
    1 year 1.7(1.4-2.3) 1.9 (1.6-3.0) 0.38 3.0 (1.8-3.8) 2.1 (1.6-3.1) 0.44
    4 years 1.6 (1.1-2.0) 1.7 (1.5-2.5) 0.36 2.5 (0.9-3.0) 1.7 (0.8-3.1) 0.95
Triglyceride (mmol/L)
    1 year 0.8 (0.7-1.0) 0.9 (0.6-1.3) 0.64 0.9 (0.7-1.2) 1.2 (0.5-1.7) 0.68
    4 years 0.9 (0.7-1.1) 0.8 (0.6-0.9) 0.30 1.2 (0.7-1.3) 0.9 (0.7-1.4) 1.00
Total cholesterol (mmol/L)
    1 year 4.6 (4.0-5.2) 4.5 (4.2-4.9) 0.99 4.9 (4.5-5.3) 4.7 (4.2-5.3) 0.51
    4 years 4.5 (4.1-4.9) 4.6 (4.2-5.1) 1.00 4.3 (4.1-5.6) 4.8 (4.3-5.5) 0.44
LDL (mmol/L)
    1 year 2.8 (2.3-3.3) 2.8 (2.4-3.3) 0.78 3.3(2.7-3.7) 3.0 (2.6-3.4) 0.54
    4 years 2.8 (2.3-3.1) 3.0 (2.2-3.4) 0.44 2.6 (2.4-3.8) 2.9 (2.7-3.6) 0.37
HDL (mmol/L)
    1 year 1.3 (1.2-1.5) 1.3 (1.1-1.5) 0.50 1.2 (1.1-1.4) 1.2 (1.1-1.3) 1.00
    4 years 1.4 (1.1-1.5) 1.2 (1.1-1.4) 0.11 1.2 (1.0-1.5) 1.4 (1.1-1.5) 0.77
Albumin/creatinine ratio (g/mol)
    1 year 1.0 (0.4-2.1) 0.8 (0.3-1.7) 0.56 0.1(0.0-0.7) 0.9 (0.3-2.3) 0.17
    4 years 0.5 (0.2-1.8) 0.6 (0.1-1.0) 0.89 0.9 (0.7-4.4) 0.5 (0.4-1.3) 0.10
SBP (mmHg)
    1 year 115 (107-123) 117 (105-122) 0.80 149 (130-157) 123 (114-126) <0.05
    4 years 116 (104-123) 112 (107-122) 0.75 130 (123-137) 119 (109-130) 0.10
DBP (mmHg)
    1 year 68 (63-74) 66 (64-71) 0.68 83 (78-94) 70 (68-78) <0.05
    4 years 72 (66-77)† 72 (69-75) 0.97 87 (77-93) 75 (66-78) 0.06
MAP (mmHg)
    1 year 83 (79-92) 82 (79-89) 0.69 104 (95-114) 87 (83-97) <0.05
    4 years 83 (77-95) 83 (80-86) 0.91 99 (89-106) 86 (80-95) 0.06
Heart rate (bpm)
    1 year 66 (60-74) 74 (62-76) 0.30 70 (66-80) 70 (63-82) 0.95
    4 years 62 (59-71) 69 (64-80) 0.15 65 (62-82) 62 (59-82) 0.37
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supplemental table 4. Metabolic variables in 65 formerly pre-eclamptic women, excluding those 
with twin pregnancy, categorized according to absence of heart failure stage b (hF-b) at 1 year and 
4 years postpartum (hF-b–/–), absence of hF-b at 1 year but present at 4 years (hF-b–/+), presence of 
hF-b at both 1 and 4 years (hF-b+/+) and presence of hF-b at 1 year but absence at 4 years (hF-b+/−). 
(continued)
Variable
hF-b–/–
(n = 40)
hF-b–/+
(n = 10) P
hF-b+/+
(n = 5)
hF-b+/–
(n = 10) P
BMI (kg/m2)
    1 year 22.6 (20.5-24.1) 24.3 (22.2-27.2) 0.15 27.3(23.0-31.2) 27.6 (22.2-34.4) 1.00
    4 years 23.3 (20.8-25.0)† 24.4 (22.4-27.2) 0.32 27.0 (21.5-33.1) 25.2 (22.7-35.0) 1.00
Antihypertensive treatment
    1 year 9/40 (23) 1/10 (10) 0.66 3/5 (60) 1/10 (10) 0.08
    4 years 7/40 (18) 1/10 (10) 1.00 3/5 (60) 2/10 (20) 0.25
Prehypertension
    1 year 7/40 (18) 4/10 (40) 0.20 0/5 (0) 4/10 (40) 0.23
    4 years 5/40 (13) 2/10 (20) 0.62 2/5 (40) 3/10 (30) 1.00
Hypertension
    1 year 9/40 (23) 1/10 (10) 0.66 4/5 (80) 2/10 (20) 0.09
    4 years 9/40 (23) 1/10 (10) 0.66 3/5 (60) 2/10 (20) 0.25
Data are given as median (interquartile range) or n/N (%).
Comparison with 1 year postpartum: *P < 0.01; †P < 0.05.
BMI, body mass index; DBP, diastolic blood pressure; HDL, high density lipoprotein; HOMAIR, homeostatic 
model assessment for insulin resistance; LDL, low density lipoprotein; MAP, mean arterial pressure; SBP, 
systolic blood pressure.
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AbstrAct
Objectives
Pre-eclampsia (PE) is associated with both postpartum endothelial dysfunction and 
asymptomatic structural heart alterations consistent with heart failure Stage B (HF-B). 
In this study, we assessed the relationship between endothelial function, measured by 
flow-mediated dilation (FMD), and HF-B in women with a history of PE.
Methods
This was an observational study in which 67 formerly pre-eclamptic women (≥ 4 years 
postpartum) and 37 healthy parous controls were assessed ultrasonographically for 
cardiac function and geometry, as well as for endothelial function by means of brachial 
artery FMD. HF-B was diagnosed as left ventricular hypertrophy (left ventricular mass 
index (LVMi) > 95g/m2), concentric remodeling (relative wall thickness > 0.42 and LVMi 
≤ 95g/m2), mild systolic dysfunction (left ventricular ejection fraction > 40% and < 55%) 
or asymptomatic valvular disease. Cardiovascular and metabolic syndrome variables 
were compared between women with history of PE and controls, as well as between 
those in the formerly pre-eclamptic group who had HF Stage A, HF-B or no HF. Logistic 
regression analysis was performed to assess the associations of FMD with PE, metabolic 
syndrome risk factors and obstetric parameters.
results
The prevalence of HF-B amongst formerly pre-eclamptic women was three-fold higher 
than that observed for controls (25% vs 8%, P < 0.05), while FMD was lower in formerly 
pre-eclamptic women compared with controls (6.12% vs 8.22%, P < 0.01); history of PE 
remained associated independently with lower FMD after adjusting for metabolic syn-
drome risk factors and obstetric parameters (β, –1.88; 95% CI, −3.59 to −0.18). However, 
HF-B did not relate to low FMD in formerly pre-eclamptic women.
conclusions
Years after pregnancy, formerly preeclamptic women have lower FMD and have HF-B 
more often compared with healthy parous controls. Nonetheless, HF-B was not related 
to reduced FMD.
Keywords
Cardiovascular disease; echocardiography; endothelial dysfunction; endothelial func-
tion; flow-mediated dilation; heart failure; pre-eclampsia
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IntrOductIOn
Cardiovascular disease (CVD) is the number one cause of death in women1,2. While there 
are classical risk factors for CVD that affect both women and men, pre-eclampsia (PE) 
is a risk factor exclusive to women, increasing the risk of CVD two to seven times in the 
first 15 years after pregnancy1,3,4. PE is a pregnancy-related endothelial disorder and is 
one of the major contributors to maternal and fetal morbidity and mortality, occurring in 
3–5% of all pregnancies5–8. PE is the common vascular endpoint of different underlying 
mechanical and biochemical disorders, mostly conventional cardiovascular risk factors 
consistent with metabolic syndrome, capable of jeopardizing both placental and endo-
thelial function9–12. As metabolic syndrome and the associated cardiovascular risk are 
sensitive to lifestyle interventions, timely detection of those specifically at risk may offer 
effective prevention opportunities for cardiovascular risk management in these women. 
In the first year after a pre-eclamptic pregnancy, the prevalence of asymptomatic struc-
tural heart disease, defined as preclinical heart failure Stage B (HF-B), is about one in four 
women13,14. HF-B is considered the stage of heart failure preceding the mortality-related 
symptomatic and clinical stages, Stages C and D15,16. Endothelial dysfunction correlates 
with symptomatic heart failure17,18. A few years after PE, endothelial dysfunction remains 
highly prevalent and it is thought that this asymptomatic vascular condition relates to the 
increased risk of CVD after PE19–28. On the one hand, the unfavorable structural heart al-
terations after PE may relate to traditional cardiovascular risk factors; on the other hand, 
they could be a result of endothelial dysfunction1,18. Therefore, in this study, we assessed 
the relationship between endothelial function, along with components of metabolic syn-
drome, and asymptomatic structural heart dysfunction in formerly pre-eclamptic women 
and healthy parous controls.
MethOds
The protocol of this observational study was approved by the Medical Ethics Committee 
of the Radboud University Medical Center (NL32718.091.10). The procedures followed 
were in accordance with institutional guidelines and adhered to the principles of the 
Declaration of Helsinki and Title 45, US Code of Federal Regulation, Part 46, Protection 
of Human Subjects, Revised November 13, 2001, Effective December 13, 2001. The study 
population was recruited between 2009 and 2011.
study population
At the Radboud University Medical Center, women with a history of PE were evaluated 
routinely for cardiovascular function at approximately 1 year postpartum. For this study, 
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those women who were at least 4 years postpartum were reinvited by mail to participate 
in a second follow-up cardiovascular assessment. The study was completed in the east of 
the Netherlands, where the average socioeconomic status is known to be representative 
of the country as a whole and where the prevalence of immigrants is low. We included for 
this study 92 women with a history of PE without comorbidity (diabetes mellitus, autoim-
mune disease or pre-existing hypertension) prior to their index pregnancy. Nine of these 
women were excluded due to incomplete echocardiographic work-up, insufficient to di-
agnose HF-B, and 16 due to an incomplete flow-mediated dilation (FMD) measurement. 
Controls were recruited by advertisement in local newspapers, schools and childcare 
centers in the same catchment area as that from which the formerly pre-eclamptic women 
originated. Forty-seven control women were included with a history of pregnancy un-
complicated by gestational hypertension, PE, HELLP syndrome, fetal growth restriction, 
placental abruption or intrauterine fetal death. Of these women, nine were excluded due 
to incomplete echocardiographic work-up, insufficient to diagnose HF-B, and one due 
to incomplete FMD measurement. Pregnancy charts were checked to ensure that preg-
nancies were uncomplicated. In total, 67 formerly pre-eclamptic women and 37 control 
women were included. 
PE was diagnosed, according to the criteria set by the International Society of Hy-
pertension in Pregnancy, as new-onset hypertension, defined as systolic blood pressure 
(SBP) ≥ 140mmHg and/or diastolic blood pressure (DBP) ≥ 90mmHg after 20weeks’ 
gestation, and proteinuria exceeding 0.3g/day29. Early-onset PE was diagnosed as the 
development of PE before 34weeks of gestation. Preterm PE was defined as PE requiring 
delivery before 37weeks of gestation. 
Five women gave birth to twins. All birth weights were analyzed. Most women in the 
PE and control groups were of European origin, but two were of Turkish and one was of 
Moroccan origin. At the time of assessment, none of the women was pregnant, and all 
had stopped breastfeeding and were not using oral contraceptives. Women who became 
pregnant after the index pregnancy had to be at least 6months postpartum to be included 
in the second follow-up cardiovascular assessment.
cardiovascular assessment
Each cardiovascular risk evaluation started at 08.00h in a temperature-controlled room 
(22 °C), after an overnight fast. Measurements were performed in the follicular phase of 
the menstrual cycle, between days 3 and 11 after the onset of menses30–32. Participants 
were not allowed to talk during measurements and external disturbances were kept to 
a minimum. Measurements were performed following a standardized study protocol by 
an experienced physician. Cardiovascular screening consisted of measuring body mass 
(kg; Seca 888 scale, Hamburg, Germany) and height (m) in order to calculate body mass 
index (BMI). Women rested for at least 15min before measurement of SBP, DBP, mean 
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arterial pressure (MAP) and heart rate (HR). Measurement lasted for 30min (at 3-min 
intervals) and was taken with the woman in the upright sitting position using a semi-
automatic oscillometric device (Dinamap Vital Signs Monitor 1846; Critikon, Tampa, 
FL, USA) with a cuff size recommended for arm circumference. Median values were used 
for analysis. Hypertension was diagnosed as SBP ≥ 140mmHg and/or DBP ≥ 90mmHg 
and/or antihypertensive medication being taken. Prehypertension was defined as SBP 
120–139mmHg and/or DBP 80–89mmHg. Venous blood samples taken at the level of 
the antecubital vein were analyzed for fasting glucose (mmol/L), fasting insulin (mmol/L) 
and lipids (mmol/L), including low-density lipoprotein (LDL), high-density lipoprotein 
(HDL), triglycerides and total cholesterol (Aeroset, Abbot Laboratories, IL, USA). The 
homeostatic model assessment index for insulin resistance (HOMAIR) was calculated as 
insulin (mU/L)×glucose (mmol/L)/22.533. All patients collected their urine in the 24h 
before cardiovascular screening. The 24-h urine sample was evaluated for albumin and 
creatinine to diagnose (micro)albuminuria corrected for creatinine output (g/mol cre-
atinine) (Aeroset). Participants filled out a validated questionnaire consisting of general 
history, current medication intake, intoxicants (smoking was defined as ≥ 1 cigarette per 
day), lifestyle factors and family history of CVD (in first line relatives < 60 years of age).
Flow-mediated dilation measurements
Measurement of FMD was used to assess endothelial function as it is a reproducible, 
accurate and non-invasive method34,35. FMD characterizes the change in artery diameter 
in response to reactive hyperemia19. The resulting increase in shear stress leads to the en-
dothelium releasing vasodilators, including nitric oxide, which cause dilation in a healthy 
artery19,34,36. FMD and brachial artery shear pattern measurements were performed under 
standardized conditions in a temperature-controlled (22 ± 0.5°C), quiet room, according 
to recent guidelines28,32,37. Subjects were supine with the arm placed in an extended posi-
tion, immobilized with foam, at an angle of ~80° from the torso28,32. To induce forearm 
ischemia, a rapid inflation and deflation pneumatic cuff (D. E. Hokanson, Bellevue, WA, 
USA) was positioned on the forearm distal to the olecranon28,32. The brachial artery was 
imaged in the distal one-third of the upper arm (2–5cm above the antecubital fossa) using 
a 10-MHz multifrequency linear array probe attached to a high-resolution ultrasound 
machine (T3000; Terason Corp., Burlington, MA, USA)28,32. Ultrasound was also used 
to measure continuous Doppler velocity with the lowest possible insonation angle of < 
60°28,32. Shear rate was calculated as 4×velocity/diameter32,38. 
Thereafter, the rapid inflation/deflation forearm cuff was inflated (> 200mmHg) for 5 
min28,32. Diameter and flow recordings were resumed 30s before deflation of the cuff and 
continued for 3min after deflation32,37. To minimize investigator bias, FMD analysis was 
performed using custom-designed edge-detection and wall-tracking Digital Imaging and 
Communications in Medicine-based software (National Electrical Manufacturers Asso-
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ciation, Rosslyn, VA, USA)28,32,37,39. Peak diameter was detected automatically according 
to an algorithm that is described in detail elsewhere32,40. Using this technique, data can 
be analyzed with a temporal resolution of 30Hz and a spatial resolution of ~0.0065cm for 
diameter and ~1cm/s for velocity32, and FMD has an intraobserver coefficient of repeated 
measures of 6.7%39. Postdeflation shear rate data (derived from simultaneously acquired 
velocity and diameter measurements at 30Hz) were used for calculating the area under 
the shear-rate curve for data up to the point of maximal postdeflation diameter (FMD) 
for each individual28,32.
echocardiographic measurements
Echocardiographic measurements were made using a phased-array echocardiographic 
Doppler system (Vivid 7, GE Vingmed Ultrasound, Horten, Norway). Two-dimensional, 
M-mode and Doppler echocardiography were performed in accordance with the recom-
mendation of the American Society of Echocardiography (ASE)41. Using M-mode in 
the parasternal long-axis view, we measured left ventricular end-diastolic (LVEDd) and 
end-systolic (LVESd) diameters (mm), end-diastolic interventricular septum thickness 
(IVST; mm) and the posterior (inferolateral) wall thickness (PWT; mm). As recom-
mended by the ASE, left ventricular mass (LVM; g) was determined using the formula 0.8 
× (1.04 ((LVEDd + PWT + IVST)3 − (LVEDd)3)) + 0.6, indexed for body surface area42. 
Relative wall thickness (RWT) was computed using the formula (2×PWT)/LVEDd)42. 
Left ventricular end-diastolic (LVEDV, mL) and end-systolic (LVESV, mL) volumes were 
determined using the Teichholz formula43. Left ventricular ejection fraction (LVEF, %) 
was calculated using the formula ((LVEDV – LVESV)/(LVEDV))×100. Heart rate (HR, 
bpm) was calculated by multiplying by 60 the reciprocal of the mean of five consecutive 
RR intervals on the electrocardiogram. Mean aortic velocity time integral (VTI, cm) was 
calculated by averaging the outer edge tracings of five consecutive continuous wave Dop-
pler registrations of the left ventricular outflow tract velocity. Stroke volume (SV, mL) was 
computed by taking the product of VTI and mid-systolic cross-sectional area (cm2) at the 
level of the left ventricular outflow tract in the parasternal long-axis view. Cardiac output 
(CO, L/min) was calculated by multiplying SV by HR. Assessments were executed offline 
using EchoPAC PC SW (GE Vingmed Ultrasound) version 6.1.2.
definition of heart failure stage A
Heart failure Stage A (HF-A) was defined as the presence of hypertension (SBP ≥ 
140mmHg and/or DBP ≥ 90mmHg and/or use of antihypertensive medication), athero-
sclerotic disease, diabetes mellitus (fasting glucose ≥ 6.1mmol/L), obesity (BMI ≥ 30kg/
m2) or metabolic syndrome16. A modified metabolic syndrome was defined, using the 
WHO criteria, as insulin resistance (fasting insulin ≥ 9.2mU/L and/or fasting glucose ≥ 
6.1mmol/L and/or HOMAIR ≥ 2.2) and two or more of the following factors: hyperten-
6 | Maastricht University
sion (SBP ≥ 140mmHg and/or DBP ≥ 85mmHg and/or use of antihypertensive medica-
tion), obesity (BMI ≥ 30kg/m2), dyslipidemia (triglycerides ≥ 1.69mmol/L and/or HDL 
< 1.0mmol/L) and/or microalbuminuria (urine albumin to creatinine ratio ≥ 2.5g/mol 
creatinine)44.
definition of heart failure stage b
HF-B was defined, according to the American Heart Association (AHA)16, as the presence 
of a former myocardial infarction, left ventricular hypertrophy (left ventricular mass in-
dex (LVMi) > 95g/m2), concentric remodeling (RWT > 0.42 and LVMi ≤ 95g/m2), mildly 
impaired left ventricular ejection fraction (LVEF > 40% and < 55%) or asymptomatic 
valvular disease42. Asymptomatic valvular disease was defined as at least mild aortic valve 
insufficiency or mild mitral valve insufficiency with mild thickening of the mitral valve. 
Asymptomatic cardiac abnormality with preserved ejection fraction was defined as HF-B 
with LVEF ≥ 55%42.
data analysis
Statistical analyses were performed using SPSS Statistics version 21.0 (IBM Corp., 
Armonk, NY, USA). Continuous data were analyzed using the Mann–Whitney U-test 
for intergroup differences. Continuous data are reported as median with interquartile 
range (IQR). The Kruskal–Wallis test was used to analyze differences between more than 
two groups of continuous data. Dichotomous data were analyzed using the chi-square 
or Fisher’s exact test for intergroup differences, reported as n (%). Associations between 
FMD and PE, metabolic syndrome risk factors and obstetric parameters were analyzed 
using uni- and multivariable linear regression. A two-sided P-value of < 0.05 was consid-
ered statistically significant. Based on findings of Melchiore et al.13 on the prevalence of 
HF-B at 1 year postpartum in formerly preterm pre-eclamptic women (41%) compared 
with controls (6%), and on our observations14 in the first year after pre-eclamptic gesta-
tion (25%) compared with controls (7%), the sample size needed was estimated using a 
prevalence of HF-B of 33% in formerly pre-eclamptic women and 6% in controls. The 
required sample size was calculated using a desired power of 0.80 and a two-sided alpha 
of 0.05. A minimum of 33 participants for each group was necessary for determining 
statistical significance. PE is a vascular disease of heterogeneous origin. To compensate 
for possible larger heterogeneity in hemodynamic assessments in formerly pre-eclamptic 
women than in controls, we aimed to include measurements of two formerly pre-eclamp-
tic women for every one healthy parous control in the analysis.
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results
Characteristics of the formerly pre-eclamptic and control groups are presented in Table 
1. The formerly pre-eclamptic group was on average 4 years younger compared with the 
control group (P < 0.01). Moreover, more women with a history of PE were obese (18% vs 
3%, P < 0.05) and used antihypertensive medication (18% vs 0%, P < 0.01). Formerly pre-
eclamptic women underwent postpartum measurement at a shorter median postpartum 
interval than the control group (5.3 (IQR, 4.4–6.4) vs 8.3 (IQR, 6.6–9.9) years, P < 0.01). 
Birth weight was lower in the formerly pre-eclamptic group compared with the control 
group (1615 (IQR, 1034–2513) vs 3260 (IQR, 3000–3690) g; P < 0.01). Forty out of 67 
women in the formerly pre-eclamptic group had a subsequent pregnancy (60%), of which 
17 (43%) had recurrent PE.
table 1. baseline characteristics of women with history of pre-eclampsia (Pe) and those with history 
of uncomplicated pregnancy (controls).
characteristic
Formerly Pe
(n = 67)
controls
(n = 37) P
Patient
    Age (years) 36 (33-39) 40 (37-43) <0.01
    Height (m) 1.68 (1.65-1.73) 1.72 (1.67-1.76) 0.14
    Weight (kg) 70 (62-83) 65 (58-76) 0.15
    BMI (kg/m2) 24 (21-29) 23 (21-25) <0.05
    Obese (BMI ≥ 30 kg/m2) 12/67 (18) 1/37 (3) <0.05
    Smoker 5/67 (7) 3/37 (8) 1.00
    Alcohol use 15/67 (22) 26/37 (70) <0.01
    Family history of CVD 30/67 (45) 15/37 (41) 0.68
    Antihypertensive treatment 12/67 (18) 0/37 (0) <0.01
    Postpartum interval (years) 5.3 (4.4-6.4) 8.3 (6.6-9.9) <0.01
Index pregnancy
    Early-onset PE 40/64 (63) NA NA
    Preterm PE 51/67 (76) NA NA
    Primiparous 49/67 (73) 3/36 (8) <0.01
    GA at birth (weeks) 33 (30-37) 40 (39-41) <0.01
    Birth weight (g) 1615 (1034-2513) 3260 (3000;3690) <0.01
    SGA neonate 30/67 (45) 4/37 (11) <0.01
    IUFD 6/66 (9) NA NA
Data are given as median (interquartile range) or n/N (%). 
BMI, body mass index; CVD, cardiovascular disease; GA, gestational age; IUFD, intrauterine fetal death; NA, 
not applicable; SGA, small-for-gestational age.
8 | Maastricht University
Formerly pre-eclamptic vs control group
Cardiovascular and metabolic variables are presented in Table 2. Incidence of HF-A was 
eight-fold higher in the formerly pre-eclamptic group compared with the control group 
(24% vs 3%, P < 0.01). Of the HF-A variables, obesity was more prevalent in the formerly 
pre-eclamptic group as compared with controls. 
HF-B was more common in formerly pre-eclamptic women as compared with controls 
(25% vs 8%, P < 0.05). In formerly pre-eclamptic women with HF-B, none had previous 
myocardial infarction, 6% had left ventricular (LV) hypertrophy, 65% had concentric 
remodeling, 29% had mildly impaired LVEF and 6% had asymptomatic valve disease. 
Of the three controls with HF-B, none had previous myocardial infarction or LV hyper-
trophy, one had concentric remodeling, two had mildly reduced LVEF, and none had 
asymptomatic valve disease. 
As shown in Table 2, the formerly pre-eclamptic group had higher SBP and HR com-
pared with controls. DBP, MAP, SV, CO, LVEDV, LVEF, EA ratio, LVM index and RWT 
did not differ between the groups. 
Formerly pre-eclamptic women had lower FMD compared with controls (6.12% (IQR, 
4.82–8.30%) vs 8.22% (IQR, 5.79–11.33%), P < 0.01), whereas baseline diameter of the 
brachial artery was similar. 
table 2. cardiovascular and metabolic syndrome variables in formerly pre-eclamptic (Pe) women 
and women with history of uncomplicated pregnancy (controls).
Parameter
Formerly Pe
(n = 67)
controls
(n = 37) P
heart failure stage A 16/67 (24) 1/37 (3) <0.01
    Hypertension 10/67 (15) 1/37 (3) 0.09
    Atherosclerotic disease 1/64 (2) 0/37 (0) 1.00
    Diabetes mellitus 3/67 (4) 0/37 (0) 0.55
    Obesity (BMI ≥ 30 kg/m2) 8/67 (12) 0/37 (0) <0.05
    Metabolic syndrome 5/67 (7) 0/37 (0) 0.16
heart failure stage b 17/67 (25) 3/37 (8) <0.05
    Myocardial infarction 0/67 (0) 0/37 (0) NA
    LV hypertrophy 1/67 (1) 0/37 (0) 1.00
    Concentric remodeling 11/67 (16) 1/37 (3) 0.05
    Mildly impaired LVEF 5/67 (7) 2/37 (5) 1.00
    Asymptomatic valve disease 1/67 (1) 0/37 (0) 1.00
    HFpEF 12/67 (18) 1/37 (3) <0.05
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table 2. cardiovascular and metabolic syndrome variables in formerly pre-eclamptic (Pe) women 
and women with history of uncomplicated pregnancy (controls). (continued)
Parameter
Formerly Pe
(n = 67)
controls
(n = 37) P
cardiac function
    SBP (mmHg) 116 (109-123) 109 (101-118) <0.01
    DBP (mmHg) 72 (68-79) 72 (68-77) 0.70
    MAP (mmHg) 85 (81-91) 83 (75-89) 0.11
    Heart rate (bpm) 65 (61-78) 62 (55-66) <0.01
    Stroke volume (mL) 77 (70-86) 73 (62-86) 0.26
    Cardiac output (L/min) 5.1 (4.4-6.1) 4.8 (4.1-6.0) 0.31
    LV end diastolic volume (mL) 93 (79-113) 87 (71-99) 0.07
    LVEF (%) 63 (60-68) 61 (59-66) 0.36
    EA ratio 1.57 (1.36-1.90) 1.49 (1.40-1.73) 0.28
    LV mass index (g/m2) 55 (49-67) 63 (55-67) 0.09
    Relative wall thickness 0.35 (0.31-0.39) 0.33 (0.29-0.36) 0.12
FMd
    Baseline diameter (cm) 0.30 (0.27-0.32) 0.30 (0.28-0.32) 0.48
    Peak diameter (cm) 0.31 (0.29-0.34) 0.33 (0.30-0.35) 0.12
    FMD (%) 6.12 (4.82-8.30) 8.22 (5.79-11.33) <0.01
    Shear rate (s -1) 22792 (17676-32480) 29484 (21024-34290) 0.06
Metabolic syndrome
    Fasting glucose (mmol/L) 4.8 (4.5-5.0) 4.7 (4.5-5.0) 0.21
    Fasting insulin (mU/L) 7.9 (5.9-10.7) 6.2 (4.3-8.1) <0.01
    HOMAIR 1.7 (1.2-2.5) 1.4 (0.9-1.7) <0.01
    Triglycerides (mmol/L) 0.9 (0.7-1.3) 0.8 (0.6-1.1) 0.12
    HDL (mmol/L) 1.3 (1.1-1.5) 1.6 (1.4-1.8) <0.01
    Albumin/creatinine ratio (g/mol) 0.7 (0.3-1.2) 0.5 (0.4-0.8) 0.51
    Pre-hypertension 14/67 (21) 8/37 (22) 0.93
    Hypertension untreated 3/67 (4) 1/37 (3) 1.00
    Antihypertensive treatment 12/67 (18) 0/37 (0) <0.01
Data are given as median (interquartile range) or n/N (%). 
BMI, body mass index; DBP, diastolic blood pressure; EA ratio, ratio of early (E) to late (A) ventricular filling 
velocity; FMD, flow-mediated dilation; HDL, high-density lipoprotein; HOMAIR, homeostatic model assess-
ment for insulin resistance; HFpEF, heart failure with preserved ejection fraction; LV, left ventricular; LVEF, 
left ventricular ejection fraction; MAP, mean arterial pressure; NA, not applicable; SBP, systolic blood pres-
sure.
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Of the metabolic syndrome variables, fasting insulin and HOMA were significantly 
higher and HDL significantly lower in the formerly pre-eclamptic group compared with 
the control group. 
A subsequent pregnancy after the index one in the formerly pre-eclamptic group did 
not affect the prevalence of HF-A or HF-B, nor FMD or its component measurements, or 
metabolic syndrome variables (Tables S1 and S2). 
The associations between FMD and PE, metabolic risk factors and obstetric parameters 
are presented in Table 3. On univariable analysis, history of PE, postpartum interval, 
primiparity, impaired fasting insulin and obesity were associated with FMD peak per-
centage. The multivariable linear regression model showed R2 =0.33. In the multivariable 
model, history of PE remained associated significantly with FMD, with β=−1.88 (95% CI, 
−3.59 to −0.18). Moreover, impaired fasting insulin had a significant β of −1.63 (95% CI 
−3.21 to −0.05). The other variables, i.e. postpartum interval, primiparity, age, diabetes 
mellitus, hypertension, obesity, dyslipidemia and microalbuminuria, were not associated 
significantly with FMD on multivariable analysis.
no hF vs hF-A vs hF-b
Table 4 presents the cardiovascular and metabolic syndrome variables in formerly pre-
eclamptic women, subdivided according to those without HF, those with cardiovascular 
risk factor (HF-A) and those with functional or structural cardiac abnormality (HF-B). 
Of the cardiovascular variables, SBP, DBP and MAP were significantly higher in the HF-A 
compared with the no-HF subgroup; HR did not differ between these subgroups. Of the 
cardiac indices, only LVEF was significantly different (lower) in the HF-A compared with 
the no-HF subgroup. The HF-B subgroup had higher SBP, DBP and MAP compared with 
table 3. univariable and multivariable linear regression model analysis of associations between 
flow-mediated dilation peak percentage and pre-eclampsia (Pe), metabolic syndrome risk factors 
and obstetric parameters.
Parameter
univariable Multivariable*
β (cI) P β (cI) P
History of PE -2.40 (-3.64 to -1.16) <0.01 -1.88 (-3.59 to -0.18) <0.05
Postpartum interval 0.31 (0.08 to 0.54) <0.01 0.28 (-0.02 to 0.58) 0.07
Primipartiy -2.17 (-3.64 to -0.71) <0.01 -1.32 (-2.82 to 0.17) 0.08
Age 0.05 (-0.10 to 0.20) 0.48 -0.15 (-0.33 to 0.03) 0.09
Impaired fasting insulin -2.16 (-3.54 to -0.79) <0.01 -1.63 (-3.21 to -0.05) <0.05
Diabetes mellitus -0.77 (-4.56 to 3.02) 0.69 0.39 (-3.29 to 4.08) 0.83
Hypertension -1.21 (-2.95 to 0.53) 0.17 0.08 (-1.90 to 2.05) 0.94
Obesity -1.96 (-3.84 to -0.07) <0.05 -0.81 (-2.82 to 1.21) 0.43
Dyslipidemia -2.36 (-4.85 to 0.13) 0.06 -0.82  (-3.27 to 1.64) 0.51
Microalbuminuria -0.69 (-2.76 to 1.39) 0.51 0.29 (-1.64 to 2.23) 0.76
*R2 =0.33, indicating amount of variability in outcome accounted for by predicted variables.
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the no-HF subgroup; HR did not differ between these subgroups. Of the cardiac indices, 
LVEF was lower in the HF-B compared with the no-HF subgroup, and RWT was higher 
in the HF-B subgroup compared with both the no-HF and HF-A subgroups. 
table 4. cardiovascular and metabolic syndrome variables in women with history of pre-eclampsia, 
according to whether they had no heart failure (no hF), hF stage A (hF-A) or hF stage b (hF-b).
Parameter
no hF
(n = 34)
hF-A
(n = 16)
hF-b
(n = 17) P
cardiac assessment
    SBP (mmHg) 112 (107-118) 125 (115-131)* 119 (109-128)* <0.01
    DBP (mmHg) 71 (66-74) 76 (69-85)* 74 (71-82)* <0.05
    MAP (mmHg) 82 (77-86) 89 (86-97)* 89 (82-93)* <0.01
    Heart rate (bpm) 65 (61-77) 66 (60-82) 66 (64-79) 0.68
    Stroke volume (mL) 77 (70-86) 83 (71-88) 75 (66-87) 0.42
    Cardiac output  (L/min) 4.8 (4.3-5.9) 5.7 (4.4-6.3) 5.1 (4.3-6.4) 0.31
    LV end diastolic volume (mL) 93 (81-103) 100 (79-121) 90 (72-113) 0.52
    LV ejection fraction (%) 66 (63-70) 61 (58-63)* 59 (54-65)* <0.01
    E/A ratio 1.68 (1.39-2.12) 1.50 (1.30-1.76) 1.50 (1.12-1.84) 0.18
    LV mass index (g/m2) 55 (50-66) 61 (49-67) 53 (42-72) 0.76
    Relative wall thickness 0.33 (0.29-0.37) 0.34 (0.32-0.36) 0.44 (0.36-0.47)* † <0.01
FMd
    Baseline diameter (cm) 0.29 (0.26-0.31) 0.30 (0.28-0.34) 0.30 (0.27-0.34) 0.41
    Peak diameter (cm) 0.31 (0.28-0.33) 0.31 (0.29-0.36) 0.32 (0.29-0.36) 0.31
    FMD (%) 5.79 (4.72-8.81) 5.31 (4.10-7.02) 6.87 (6.07-7.88) 0.14
    Shear rate (s-1) 21228 (18579-29731) 25334 (15614-40402) 28143 (12864-39895) 0.87
Metabolic syndrome
    Fasting glucose (mmol/L) 4.7 (4.4-4.9) 5.3 (4.9-5.8)* 4.7 (4,5-4.9) † <0.01
    Fasting insulin (mU/L) 6.7 (5.1-8.9) 10.3 (7.5-13.5)* 9.0 (6.2-14.6)* <0.01
    HOMAIR 1.3 (1.1-1.9) 2.5 (1.9-3.4)* 1.9 (1.2-3.0)* <0.01
    Triglycerides (mmol/L) 0.8 (0.7-1.1) 1.2 (0.9-1.4)* 0.8 (0.7-1.3) † <0.05
    HDL (mmol/L) 1.3 (1.1-1.5) 1.3 (1.1-1.4) 1.3 (1.1-1.5) 0.85
    Albumin/creatinine ratio (g/mol) 0.4 (0.1-1.1) 0.8 (0.4-5.1) 0.7 (0.4-1.1) 0.18
    Pre-hypertension 4/34 (12) 4/16 (25) 6/17 (35) 0.11
    Hypertension untreated 0/34 (0) 3/16 (19)* 0/17 (0) <0.05
    Antihypertensive treatment 0/34 (0) 7/16 (44)* 5/17 (29)* <0.01
Data are given as median (interquartile range) or n/N (%).
*P < 0.05 vs no HF. †P < 0.05 vs HF-A.
DBP, diastolic blood pressure; E/A ratio, ratio of early (E) to late (A) ventricular filling velocity; FMD, flow-
mediated dilation; HDL, high-density lipoprotein; HOMAIR, homeostatic model assessment for insulin resis-
tance; LV, left ventricular; MAP, mean arterial pressure; SBP, systolic blood pressure.
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The baseline diameter of the brachial artery was comparable between the three sub-
groups. Moreover, FMD (%), FMD peak diameter and shear rate did not differ between 
the subgroups. Of the metabolic syndrome variables, fasting glucose, fasting insulin, 
HOMA and triglycerides were significantly higher in the HF-A subgroup compared 
with the no-HF subgroup. Moreover, more women in the HF-A subgroup had untreated 
hypertension and were using antihypertensive medication compared with the no-HF 
subgroup. Fasting insulin and HOMA were higher in the HF-B compared with the no-HF 
subgroup. Furthermore, more women in the HF-B subgroup were using antihypertensive 
medication compared with the no-HF subgroup.
dIscussIOn
To the best of our knowledge, this is the first demonstration of the assumed association 
between endothelial dysfunction, measured by FMD, and prevalence of HF-B after pre-
eclampsia. First, we showed that formerly pre-eclamptic women have lower endothelium-
dependent FMD compared with women with a history of only normotensive gestation, 
indicating attenuated endothelial function in the formerly pre-eclamptic group. More-
over, compared with controls, formerly pre-eclamptic women had an eight-fold higher 
prevalence of cardiovascular risk factor (HF-A) and three-fold higher prevalence of 
HF-B. Nonetheless, we did not observe any association between endothelial dysfunction 
and the prevalence of HF-A or HF-B in formerly pre-eclamptic women. 
PE is associated with endothelial dysfunction that may persist during the first years 
after PE7,9,10,12,19–28. In this study, we found that at least 4 years postpartum, endothelial 
function, as indicated by FMD, was significantly lower in formerly pre-eclamptic women 
than in healthy controls, which is in line with earlier findings19–28 and in contrast with 
other studies with a follow-up period of at least 10 years20. We also found that PE was 
associated independently with reduced FMD after correction for metabolic risk factors, 
as was insulin. 
Vessel dilation is mediated by endothelium-dependent release of nitric oxide (NO) in 
response to reactive hyperemia and increased endothelial shear stress occurring after 
deflation of a perfusion-obstructive cuff19,34,36. As such, healthy endothelium has an 
important vasoactive function in stabilizing blood pressure intrinsically in response to 
alterations in flow, by the production of rapidly released short-acting NO, which instantly 
lowers underlying vessel muscle tone34,45. On the one hand, shallow FMD may therefore 
reflect impaired endothelial function. On the other hand, in general, the observed de-
creased endothelial function after PE can also originate from impaired bioavailability 
of NO, restricted vasodilatory capacity due to mechanical changes stiffening the arterial 
wall or diminished signaling in smooth-muscle cells46. A few postpartum studies have 
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showed reduced FMD originating from NO-dependent mechanisms, suggesting a less 
prominent effect of vascular stiffening in hampering FMD21,26–28. However, one study 
observed that formerly pre-eclamptic women had reduced endothelium-dependent and 
NO-mediated FMD, as compared with controls23. Moreover, endothelial function could 
be normalized by aerobic exercise28. Even though we did not perform FMD with NO 
donor administration, given the young age of the cohort, endothelial dysfunction is most 
likely the cause of reduced FMD in the formerly pre-eclamptic group21. 
Impaired FMD is considered a strong predictor for cardiovascular events, independent 
of other traditional risk factors, and may be an important mediator between PE and 
the two- to seven-fold increased risk of remote CVD at a relatively young age4,47–49. A 
meta-analysis by Inaba et al. showed that a 1% decrease in FMD is related to an 8% in-
creased risk of CVD events in population-based convenience cohort studies49. Moreover, 
several studies showed impaired FMD in symptomatic stages of HF (i.e. HF-C or -D)50. 
Therefore, we expected to find a positive relationship between impaired FMD after PE 
and HF-B. In our cohort, we did not find such a relationship; although not expected, 
this is in line with the findings of a study by Muiesan et al., in which FMD was studied 
in relation to different LV geometric patterns in hypertensive patients51. They observed 
that the presence of endothelial dysfunction was not associated with differences in LV 
geometric patterns, suggesting that independent and different mechanisms may account 
for the presence of LV hypertrophy and endothelial dysfunction51. Moreover, the use of 
antihypertensive medication in the HF-B subgroup may also have attenuated the dif-
ferences in endothelial function between the HF-B subgroup and the HF-A and no-HF 
subgroups. Antihypertensive treatment may reverse cardiac remodeling, enhance cardiac 
function and improve endothelial function, by reducing afterload or shear stress, or by 
their antioxidant activity52,53. The role of changes in morphological, mechanical and 
functional properties of peripheral conduit arteries in relation to HF still needs to be 
elucidated. 
This study has several limitations that should be taken into account. First, most of the 
formerly pre-eclamptic women were of European ethnic origin. Therefore, our results 
might not be fully generalizable to women of other ethnic origins. Second, HF is a cluster 
of different entities that are likely to have different physiological backgrounds that might 
have influenced our findings. However, we used the currently used definition of the AHA 
in the hope that this gives an accurate reflection of HF-B. Dividing the HF-B group into 
subgroups would have resulted in very low sample sizes with insufficient power. Subdi-
viding the formerly pre-eclamptic women into three subgroups and therefore reducing 
the number of women per group increased the type 1 error risk. In anticipation of this, we 
analyzed our data non-parametrically. Despite smaller numbers, we did detect clinically 
relevant significant differences, which also shed light on the pathophysiological course 
of cardiac adjustments in women at risk for CVD. Therefore, it would be useful in future 
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studies to include more women. Third, both groups had different recruitment procedures 
as healthy women do not routinely visit a gynecologist in the Netherlands. Therefore, 
we had to recruit controls by advertisement. It could be that women who replied had 
subtle signs of CVD that led them to question their risk. However, they may also have 
been concerned about their health, which could suggest that they have a healthy lifestyle. 
Moreover, controls had a longer postpartum interval, which might also induce certain 
bias as postpartum recovery can take, in certain cases, a few months to complete. How-
ever, it is not known at what interval it is optimal to perform cardiovascular screening. In 
this study, short-term pregnancy effects were excluded. 
In conclusion, we showed lower FMD in formerly pre-eclamptic women 5–8 years 
postpartum as compared with women with a history of healthy pregnancy. Formerly 
pre-eclamptic women had an eight-fold higher prevalence of HF-A and a three-fold 
higher prevalence of HF-B compared with controls. However, no difference in FMD was 
found between formerly PE patients with HF-B and those without, suggesting different 
mechanisms underlying the subclinical stages of HF.
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supplemental information
supplemental table 1. baseline characteristics of women with history of pre-eclampsia (Pe) sub-
divided in women who did not became pregnant again after the index pregnancy (no subsequent 
pregnancy) and women who did become pregnant after the index pregnancy (subsequent preg-
nancy).
no subsequent pregnancy
(n = 27)
subsequent pregnancy
(n = 40) P
Patient
    Age (years) 36 (32-40) 36 (34-39) 0.91
    Height (m) 1.69 (1.65-1.73) 1.68 (1.65-1.74) 0.83
    Weight (kg) 73 (63-88) 69 (61-81) 0.41
    BMI (kg/m2) 25 (22-29) 24 (21-28) 0.31
    Obesity (BMI ≥ 30 kg/m2) 6/27 (22) 6/40 (15) 0.52
    Smoker 4/27 (15) 1/40 (3) 0.15
    Alcohol use 5/27 (19) 10/40 (25) 0.53
    Family history of CVD 10/27 (37) 20/40 (50) 0.30
    Antihypertensive treatment 3/27 (11) 9/40 (23) 0.34
    Postpartum interval (years) 4.6 (4.3-5.8) 5.4 (4.6-7.2) <0.05
Index pregnancy
    Early-onset PE 19/27 (70) 21/37 (57) 0.27
    Preterm PE 24/27 (89) 27/40 (68) <0.05
    Primiparous 20/27 (74) 29/40 (73) 0.89
    GA at birth (weeks) 33 (30-35) 35 (31-37) 0.22
    Birth weight (g) 1511 (955-2075) 1730 (1066-2800) 0.20
    SGA neonate 13/27 (48) 17/40 (43) 0.65
    IUFD 0/27 (0) 6/39 (15) 0.07
Data are given as median (interquartile range) or n/N (%). 
BMI, body mass index; CVD, cardiovascular disease; GA, gestational age; IUFD, intrauterine fetal death; NA, 
not applicable; SGA, small-for-gestational age.
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supplemental table 2. cardiovascular and metabolic syndrome variables in former pre-eclamptic 
women (Pe) subdivided in women who did not became pregnant again after the index pregnancy 
(no subsequent pregnancy) and women who did become pregnant after the index pregnancy (sub-
sequent pregnancy).
no subsequent pregnancy
(n = 27)
subsequent pregnancy
(n = 40) P
heart failure stage A 5/27 (19) 11/40 (28) 0.40
    Hypertension 4/27 (15) 6/40 (15) 1.00
    Atherosclerotic disease 0/26 (0) 1/38 (3) 1.00
    Diabetes mellitus 1/27 (4) 2/40 (5) 1.00
    Obesity (BMI ≥ 30 kg/m2) 3/27 (11) 5/40 (13) 1.00
    Metabolic syndrome 2/27 (7) 3/40 (8) 1.00
heart Failure stage b 7/27 (26) 10/40 (25) 0.93
    Myocardial infarction 0/27 (0) 0/40 (0) NA
    LV hypertrophy 1/27 (4) 0/40 (0) 0.40
    Concentric remodeling 4/27 (15) 7/40 (18) 1.00
    Mildly impaired LVEF 2/27 (7) 3/40 (8) 1.00
    Asymptomatic valve disease 0/27 (0) 1/40 (3) 1.00
    HFpEF 5/27 (19) 7/40 (18) 1.00
cardiac function
    SBP (mmHg) 116 (110-127) 116 (109-123) 0.52
    DBP (mmHg) 73 (70-80) 72 (66-76) 0.19
    MAP (mmHg) 85 (82-91) 85 (78-91) 0.42
    Heart rate (bpm) 66 (63-80) 65 (60-78) 0.31
    Stroke volume (mL) 79 (70-88) 77 (70-86) 0.78
    Cardiac output (L/min) 5.3 (4.4-6.2) 4.9 (4.3-5.9) 0.58
    LV end diastolic volume (mL) 94 (82-102) 91 (76-121) 0.62
    LVEF (%) 61 (59-66) 64 (60-68) 0.12
    E/A ratio 1.59 (1.43-1.93) 1.56 (1.29-1.89) 0.48
    LV mass index (g/m2) 61 (50-70) 55 (47-64) 0.28
    Relative wall thickness 0.34 (0.31-0.39) 0.35 (0.30-0.41) 0.92
FMd
    Baseline diameter (cm) 0.30 (0.28-0.31) 0.29 (0.27-0.32) 0.72
    Peak diameter (cm) 0.31 (0.29-0.34) 0.31 (0.29-0.35) 0.85
    FMD (%) 6.12 (4.76-7.11) 6.18 (5.07-9.01) 0.40
    Shearrate (s -1) 22890 (17936-29002) 22665 (15998-36248) 0.64
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supplemental table 2. cardiovascular and metabolic syndrome variables in former pre-eclamptic 
women (Pe) subdivided in women who did not became pregnant again after the index pregnancy 
(no subsequent pregnancy) and women who did become pregnant after the index pregnancy (sub-
sequent pregnancy). (continued)
no subsequent pregnancy
(n = 27)
subsequent pregnancy
(n = 40) P
Metabolic syndrome
    Fasting glucose (mmol/L) 4.8 (4.5-5.0) 4.8 (4.5-5.2) 0.56
    Fasting insulin (mU/L) 8.0 (6.1-14.6) 7.8 (5.3-10.0) 0.26
    HOMAIR 1.6 (1.2-3.1) 1.8 (1.2-2.4) 0.39
    Triglycerides (mmol/L) 0.9 (0.7-1.2) 0.9 (0.7-1.3) 0.90
    HDL (mmol/L) 1.3 (1.1-1.4) 1.3 (1.1-1.5) 0.42
    Albumin/creatinine ratio   (g/mol) 0.4 (0.1-1.1) 0.7 (0.4-1.6) 0.14
    Pre-hypertension 7/27 (26) 7/40 (18) 0.41
    Hypertension untreated 1/27 (4) 2/40 (5) 1.00
    Antihypertensive treatment 3/27 (11) 9/40 (23) 0.34
Data are given as median (interquartile range) or n/N (%). 
BMI, body mass index; DBP, diastolic blood pressure; EA ratio, ratio of early (E) to late (A) ventricular filling 
velocity; FMD, flow-mediated dilation; HDL, high-density lipoprotein; HOMAIR, homeostatic model assess-
ment for insulin resistance; HFpEF, heart failure with preserved ejection fraction; LV, left ventricular; LVEF, 
left ventricular ejection fraction; MAP, mean arterial pressure; NA, not applicable; SBP, systolic blood pres-
sure.
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AbstrAct
background
During uncomplicated pregnancy, left ventricular remodeling occurs in an eccentric way. 
In contrast, during pre-eclamptic gestation, the left ventricle hypertrophies concentri-
cally, concurrent with loss in circulatory volume and increased blood pressure. Concen-
tric cardiac structure persists in a substantial proportion of women and may be associated 
with pressure and volume load after pre-eclampsia. We hypothesize that low volume load 
as indicated by plasma volume (PV) after pre-eclampsia and increased pressure load is 
associated with remote concentric remodeling.
Method and results
In this longitudinal cohort study, we included 100 formerly pre-eclamptic women. Two 
visits were performed; at 0.8 years postpartum and the second visit 4.8 years postpartum. 
During visit one we measured blood pressure and PV (I125 dilution technique, low PV ≤ 48 
mL/kg lean body mass (LBM)). During the second visit we assessed cardiac geometry by 
cardiac ultrasound. Concentric remodeling was defined as relative wall thickness (RWT) 
> 0.42 and left ventricular mass index (LVMi) ≤ 95 g/m2. We adjusted multivariable 
analysis for primiparity, systolic blood pressure, PV mL/kg LBM and antihypertensive 
medication at visit one. 
Low PV is associated with remote concentric remodeling (odds ratio (OR): 4.37, 95% 
CI 1.06-17.40 and adjusted OR 4.67, CI 95% 1.02-21.42. Arterial pressure load (systolic, 
diastolic and mean arterial pressure) is also associated with development of concentric 
remodeling (OR 1.15, 95% CI 0.99-1.35 OR 1.24 , 95% CI 0.98-1.58 and OR 1.20, 95% CI 
0.98-1.47 respectively).
conclusions
In former pre-eclamptic women, development towards left ventricular concentric re-
modeling is associated with low volume load and increased pressure load.
Key words
Plasma volume, concentric remodeling, pre-eclampsia, echocardiography, blood pres-
sure.
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IntroductIon
Pre-eclampsia (PE), a gestational hypertensive disease, is characterized by new-onset 
hypertension and proteinuria, and complicates 3-5% of all pregnancies1. PE is associ-
ated with a 2-7 fold increased risk for cardiovascular disease (CVD) within 15 years after 
pregnancy and has been recognized as an important women-specific CVD risk factor2, 3.
PE and CVD share many classical risk factors as hypertension, hyperinsulinemia, obe-
sity and dyslipidemia4-6. The elevated risk for CVD after PE may in part relate to abnormal 
cardiovascular (CV) risk profiles in these women, but may also partly be contributed to 
differences in patterns of cardiac remodeling during pregnancy and incomplete cardiac 
recovery afterwards7-10. During normotensive pregnancies, the left ventricle (LV) remod-
els in an eccentric way, while during PE the LV remodels in an aberrant concentric way, 
which remains present in 11-26% of affected women in the first decade after delivery11-13. 
Eccentric cardiac remodeling during normal pregnancy is viewed upon as a physiologically 
reversible phenomenon as a response to decreased gestational pressure load along with 
concomitant increased volume load12, 14, 15. Concentric remodeling during pre-eclamptic 
gestation may be the result of increased pressure load along with lower volume load16.
In hypertensive individuals concentric remodeling, amongst other forms of remodel-
ing, was significantly associated with more CVD and death17, 18. Interestingly, compared 
to eccentric remodeling, concentric remodeling is associated with cardiac fibrosis and 
this stiffened cardiac concentric condition is associated with a fourfold risk of subsequent 
cardiovascular events17, 19. Concentric remodeling is thought to be an important step in 
the progression from asymptomatic heart disease to symptomatic heart failure, often in 
response to chronic pressure overload16.
After pre-eclamptic pregnancy, many women continue to have persistently higher blood 
pressure and decreased plasma volume (PV) compared to healthy parous women7-9, 20, 21. 
It is not known to what extent both pressure load and volume load shortly after delivery 
is associated with persistent or de-novo concentric remodeling in the following decade. 
Cardiac remodeling is a dynamic and progressive process, susceptible to pressure and 
volume modulating medication22-26. Better insight in the system biology of concentric 
remodeling is of clinical value to predict the possible effect of modulating pressure and 
volume load including angiotensin converting enzyme (ACE) inhibitors and angiotensin 
II receptor blockers (ARB) on reversibility of concentric remodeling in these women in 
order to decrease their CV risk24-26. This is of importance because the LV continues to 
remodel when the stressor persists27. Therefore, we performed in former pre-eclamptic 
women, a longitudinal study to evaluate whether pressure and/or volume load, assessed 
shortly after delivery, is associated with concentric remodeling in the following decade. 
We hypothesize that low PV after pre-eclampsia and increased pressure load is associated 
with concentric remodeling in the subsequent years.
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Methods
The Medical Ethics committee of the Radboud University Medical Center 
(NL32718.091.10) approved the protocol of this explorative longitudinal cohort study. 
Before participation, all subjects provided written informed consent. The followed pro-
cedures were in conformity with institutional guidelines and adhered to the principles of 
the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulation, Part 46, Protec-
tion of Human Subjects, Revised November 13, 2001, effective December 13, 2001. We 
invited women who previously had a clinical cardiovascular risk assessment following a 
pregnancy complicated by PE for a second follow-up screening between 2009 and 2011.
study population
Formerly pre-eclamptic women were recruited at their routine 6 weeks postpartum 
medical appointment and were asked to participate in the first cardiovascular screen-
ing assessment, at a median interval of 0.8 years postpartum. They underwent blood 
pressure measurements and PV measurements. A second visit was planned at 4.8 years 
postpartum. During this second cardiovascular evaluation, we performed blood pressure 
measurements and cardiac ultrasound (Figure 1). Inclusion criteria were women with a 
history of pre-eclampsia, not pregnant, not breastfeeding and not using oral contraceptives. 
Women who had become pregnant again after their index pregnancy had to be at least 6 
months postpartum for their second measurement. Exclusion criteria were pre-existing 
comorbidity (diabetes mellitus, autoimmune diseases or pre-existing hypertension) prior 
to their index pregnancy. Other exclusion criteria were an unsuccessful PV measurement at 
visit 1 and/or inadequate cardiac ultrasound at visit 2. All subjects were recruited from the 
eastern region of the Netherlands, a region with an average socioeconomic status. PE was 
diagnosed according to the International Society of Hypertension in Pregnancy criteria 
as: new-onset hypertension (systolic blood pressure (SBP) ≥ 140 mmHg and/or diastolic 
blood pressure (DBP) ≥ 90 mmHg) after 20 weeks of gestation and proteinuria > 0.3g/day28. 
Early-onset PE was defined as PE developing < 34 weeks of gestation. Preterm PE was 
defined as PE requiring delivery before 37 weeks gestation. Small-for-gestational age was 
defined as a birth weight below or equal to the 10th percentile based on the Dutch reference 
curves29. Four women gave birth to twins. All birth weights were analyzed in our analysis.
First visit: cardiovascular assessment
The first visit consisted of the standard cardiovascular assessment, which is embedded in 
standard clinical care. The examinations started at 08:00 a.m. in a temperature controlled 
room (22°C) after an overnight fast. Body weight (kg, Seca 888, Hamburg, Germany) 
and height (m) were measured to calculate body mass index (BMI). BMI ≥ 30 kg/m2 
was defined as obesity. After at least 15 minutes of acclimatization, SBP, DBP and mean 
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arterial pressure (MAP) were measured for 30 minutes (at a three minute interval) in 
upright sitting position, using a semi-automatic oscillometric device (Dinamap Vital 
Signs Monitor 1846; Critikon, Tampa, Florida (USA)). The cuff-size was appropriate for 
arm circumference. We used the median values for statistical analysis. During the 30 
minutes blood pressure measurement, participants were not allowed to talk and external 
disturbances were minimalized. Hypertension was defined as SBP ≥ 140 mmHg and/or 
DBP ≥ 90 mmHg and/or the use of antihypertensive medication. Prehypertension was 
defined as SBP ranging from 120 - 139 mm Hg and/or DBP ranging from 80 - 89 mm Hg. 
Participants were asked to complete a questionnaire at both visits consisting of general 
history, current medication intake, intoxications (smoking is defined as ≥ 1 cigarette a 
day), lifestyle factors and family history for CVD (in first line relatives < 60 years).
During the first visit, PV was measured using the iodine125 albumin indicator dilution 
technique (iodine125 human serum albumin (125I-HSA)) as described elsewhere and in-
dexed for body mass (lean body mass (LBM)) 30-32. LBM was calculated using the formula:
 LBM = Body mass – ((1.20 × BMI) + (0.23 × age) – 5.4) × body mass / 10032, 33.
Body mass index (kg/m2) is calculated as weight (kg) divided by height in meters2. Nor-
mal PV was defined as a PV index > 48 mL/kg LBM and we consider a low PV as  a PV 
index ≤ 48 mL/kg LBM21, 34.
Formerly PE women 3 months 
postpartum (visit 1) 
n = 121
Formerly PE women eligible 
for follow-up (visit 2)
n = 119
Formerly PE women with data available 
on visit 1 and visit 2 
n = 100
Visit 1:
- Blood pressure measurements
- Plasma volume measurements
Meeting the exclusion criteria (n = 19)
- Incomplete cardiac ultrasound (n = 13)
- ≤ 2 years after visit 1 (n = 6)
Meeting the exclusion criteria (n = 2):
- Failed plasma volume measurement (n = 2)
Visit 2:
- Blood pressure measurements
- Cardiac ultrasound measurements
Figure 1. Flowchart of included formerly pre-eclamptic (Pe) women in our explorative longitudinal 
cohort study.
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second visit: follow-up cardiovascular assessment
At the second visit, we performed the same protocol to determine blood pressure and 
performed cardiac ultrasound to determine cardiac structure and function. Echocardio-
graphic measurements were obtained using a phased array echocardiographic Doppler 
ultrasound system (ViVid 7, GE Vingmed Ultrasound, Horten, Norway). The assessments 
were performed offline using EchoPAC PC SW Vingmed Ultrasound, Version 6.1.2. We 
performed two-dimensional, M-mode and Doppler echocardiography according to the 
guidelines of the American Society of Echocardiography (ASE)35. Using M-mode in the 
parasternal long-axis view, we measured left ventricular end-diastolic and end-systolic 
diameters (LVEDd and LVESd, respectively in mm), as well as end-diastolic thickness of 
the interventricular septum (IVST, in mm) and of the posterior wall (PWT, in mm). Left 
ventricular mass (LVM) (in g) was calculated using the formula = 0.8 × (1.04 ((LVEDd + 
PWT + IVST)3−(LVEDd)3)) + 0.6 and indexed for body surface area (LVM index (LVMi)), 
as recommended by the ASE36. The relative wall thickness (RWT) was calculated using 
the formula RWT = 2 × PWT / LVEDd as recommended by the ASE36. LV end-diastolic 
volume (LVEDV, in mL) and end-systolic volume (LVESV, in mL) were estimated using 
the Teichholz formula37. Left ventricular ejection fraction (LVEF, %) was calculated by 
((LVEDV – LVESV) / (LVEDV)) × 100.
Heart rate (HR, in bpm) was obtained by calculating the reciprocal of the mean of 
five consecutive RR-intervals on the electrocardiogram multiplied by 60. We estimated 
the mean aortic velocity time integral (VTI) by averaging the outer edge tracings of five 
consecutive continuous-wave Doppler recordings of the LV outflow tract velocity. By 
taking the product of VTI and the mid-systolic cross-sectional area at the level of the LV 
outflow tract in the para sternal long-axis view, we obtained stroke volume (SV, in mL). 
Cardiac output (CO, in L/min) was obtained by multiplying SV by heart rate. Cardiac 
index (CI) was calculated as CI = CO / body surface area. Total peripheral vascular 
resistance (TPVR in dyn·s·cm-5) was obtained using the formula TPVR = 80 × MAP (in 
mmHg) / CO20. Total peripheral vascular resistance index (TPVRi), normalized for body 
surface area, was calculated as TPVR = 80 × MAP (in mmHg) / CI20.
Left ventricular hypertrophy was defined as LVMi > 95 g/m2, concentric remodeling 
was defined as RWT > 0.42 and LVMi ≤ 95 g/m2, mildly impaired left ventricular ejec-
tion fraction was defined as LVEF > 40 and < 55%36. We defined asymptomatic valvular 
disease as mild aortic valve insufficiency, mild thickening of mitral valve or central aortic 
valve insufficiency.
data analysis
For all statistical analyses, we used SPSS version 21.0 (IBM SPSS Statistics, Armonk NY, 
USA) and R version 3.6.1. Data are expressed as mean with standard deviation for con-
tinuous variables and number with percentage for dichotomous variables. Postpartum 
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intervals were reported as median with interquartile range (IQR). We used the indepen-
dent t-test to test for group differences of continuous variables. Differences in propor-
tions between groups were tested using the Chi-square test if at least 5 cases were present 
in each category and the Fisher exact test if one of the categories contained less than 5 
cases. Postpartum intervals were analyzed using the Mann-Whitney U test for intergroup 
differences. A logistic regression was performed to test the associations between both 
volume load and pressure load at the first visit with the presence of concentric remodel-
ing at the second visit. We selected potential confounders based on clinical reasoning, as 
opposed to statistical significance. Using multivariable logistic regression we adjusted the 
associations for primiparity, antihypertensive medication, and either systolic blood pres-
sure or PV mL/kg LBM dependent on the variable to be tested. Logistic regression with 
the Firth correction was used as the number of events was limited. Results were reported 
as odds ratio (OR) and 95% confidence intervals computed using the profile penalized log 
likelihood. P-values were computed using the likelihood ratio test. A two-sided p-value of 
< 0.05 was considered statistically significant.
results
We included 121 formerly pre-eclamptic women in our longitudinal cohort study who 
had their first visit at a median interval of 0.8 years postpartum and their second visit at a 
median interval of 4.8 years postpartum. At visit 1, 2 women were excluded due to a failed 
PV measurement. At visit 2 when we examined blood pressure and cardiac ultrasound, 
19 women were excluded: 13 women due to an incomplete cardiac ultrasound evalu-
ation and 6 women because of a time interval of ≤ 2 years between both visits (Figure 
1). Ultimately 100 women met our criteria for both visits. The included patients (n = 
100) differed from the excluded patients (n = 21) by having had more often a follow-up 
pregnancy (68% vs 38%, P < 0.05, respectively) and a lower prevalence of smoking at 
visit 1 (5% vs 24%, P < 0.05, respectively). All of the included participants, except for 2, 
were Caucasian. One woman was of Turkish ancestry and one woman was of Moroccan 
ancestry.
Of the 100 women eligible for our statistical analysis, 18 women (18%) showed concen-
tric remodeling at 4.8 years postpartum while 82 (82%) had no concentric remodeling. 
Among the 18 women with concentric remodeling, 1 (6%) had asymptomatic valve dis-
ease (mild aortic valve regurgitation) and none had reduced LVEF. In the no concentric 
remodeling group, 2 women (2%) had asymptomatic valve disease (1 woman with mild 
mitral valve regurgitations with mild thickening of mitral valve and 1 woman with mild 
aortic valve regurgitation) and 6 women (7%) had mildly impaired LVEF.
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Table 1 demonstrates the baseline characteristics of both groups. There were no statis-
tically significant differences in obstetrical characteristics between both groups, except 
less women were primiparous at the first visit in the subsequently concentric remodeling 
table 1. Patient characteristics at visit 1 and 2 in former pre-eclamptic women with and without con-
centric remodeling defined at visit 2. data are presented as mean with standard deviation or number 
with percentage.
concentric remodeling
(n = 18)
no concentric remodeling
(n = 82) P-value
Index pregnancy
Early-onset PE, n (%) 11/15 (73) 50/80 (63) 0.42
Preterm PE, n (%) 13/18 (72) 62/82 (76) 0.77
Primiparous at 0.8 years, n (%) 8/18 (44) 67/82 (82) <0.01
Primiparous at 4.8 years, n (%) 3/18 (17) 21/82 (26) 0.55
Parity at 0.8 years, n (%) 1.7 ± 0.7 1.2 ± 0.6 <0.05
Parity at 4.8 years, n (%) 2.2 ± 0.7 1.9 ± 0.7 0.16
GA at birth, weeks 33 ± 5 34 ± 4 0.55
Birth weight, g 1717 ±1086 1868 ± 942 0.55
SGA neonate, n (%) 10/18 (56) 31/82 (38) 0.17
IUFD, n (%) 4/18 (22) 6/81 (7) 0.08
Follow-up pregnancy, n (%) 11/18 (61) 57/82 (70) 0.49
Recurrent PE, n (%) 5/11 (45) 18/57 (32) 0.49
Patient characteristics at visit 1
Postpartum, median years (IQR) 1.3 (0.5 to 2.6) 0.7 (0.5 to 1.9) 0.31
Age, years 32 ± 5 33 ± 4 0.34
Weight, kg 76 ±13 71 ± 19 0.27
BMI, kg/m2 26.5 ± 3.2 24.8 ± 6.4 0.28
Obesity, BMI ≥ 30 kg/m2, n (%) 4/18 (22) 11/82 (13) 0.46
Smoking, n (%) 1/18 (6) 4/82 (5) 1.00
Alcohol, n (%) 2/18 (11) 13/82 (16) 1.00
Family history of CVD, n (%) 9/18 (50) 27/82 (33) 0.17
Antihypertensive treatment, n (%) 4/18 (22) 14/81 (17) 0.74
Patient characteristics at visit 2
Postpartum, median years (IQR) 5.7 (4.3 to 6.9) 4.8 (4.1 to 6.1) 0.30
Age, years 35 ± 5 36 ± 4 0.36
Weight, kg 79 ± 15 72 ± 18 0.19
BMI, kg/m2 27.2 ± 3.8 25.3 ± 6.3 0.21
Obesity, BMI ≥ 30 kg/m2, n (%) 6/18 (33) 12/82 (15) 0.09
Smoking, n (%) 1/18 (6) 6/82 (7) 1.00
Alcohol, n (%) 2/18 (11) 22/82 (27) 0.23
Family history of CVD, n (%) 11/18 (61) 43/82 (52) 0.50
Antihypertensive treatment, n (%) 6/18 (33) 14/82 (17) 0.19
PE, pre-eclampsia; GA, gestational age; SGA, small-for-gestational age; IUFD, intrauterine fetal death; IQR, 
interquartile range; BMI, body mass index; CVD, cardiovascular disease.
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group (44%) compared with the no concentric remodeling group at follow-up (82%). 
There were no statistically significant differences in age, weight, BMI, obesity, smoking, 
alcohol consumption, family history of CVD, antihypertensive treatment and postpartum 
interval between both groups at 0.8 and subsequent 4.8 years postpartum.
concentric remodeling versus no concentric remodeling
Table 2 presents the hemodynamic indices, measured at the first evaluation after index 
pregnancy (median 0.8 years postpartum, IQR 0.5 to 2.1 years postpartum). There were 
no statistically significant differences in SBP, DBP and MAP between the groups. HR did 
not differ between the concentric remodeling group and no concentric remodeling group. 
TPVR was significantly lower in the concentric remodeling group at follow-up compared 
to the no concentric remodeling group. TPVR index, prehypertension, hypertension 
and untreated hypertension were comparable between both groups. PV was lower in the 
concentric remodeling group at follow-up compared with the no concentric remodel-
ing group (54 ± 6 versus 59 ± 7 mL/kg LBM, P < 0.05, respectively). Consequently, the 
concentric remodeling group seemed to have more often low PV (≤ 48 mL/kg LBM) 
compared with the no concentric remodeling group (22% vs 6%, respectively P = 0.05).
table 2. hemodynamics and volume load at visit 1 in former pre-eclamptic women. the group is 
subdivided in women with concentric remodeling and no concentric remodeling defined at visit 2 
in formerly pre-eclamptic women. data are presented as mean with standard deviation or number 
with percentage.
concentric remodeling
(n = 18)
no concentric remodeling
(n = 82) P-value
hemodynamics
SBP, mmHg 126 ± 17 119 ± 15 0.06
DBP, mmHg 74 ± 12 69 ± 10 0.07
MAP, mmHg 92 ±13 86 ± 12 0.08
HR, bpm 69 ± 7 69 ± 11 0.93
TPVR, x 103 dyn·s·cm-5 1.3 ± 0.4 1.5 ± 0.4 <0.05
TPVR index, x 103 dyn·s·cm-5 2.5 ± 0.8 2.8 ± 0.7 0.13
Prehypertension, n (%) 5/18 (28) 15/82 (18) 0.35
Hypertension, n (%) 6/18 (33) 20/82 (24) 0.55
Hypertension untreated, n (%) 2/18 (11) 6/82 (7) 0.63
Plasma volume
PV mL/kg LBM 54 ± 6 59 ± 7 <0.05
Low PV, n (%)* 4/18 (22) 5/82 (6) 0.05
SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; HR, heart rate; TPVR, 
total peripheral vascular resistance; PV, plasma volume; kg, kilogram; LBM, lean body mass;
*Low PV mL kg/LBM is defined as PV index ≤ 48 mL/kg LBM.
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Table 3 demonstrates the odds ratio’s on concentric remodeling of volume and pressure 
load measured at visit 1. PV mL/kg LBM at the first evaluation associates inversely with 
remote concentric remodeling (odds ratio (OR): 0.91, 95% confidence interval (CI): 0.84-
0.99), and remained so after adjustments for SBP, primiparity and antihypertensive treat-
ment measured at visit 1 (adjusted OR (aOR) 0.91, 95% CI 0.82-0.99). Moreover, low PV 
was associated with concentric remodeling at follow-up (OR 4.37, 95% CI 1.06-17.40), 
also after adjustments (aOR 4.67, 95% CI 1.02-21.42). Arterial pressure load is associated 
with the risk development of concentric remodeling at follow-up, but part of this effect 
seemed to originate from concurrent decrease in volume load, as after correction the 
effect of pressure load on the concentric cardiac phenotype was less.
Table 4 shows the hemodynamic and cardiac measurements at visit 2 (median 4.8 years 
postpartum, IQR 4.2 to 6.4 years postpartum) in both groups. The concentric remodeling 
group differed from the no concentric remodeling group by having a higher DBP. More-
over, SBP and MAP showed a trend towards significance with a higher blood pressure in 
the concentric remodeling group compared with the no concentric remodeling group. 
HR, TPVR, TPVR index were comparable between the two groups. Prehypertension was 
more prevalent in the concentric remodeling group (39%) compared to the no concentric 
remodeling group (16%). The presence of hypertension and untreated hypertension did 
not differ between both groups. Of the cardiac measurements, RWT, IVST and PWT 
were higher in women with concentric remodeling while LVEDd, LVEDd index and 
LVESd were lower in the concentric remodeling group.
table 3.Volume and pressure load at visit 1 in former pre-eclamptic women with the odds ratio on 
remote concentric remodeling defined at visit 2.
crude or P-value crude or Adjusted or P-value adjusted or
Plasma volume
PV mL/kg LBM 0.91 (95% CI 0.84-0.99) <0.05 0.91 (95% CI 0.82-0.99) † <0.05
Low PV* 4.37 (95% CI 1.06-17.40) <0.01 4.67 (95% CI 1.02-21.42) † <0.05
Pressure load
SBP (per 5 mmHg) 1.15 (95% CI 0.99-1.35) 0.07 1.08 (95% CI 0.90-1.29)‡ 0.39
DBP (per 5 mmHg) 1.24 (95% CI 0.98-1.58) 0.08 1.12 (95% CI 0.85-1.50)‡ 0.41
MAP (per 5 mmHg) 1.20 (95% CI 0.98-1.47) 0.08 1.12 (95% CI 0.89-1.42)‡ 0.34
OR, odds ratio; CI, confidence interval; PV, plasma volume; kg, kilogram; LBM, lean body mass; SBP, systolic 
blood pressure; DBP, diastolic blood pressure, MAP, mean arterial pressure.
* Low PV mL/kg LBM is defined as PV ≤ 48 mL/kg LBM.
† adjusted for SBP, primiparity and antihypertensive treatment measured at visit 1.
‡ adjusted for PV mL/kg LBM, primiparity and antihypertensive treatment measured at visit 1.
10 | Maastricht University
table 4. hemodynamic and cardiac indices at visit 2 in former pre-eclamptic women with and with-
out concentric remodeling defined at visit 2. data are presented as mean with standard deviation or 
number with percentage.
concentric remodeling
(n = 18)
no concentric 
remodeling
(n = 82) P-value
hemodynamics
SBP, mmHg 123 ± 11 116 ± 13 0.06
DBP, mmHg 79 ± 9 72 ± 10 <0.05
MAP, mmHg 91 ± 10 86 ± 11 0.08
HR, bpm 66 ± 9 66 ± 11 0.93
TPVR, x 103 dyn·s·cm-5 1.4 ± 0.3 1.4 ± 0.3 0.93
TPVR index, x 103  dyn·s·cm-5 2.6 ± 0.5 2.5 ± 0.6 0.50
Prehypertension, n (%) 7/18 (39) 13/82 (16) <0.05
Hypertension, n (%) 6/18 (33) 19/82 (23) 0.38
Hypertension untreated, n (%) 0/18 (0) 5/82 (6) 0.58
cardiac measurements
RWT 0.46 ± 0.03 0.32 ± 0.05 <0.01
LVM, g 120 ± 29 107 ± 28 0.09
LVM index, g/m2 63 ± 12 58 ± 13 0.16
SV, mL 82 ±17 80 ± 18 0.65
CO, l/min 5.4 ±1.0 5.2 ± 1.1 0.46
CI, l/min/m2 2.8 ± 0.4 2.8 ± 0.6 0.99
LVEF, % 63 ± 5 63 ± 6 0.94
LVEDd, cm 4.1 ± 0.3 4.6 ± 0.4 <0.01
LVEDd index, cm/m2 2.2 ± 0.2 2.5 ± 0.2 <0.01
LVESd, cm 2.6 ± 0.4 2.9 ± 0.4 <0.05
IVST, cm 0.87 ± 0.12 0.73 ± 0.16 <0.01
PWT, cm 0.95 ± 0.09 0.74 ± 0.12 <0.01
LAD, cm 3.6 ± 0.5 3.5 ± 0.5 0.60
SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; HR, heart rate, TPVR, 
total peripheral vascular resistance; RWT, relative wall thickness; LVM, left ventricular mass; SV, stroke vol-
ume; CO, cardiac output; CI, cardiac index; LVEF, left ventricular ejection fraction; LVEDd, left ventricular end 
diastolic diameter; LVESd, left ventricular end systolic diameter; IVST, interventricular septal thickness; PWT, 
posterior wall thickness; LAD, left atrium diameter.
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dIscussIon
In this current explorative longitudinal cohort study, we observed that low volume load 
as indicated by PV and increased pressure load in the first year after pre-eclamptic gesta-
tion relates to an increased risk to develop later concentric cardiac remodeling.
Formerly pre-eclamptic women have an increased risk for CVD and share cardiovascu-
lar risk factors which may, at least in part, explain the relation between both diseases3-6, 38. 
Besides the elevated prevalence of common CVD risk factors, that mostly predispose to 
macrovascular disease, the concentric cardiac adaptation to hypertensive complicated 
pregnancy may play an (additional) role in the associated elevated remote risk for CVD, 
especially when the additional increase in LV mass in women with PE does not resolve 
after delivery7-11. In the first decade after delivery 25% of formerly pre-eclamptic women 
have structural or functional cardiac abnormalities, consistent with asymptomatic heart 
failure stage B, mostly along with a concentric phenotype11, 13, 39. This type of heart failure 
is thought to originate from a systemic proinflammatory state with the involvement of 
microvascular endothelial inflammation40. Both traditional cardiovascular risk factors 
and incomplete deconditioning from the vascular complicated pregnancy are thought to 
contribute to the increased risk of future heart failure41, 42. It is believed that this increased 
risk is susceptible to preventive intervention while the disease is still in a preclinical stage.
Structural cardiac remodeling is an important compensatory mechanism to maintain 
the pumping capacity of the heart in response to alterations in either volume or pressure 
load16, 43. Volume and pressure load-induced stimuli induce various signalling pathways 
leading to a hypertrophic response of the cardiomyocytes44, 45. This induces eccentric 
cardiac hypertrophy with concomitant widening of the ventricle in uncomplicated 
normotensive pregnancies or concentric adjustments with relative loss of ventricular 
volume when facing muscular hypertrophy in hypertensive pregnancies16, 44, 45. Cardiac 
myocyte hypertrophy is dose-dependently associated with increased circulatory load. On 
the one hand, the difference in concentric or eccentric cardiac adaptation in our cohort 
is associated more to volume load than pressure load, in which each additional mL/kg 
LBM PV lowered the odds on concentric cardiac phenotype. On the other hand, the 
contribution of blood pressure should not be underestimated as we observed that blood 
pressure seems to be associated with the odds on concentric remodelling at follow-up. 
Nonetheless, when correcting for low volume load, part of the effect of pressure load on 
concentric remodeling at follow-up disappeared, suggesting that part of the effects that 
are associated with pressure load could originate from volume load. At any rate, both 
volume and pressure load affected the development towards concentric cardiac remodel-
ing in a dose dependent fashion.
Given the large prevalence of persistent or de-novo elevated blood pressure in formerly 
pre-eclamptic women, especially in women with low PV, low volume status may be an 
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alarming characteristic even in apparently healthy normotensive formerly pre-eclamptic 
women30, 46.
Clinically, in normotensive formerly pre-eclamptic women, on the one hand, pre-preg-
nancy low PV is associated with recurrent hypertensive complicated pregnancy, growth 
restriction and preterm birth and, on the other hand, low PV is associated with remote 
hypertension within the first decade after the hypertensive index pregnancy30, 47. PV is 
considered to mirror cardiovascular reserve capacity in case of healthy cardiac function-
ing47. 65-75% of the blood volume is localized in the venous system and can be mobilised 
in times of increased arterial demand as in pregnancy or during exercise48-50. PV can be 
fundamentally diminished, either genetically or secondary to a structurally small venous 
compartment in line with the fetal origin of adult disease complex (Barkers hypothesis) 
47, 51, 52. Alternatively, low PV status may result from a functionally more constricted ve-
nous system diminishing venous dimensions and (resting) elastic properties of the venous 
wall and with it decreasing the venous capacitance as part of sympathetic over-activity, 
such as seen in obesity or the metabolic syndrome30, 49, 53. Given the commonly present 
low PV status in formerly pre-eclamptic women and the increased tendency to develop 
chronic hypertension, one could anticipate on a synergistic detrimental effect of volume 
and pressure load on concentric cardiac remodeling in these women while aging7-9, 20, 21. 
From this perspective, close monitoring of blood pressure and timely intervention with 
blood pressure modulating medication, not only capable in lowering pressure load but 
also increasing volume load may be most promising in the effective and preventive treat-
ment of concentric remodeling. Along these lines, as such, diuretics as primary treatment 
option for hypertension in these women should not be advisable.
limitations
There are a few limitations in this study. First, most women in our study were Caucasian. 
Therefore, our study results might not be entirely generalized to other populations. Sec-
ond, although we adjusted for the use of antihypertensive medication in our analysis, we 
cannot completely rule out the effect of antihypertensive drugs at the time of the measure-
ments, as cardiac remodeling also independently results from other biochemical factors 
apart from blood pressure and PV. Third, the observational nature of our study and the 
lack of a matched control group does not allow us to conclude whether the relationship 
between volume status and persistence of concentric remodeling is causal or not and to 
evaluate the potential effect of complicated- or uncomplicated pregnancy itself on cardiac 
changes in time. Therefore, additional studies confirming our findings are needed.
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conclusIon
One out of six formerly pre-eclamptic women have a concentric remodeled left ventricle 
4.8 years after gestation. In these women, concentric remodeling is associated with low 
volume load and increased pressure load.
PersPectIVes
Recognizing the role of diminished volume load along with elevated blood pressure, even 
without reaching the threshold of overt hypertension, may help in the clinical fine-tuning 
of preventive measures in these women to prevent the development of heart failure.
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IntroductIon
Preeclampsia (PE) is a pregnancy-related hypertensive disorder complicating 3-5% of 
all pregnancies and is associated with a two-to sevenfold increased risk of developing 
ischemic cardiac disease within 15 years after pregnancy1, 2. It is believed that PE is an 
obstetric resultant of placental microvascular dysfunction1, 3. Traditional cardiovascular 
risk factors can lead to an elevated risk of placental dysfunction, as well as an increase in 
risk of cardiovascular disease in women with a history of preeclampsia4-6. It is hypoth-
esized that in women with a hypertensive pregnancy complication, cardiac remodeling 
both reflects an adjustment to increased strain but also represents pathologic stress to 
the myocardium at a young age. During preeclampsia, the unfavorable increase in left 
ventricular mass and loss in diastolic function does not always normalize after giving 
birth7, 8.
This thesis provides insight on cardiovascular (CV) function during and after pre-
eclamptic pregnancies and the risk for remote CV disease (CVD) in these women. First, 
it describes the adaptation of and changes in systolic cardiac function over the course 
of gestation in normotensive and hypertensive pregnancies. Secondly, it elaborates on 
the prevalence of subclinical heart failure (HF-B) and how this subclinical phase relates 
to endothelial function and circulatory plasma volume after preeclampsia. Finally, the 
calculated risk for remote CVD based on predefined risk scores is described.
cardIac geometry durIng pregnancy
Normotensive pregnancy is characterized by increased volume load and decreased pres-
sure load, most likely triggered by an early pregnancy drop in total peripheral vascular 
resistance (TPVR)9, 10. The reduction in cardiac afterload during the first-trimester and 
imminent decline in blood pressure activates compensatory mechanisms by stimulat-
ing central autonomic mechanisms and by activating the renin-angiotensin-aldosterone 
system (RAAS) to re-establish the circulatory filling state and blood pressure stabilizing 
rise in cardiac output (CO)10, 11. In the clinical phase of a preeclamptic pregnancy, TPVR 
increases along with blood pressure10, 12. Moreover, in a recent meta-analysis, de Haas et 
al. showed that plasma volume expansion was 13.3% lower in complicated pregnancies 
(pregnancy-induced hypertension, preeclampsia or fetal growth restriction) than in nor-
motensive pregnancies (0.80 L (32.3%) versus 1.13 L (45.6%), respectively)13. The reason 
for these differences in circulatory volume is unknown but may relate to inadequate 
plasma volume expansion, loss in gained volume and with it edema formation or differ-
ences in pre-pregnancy volume10. In contrast to the clinical phase, preclinical responses 
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have been more divergent based on clinical onset of the disease, and are characterized by 
subnormal first trimester circulatory adjustments and suboptimal placentation10, 12.
Early-onset PE seems to be preceded by low cardiac index along with high TPVR while 
this is not well described in women destined to develop late-onset PE, with some authors 
indicating at least normal cardiac index and slightly increased TPVR at mid-gestation, 
while others report supra-normal CO along with low TPVR10, 12. However, although the 
latter authors did not normalize hemodynamic measurements for body surface area or 
body mass index, despite of significant differences in the anthropometric parameters in 
the analyzed study groups, the hyperdynamic circulatory state may underlie the BMI 
associated increased risk of PE10, 12, 14, 15.
During normal pregnancy, the heart undergoes remodeling which can be compared to 
morphological alterations seen in athletes, which is referred to as eccentric hypertrophy, 
a process of proportional increase in chamber dimensions and left ventricular wall thick-
ness (relative wall thickness = RWT)8, 10, 16. A recent meta-analysis studied the pattern of 
cardiac remodeling in normotensive and hypertensive pregnancy16. During normotensive 
pregnancy, left ventricular mass (LVM) increased by 28 g (24%) and RWT increased by 
0.03 (10%) while in pregnancy complicated by hypertension, LVM and RWT increased 
disproportionally and respectively 3 and 5 times more than during normotensive preg-
nancy, (92 g (95%) and 0.14 (56%), respectively)16.
Although the underlying causal mechanism of developing concentric remodeling dur-
ing PE has not been evaluated, based on physiological principles, increased pressure- and 
attenuated volume load, along with vasoactive(neuro)hormonal factors stimulating vari-
ous signaling pathways that are essential for the induction of a hypertrophic response of 
the cardiomyocyte10, 17, 18. LV remodeling in preeclampsia is asymmetrical, predominantly 
involving the basal anteroseptum19.
Even though almost all evident geometric changes become visible from second trimes-
ter onwards, Melchiorre et al. showed that women destined to develop preterm PE, LV 
mild diastolic dysfunction (30%) and segmental impaired myocardial relaxation (70%) 
was highly present, along with increased afterload (higher mean arterial pressure and 
TPVR index) and LV concentric hypertrophy10, 12, 20.
SyStolIc and dIaStolIc cardIac functIon In pregnancy
Regardless of the primary favorable effect of an increased wall thickness to reduce wall 
stress, concentric LV remodeling co-occurs with an increase in extracellular matrix, with 
increased fibroblasts and collagen accumulation between individual myocytes18. As such, 
concentric remodeling preludes loss in diastolic function as consequence of reduced 
ventricular compliance10. A study by Vaught et al. described lower values for diastolic 
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function in PE women with severe features like severe hypertension and end-organ dys-
function compared with healthy pregnant women, supporting this theory21. These find-
ings are in line with other studies, describing a high prevalence of LV global diastolic 
dysfunction in predominantly preterm PE women8, 22, 23. There are conflicting findings of 
global left ventricular systolic function in PE, nevertheless, when corrected for heart rate 
dependency and load, preserved contractility during PE was suggested10, 12, 24.
In chapter 2 of this thesis, we present the changes in systolic function during pregnancy 
based on a systematic review and meta-analysis. During normotensive pregnancies, 
LVEDV, LVESV increased while EF showed an initial small rise in early second trimester 
to normalize towards baseline afterwards. In contrast to normotensive pregnancies, dur-
ing gestational hypertensive pregnancies, the left ventricle is apparently unable to main-
tain contractility, reflected by 10% reduced ejection fraction. The underlying mechanisms 
leading to the reduction in cardiac contractility needs to be elucidated.
Impaired contractility, measured as decreased ejection fraction appears in end-stage 
cardiac disease expression10. Before abnormalities in conventional measures of LV per-
formance like ejection fraction become visible, in patients with subclinical LV dysfunc-
tion impaired myocardial contractility and relaxation may precede the development of 
overt systolic and/or diastolic dysfunction25. Speckle tracking echocardiography (STE) is 
a new echocardiographic technique, which may be capable to estimate more subtle func-
tional myocardial abnormalities and LV diastolic and systolic dynamics10, 25. Moreover, 
STE enables more detailed information in hypertensive patients (also in the early phase 
of hypertension) to recognize systolic dysfunction in patients with normal LV ejection 
fraction25. Using 3D STE, Cong et al. found that in women with early-onset preeclampsia 
all strain directions appear to be impaired whereas in late onset preeclampsia all but LV 
global radial strain were impaired compared to normal pregnancy10, 26.
Because of the promising idea of the clinical application of STE in preeclampsia, several 
research groups are now investigating the role of STE in different subtypes of complicated 
pregnancy.
SubclInIcal heart faIlure after preeclampSIa
Heart failure (HF) is generally viewed as a progressive disorder that begins with some 
injury to, or stress on, the myocardium and proceeds from asymptomatic to symptomatic 
stages27, 28. The principal manifestation of this progression is a change in the structure 
and geometry of the left ventricle27, 28. According to the American Heart Association 
(AHA), asymptomatic stages of HF include HF stage A which are those with risk factors 
but without structural heart disease (HF-A) and HF-stage B defined as the presence of 
a former myocardial infarction, left ventricular hypertrophy, concentric remodeling, 
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mildly impaired left ventricular ejection fraction or asymptomatic valvular disease (HF-
B)27. These asymptomatic stages precedes the symptomatic stages C and D27. Ammar 
et al. showed that the 5 year survival reduced most sharply at the transition of HF-B 
(96%) to HF-C (75%)29. Moreover, this transition is accompanied by a fivefold increase in 
mortality risk29. Untreated asymptomatic LV dysfunction have a 10% risk of developing 
HF symptoms and a 8% risk of death or HF hospitalization annually30, 31. The transition 
from asymptomatic to symptomatic HF disease is affected by the presence of traditional 
cardiovascular and cardio-metabolic risk factors27, 32.
Melchiorre et al. described that in the first year after preterm preeclampsia, women still 
show an abnormal LV geometric pattern and diastolic dysfunction, 41% and 52%, respec-
tively7. Moreover, in chapter 4 we showed that after an preeclamptic pregnancy, 75% of 
those diagnosed with asymptomatic heart failure demonstrate impaired diastolic func-
tion but preserved ejection fraction (HFpEF) at 4 years postpartum. In general, HFpEF 
is thought to develop from a ‘systemic pro-inflammatory state’ induced by comorbidities 
and accompanied with microvascular endothelial inflammation, and these elements are 
also involved in the etiology of PE33, 34. Besides the elevated prevalence of cardiac abnor-
malities after a preeclamptic pregnancy, a quarter of women with a history of preterm PE 
report symptoms like less interest, intrusive recollections, psychogenic amnesia, difficulty 
sleeping and concentrating problems and 17% after term PE report these symptoms35.
It could be that the microvascular dysfunction after PE may lead to cognitive impair-
ment because a recent study have indicated that former preeclamptic women have greater 
changes in temporal white matter and lower cortical gray matter volume in comparison 
with women with a normotensive pregnancy in the past36. However, the earlier mentioned 
symptoms of cognitive impairment are similar to those patients in the general population 
with chronic heart failure37. If we take this into account, the CV deterioration in women 
with a history of PE is probably related to an underlying microvascular dysfunction 
which could be worsened by untreated (pre)hypertension, probably sooner than matched 
women who had normotensive pregnancies.
heart faIlure Stage b after preeclampSIa
The cardiovascular risk factors, that are increased after a preeclamptic pregnancy38-41 
could influence the PE-induced cardiac remodeling resolving process. We observed in 
our study, a prevalence of 23% of HF-B at 1 and 4 years postpartum in former preeclamp-
tic women. The same prevalence at both timepoints suggest a persistent cardiac function, 
however there is a shift in women who are recovering of this disease between the two 
timepoints (more than 60%) and women who developed HF-B (about 20%). Moreover, 
the prevalence of either diastolic or systolic dysfunction were different at both timepoints. 
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We suggest that diastolic dysfunction, the most prevalent form of HF-B in our women 
at 4 years postpartum, could be a more persistent condition compared to the systolic 
dysfunction variant. HF can be subdivided in a reduced ejection fraction (HFrEF) or with 
a preserved EF (HFpEF), where women outnumber men (2:1 ratio)42. The prevalence of 
subclinical HFpEF increased more than two-fold, between 1 and 4 years postpartum. It 
is tempting to speculate that the shift in concentric remodeling between both visits and 
the borderline significant increase of HFpEF demonstrate a mechanistic response to the 
persistently high blood pressure that lead to an increased concentric remodeling43. In two 
of our studies, we have evaluated the relation between pressure load, volume load and 
endothelial function on aberrant cardiac remodeling.
rISk factorS for heart faIlure after preeclampSIa
Cardiovascular disease and preeclampsia share many classical risk factors like dyslipid-
emia, hyperinsulinemia, hypertension and obesity44-46. The increased CVD risk after pre-
eclamptic pregnancy, could partially relate to abnormal cardiovascular risk profiles in PE 
women, but also partially be contributed to differences in patterns of cardiac remodeling 
during pregnancy and uncomplete cardiac recovery afterwards12, 39-41. We have mentioned 
already that during normotensive pregnancies, the left ventricular (LV) remodels in an 
eccentric way while during PE, the LV remodels in the aberrant concentric way8, 10, 16. 
Cardiac remodeling is a dynamic and progressive process, which is likely to be influenced 
by pressure and volume modulating medication47-51.
After PE, many women remain having on average a persistently elevated blood pressure 
and decreased PV compared to healthy parous women39-41, 52, 53. In chapter 6 we pres-
ent a longitudinal cohort study where we found that both elevated SBP as well as low 
plasma volume 0.8 years after delivery raised the risk on concentric remodeling at 4.8 
years postpartum. These findings indicate a significant role not only for pressure load, 
but also volume load as indicated by plasma volume. Moreover, former PE women with a 
low plasma volume have an odds ratio of 4-5 to develop concentric remodeling and with 
it heart failure stage B. Our observations suggest that it should be re-evaluated whether 
diuretics are the most suitable therapy for lowering the blood pressure in formerly PE 
women, especially with already diminished PV.
Many studies showed that PE is associated with endothelial dysfunction that may 
persist during the first years after PE34, 54-66. This is in line with our findings (chapter 5) 
in which we showed a lower endothelial function, measured with flow mediated dilation 
(FMD) at 4 years postpartum compared to healthy controls. On the other hand endo-
thelial dysfunction is also correlated with symptomatic heart failure67, 68. In our study, we 
found that PE was indeed independently associated with reduced flow mediated dilation 
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(FMD) after adjusting for metabolic risk factors. Moreover, formerly PE women had 
an eight-fold higher prevalence of HF-A and a three-fold higher prevalence of HF-B. 
Nevertheless, no association was found between the prevalence of HF-A or HF-B on the 
one hand with endothelial dysfunction on the other hand. This was in contrast to our 
expectations, since we expected to find a positive relation between impaired FMD after 
PE and HF-B. The use of antihypertensive treatment in part of individuals of the HF-B 
group may have attenuated the differences in endothelial function between the HF-B 
group and the other groups. In fact, antihypertensive treatment may reverse cardiac re-
modeling, enhance cardiac function and improve endothelial function either by reducing 
afterload, shear stress or by improvement of volume load32, 69. However, it is in line with 
previous research that endothelial dysfunction was not associated with differences in LV 
geometric patterns70. Moreover, maybe we are looking at a different type of heart failure 
seen in these women. FMD is giving us information about the macrovascular system, but 
it could be that we are looking at a microvascular problem in these preeclamptic women.
cardIovaScular dISeaSe rISk after preeclampSIa
CVD disease is the number one cause of death in women71, 72. Until now it is unknown 
whether PE itself as a gender specific disorder increases this CVD risk independently 
or whether it is a result of risk factors that are known to be associated with both CVD 
and PE. Women with a previous preeclampsia demonstrate more often constituents of 
the metabolic syndrome, like insulin resistance, hypertension, dyslipidemia, obesity and 
micro-albuminuria compared to women with a healthy pregnancy38-41. These risk factors 
may be modifiable when detected in time73, underscoring the importance of cardiovas-
cular follow-up in these specific group of young women. It could be favorable to estimate 
the person-specific CVD risk in former preeclamptic women. Currently, no tailored risk 
score is available to determine the cardiovascular disease risk in women with a history 
of preeclampsia. In other risk populations, several risk scores are applicable and have 
been proven of predictive value. The Framingham risk score calculator is the most widely 
used and well validated strategy to assess personalized risk74, 75. In chapter 3 we aimed to 
compare to CVD predicted risk in the next 10- and 30- years (computed with the Fram-
ingham risk score calculator) between women with a history of PE and women with an 
uncomplicated pregnancy in the past and subsequently compared subgroups within the 
former PE group based on onset of disease and/or whether hypertension was developed.
Against our expectations, as group, women with a history of PE had comparable risk 
estimates compared to healthy parous controls. Other risk factors that are known to be 
increased after PE (e.g. cholesterol, BMI), except for hypertension, did not contribute 
substantially to the modelled CVD increased risk in our studied population. However, 
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treated hypertensive women with a history of PE had a twofold CVD risk, compared to 
both normotensive formerly PE women and controls. Moreover, we found the highest 
prevalence of hypertension after early-onset PE. Our results suggest that the increased 
risk of CVD after PE is primarily related to blood pressure control and not with sub-
clinical classical cardiovascular risk factors. Our study is a translation of the increased 
CVD risk after PE to a predicting risk score to the patient. Our findings stress again the 
importance of CVD screening and follow-up in former PE patients with a special focus 
on early-onset PE and blood pressure measurement and treatment
The Framingham risk score is the most compared risk calculator and widely used in 
North American countries76. There are also other risk models for ischemic heart disease 
(IHD) and stroke, which are SCORE, CUORE and the Reynolds risk score76, 77. Of the 
different risk models, the Framingham risk score is the only model to predict the 10- and 
30- year CVD risk78. Nevertheless, the Framingham risk score has not been validated in 
women with a history of PE. Maybe this risk score is not fully applicable in this specific 
group. Although we were unable to substantiate an intrinsic detrimental effect of PE itself 
on remote CV health, we cannot completely rule out PE to be an independent risk fac-
tor for CVD that should be included in the CVD risk prediction independent of other 
conventional risk factors.
Originally, the Framingham risk prediction calculator is developed using older popula-
tion of men and women79, and may not be immediately applicable into our study popula-
tion with women with an average age of 37 years. So it could be that the risk prediction 
may underestimate the risk score in our population. To determine alternate cut-offs for 
the 10-year and 30-year risk estimates for CV events, a very long-term follow-up would 
be required of a large cohort of postpartum women.
cardIovaScular rISk management after preeclampSIa
Although we know that former PE women have this increased CVD risk, a careful follow-
up program is still not implemented. It is not known how much time after the pregnancy, 
women should be examined to rule out the pregnancy-induced alterations in the car-
diovascular system. Earlier research have noted that former preeclamptic women may 
benefit of a cardiovascular screening for cardiovascular disease at 1 -2 years postpartum7. 
Our studies suggest that it is necessary that it may be indicated that women should have 
an additional assessment a few years later, regarding the high prevalence of heart failure 
stage B a few years later and because women shift from no HF to heart failure stage B and 
vice versa in these years. The outcomes of the follow-up measurements should be used 
to counsel these women, with a long-term risk management plan and advice. Nijdam et 
al. concluded in 2009 that the follow-up of former preeclamptic women is insufficient 
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and undeveloped in the primary care in the Netherlands80. To date, there is an increas-
ing number of obstetricians that would advise women after preeclampsia on preventive 
interventions like blood pressure measurements and increasing their physical activity81. 
However, when we look at the percentages (46-65% advised yearly blood pressure mea-
surements in 2014 for late and early preeclampsia, respectively) there are still possibilities 
to improve the awareness for reducing CVD81. Almost half of the gynecologists still miss 
an chance in CVD counseling and management in former PE women81. We should con-
sider a structured follow-up path for these women and create more awareness to address 
the relevance of a CVD screening, not only for the general practitioners and obstetricians 
but also for women involved.
concluSIon
Taken together, our findings underscore the cardiovascular complications during and 
after a preeclamptic pregnancy. Although almost only Caucasian women were studied, 
making generalizability not applicable to all women, the studies in this thesis provide 
experimental evidence for a high prevalence of endothelial dysfunction and features of 
the metabolic syndrome in former PE patients a few years postpartum. Heart failure stage 
B was prevalent in 1 out of 4 former PE patients. Moreover, we showed that these women 
had a low volume and high pressure load, all associated with heart failure stage B. Espe-
cially, hypertensive young women after a preeclamptic pregnancy had higher predicted 
cardiovascular risk score in the next 10-30 years. It is important that former preeclamptic 
women should have a CVD screening and follow-up, with a special focus on blood pres-
sure and echocardiography measuring systolic and diastolic function. Importantly, these 
risk assessments should not only be offered to these women 1 year after their complicated 
pregnancy, but our results showed that an additional assessment a few years later is also 
necessary.
future perSpectIveS
Even though the survival rates of clinical HF have improved over time, within 5 years 
after diagnosis the absolute mortality rates of HF remain approximately 50%30. To date, 
there is no proven effective treatment in patients with clinical HFpEF in randomized 
clinical trials82. HF, especially in women, significantly decrease quality of life, specifically 
in the domains of physical functioning, vitality, mental health, wellbeing and depressive 
symptoms83. There are therapeutic agents to intervene in the CV continuum, like angio-
tensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) 
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which can modify the process of cardiac remodeling by influencing the cascade of renin-
angiotensin system84. There is no difference between ARBs and ACE inhibitors in total 
mortality or cardiovascular outcomes in people with primary hypertension, however 
ARBs can cause slightly fewer adverse effects compared to ACE inhibitors85. On the other 
hand, ACE inhibitors are less expensive than ARBs.
Hence, preventing the transition between asymptomatic HF to clinical overt HF is 
paramount in improving disease prognosis at the moment.
At present, we still not have a complete understanding of the pathophysiology link 
between preeclampsia and cardiovascular disease. Whether PE induces CVD or whether 
PE and CVD are a common vascular result of the same susceptibility, needs to be unrav-
eled. When we enhance our knowledge, the screening and management of these former 
preeclamptic women will improve to prevent or stop the progression of cardiovascular 
disease in relatively young women. In order to get a better interpretation of the link be-
tween PE and CVD and the corresponding cardiovascular risk factors, a large cohort of 
women should have a cardiovascular screening before, during and after their pregnancy. 
With the help of the outcomes of this series, a new research program has been developed 
in Maastricht; the Queen of Hearts study. This study has started to include a large cohort 
of women with a healthy pregnancy in the past and women with a history of preeclampsia 
to examine biomarkers and cardiovascular risk factors. This trial will allow us to make an 
early identification in a preclinical stage of CVD in high-risk women. Other trials have 
been added to the Queen of Hearts study in order to determine whether pharmacological 
therapy is effective at preventing progression or development towards heart failure in 
former preeclamptic women. With these results, we hopefully get a better understanding 
to prevent cardiovascular disease in these relatively young women.
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Deze factsheet zal worden gepubliceerd bij de hart voor HELLP stichting. Deze stichting zet 
zich in voor meer begrip, (h)erkenning en acceptatie voor vrouwen die pre-eclampsie en/of 
het HELLP syndroom hebben gehad.
InleIdIng
Vrouwen die zwangerschapsvergiftiging/pre-eclampsie hebben ontwikkeld, hebben een 
groter risico op hart- en vaatziekten (HVZ)1. In deze factsheet zullen nieuwe conclusies 
gepresenteerd worden, aan de hand van recent promotie-onderzoek.
RIsIco op haRt- en vaatzIekten na de zwangeRschap
•	 Aan	de	hand	van	een	risico-score	 is	uitgerekend	wat	het	risico	is	op	hart-	en	vaat-
ziekten bij vrouwen die pre-eclampsie hebben gehad en een controle groep, die een 
ongecompliceerde zwangerschap hebben gehad (zie Tabel 1). Het risico is 5-10 jaar 
na de zwangerschap berekend, gebaseerd op lipidenwaardes van deze vrouwen. Het 
risico op HVZ is gelijk voor de controle groep, in vergelijking met de pre-eclampsie 
groep (Tabel 1)2.
•	 Daarna	is	de	groep	pre-eclampsie	vrouwen	verdeeld	in	een	groep	zonder	bloeddrukver-
lagende medicatie (normotensief) en met bloeddrukmedicatie (hypertensief) (Tabel 1)2.
•	 Het	risico	op	hart-	en	vaatziekten	is	twee	keer	zo	groot	voor	de	pre-eclampsie	groep	
met hypertensie (Tabel 1)2.
•	 Bijna	1	op	de	5	voormalig	pre-eclampsie	patiënten	was	hypertensief	en	had	dus	een	
hoger HVZ risico2.
RIsIco op haRtfalen na de pe zwangeRschap
hartfalen – prevalentie
•	 Hartfalen	kan	worden	verdeeld	in	vier	stadia	(Tabel	2)3.
•	 23%	van	de	vrouwen	heeft	op	1	en	4	jaar	na	de	bevalling	hartfalen	stadium	B4.
tabel 1. Risicoscores voor hvz.
controle
groep
pre-eclampsie groep pre-eclampsie, 
normotensief
pre-eclampsie, 
hypertensief
10 jaar hvz risico 1.5% 1.6% 1.5% 3.1%
30 jaar hvz risico 9.0% 9.0% 8.0% 19.0%
HVZ = hart- en vaatziekten, normotensief = geen bloeddrukverlagende medicatie, hypertensief = wel 
bloed drukverlagende medicatie.
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hartfalen - endotheelfunctie
•	 Pre-eclampsie	is	een	aandoening	van	de	vaatwand	(endotheel)5.
•	 De	endotheelfunctie	(functie	van	de	vaatwand)	is	4	jaar	na	de	zwangerschap	minder	
goed in vergelijking met vrouwen, die een ongecompliceerde zwangerschap hebben 
gehad.
•	 Vrouwen	met	pre-eclampsie	hadden	een	8	keer	hogere	kans	op	Hartfalen	stadium	A	
(voor uitleg stadia zie Tabel 2)6.
•	 Vrouwen	met	pre-eclampsie	hadden	een	3	keer	hogere	kans	op	Hartfalen	stadium	B	
(voor uitleg stadia zie Tabel 2)6.
•	 De	 endotheelfunctie	 was	 niet	 slechter	 bij	 vrouwen	 met	 hartfalen	 stadium	 A	 en/
of	hartfalen	stadium	B	in	vergelijking	met	controle	vrouwen6.	Dit	suggereert	dat	er	
mogelijk andere mechanismes dan de functie van de vaatwand zijn, die bijdragen aan 
hartfalen	stadium	B	bij	deze	vrouwen.
hartfalen – plasma volume
•	 Bloedplasma	 is	 een	 onderdeel	 van	 het	 totale	 volume	 aan	 bloed	 in	 het	 lichaam	 en	
bestaat uit water met daarin opgeloste zouten en eiwitten7.
•	 Na	de	pre-eclampsie	zwangerschap,	hebben	deze	vrouwen	een	lager	plasma	volume	
vergeleken met vrouwen, die een ongecompliceerde zwangerschap hebben gehad8.
•	 Een	lager	plasmavolume	en	een	hoge	bloeddruk	gemeten	0.8	jaar	na	de	zwangerschap	
was	gerelateerd	aan	meer	hartfalen	stadium	B	4.8	jaar	na	de	zwangerschap9.
•	 Mocht	een	vrouw	na	de	zwangerschap	nog	steeds	een	hoge	bloeddruk	hebben,	moet	
er goed nagedacht worden wanneer er met bloeddrukverlagers gestart dient te wor-
den.	Middelen	die	een	gunstig	effect	hebben	op	de	hartstructuur	(ACE-remmers	of	
angiotensine receptor blokkers) verdienen een voorkeur.
conclusIe
•	 Tijdens	de	zwangerschap	past	het	hart	zich	anders	aan	bij	vrouwen	met	pre-eclampsie,	
in vergelijking met vrouwen, die een ongecompliceerde zwangerschap hebben gehad. 
•	 Vrouwen	met	 pre-eclampsie	 hebben	 een	 sterk	 verhoogd	 risico	 op	 het	 krijgen	 van	
hartfalen	en	daarmee	hart-	en	vaatziekten	op	een	relatief	jonge	leeftijd.
tabel 2. hartfalen stadia.
hartfalen stadium a hartfalen stadium B hartfalen stadium c hartfalen stadium c
kenmerken Risicofactoren Structurele afwijkingen 
aan het hart, geen 
symptomen
Structurele afwijkingen 
aan het hart, wel 
symptomen
Aanhoudend hartfalen 
waarvoor speciale zorg 
nodig is
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•	 Een	 zorgvuldige	 follow-up	 is	 belangrijk	met	 speciale	 aandacht	 voor	 bloeddruk	 en	
echocardiografie.
•	 Een	follow-up	meting	1	jaar	na	de	zwangerschap	is	belangrijk,	maar	recente	resultaten	
laten zien, dat een aanvullende follow-up meting een aantal jaar later ook noodzake-
lijk is.
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Deze thesis beschrijft de hart- en vaatfunctie bij vrouwen tijdens en na een doorgemaakte 
pre-eclampsie en de relatie met het verhoogde risico op hart- en vaatziekten (HVZ) later 
in het leven.
In Hoofstuk 1 wordt een algemene introductie gegeven met de doelstellingen van dit 
proefschrift.
In Hoofdstuk 2 wordt de grootte en het beloop van verandering in de systolische 
hartfunctie tijdens de zwangerschap beschreven. Aan de hand van een meta-analyse 
en systemisch methodologische beoordeling hebben we alle studies bestudeerd, die de 
systolische functie bij normotensieve zwangere vrouwen hebben weergegeven en deze 
vergeleken met vrouwen met een hypertensieve zwangerschap. Tijdens gezonde zwan-
gerschappen stijgt het eind-systolisch volume van de linkerkamer en de ejectiefractie van 
de linkerkamer met 18% en 4% respectievelijk, terwijl tijdens hypertensieve zwanger-
schappen het eind-systolisch volume van de linkerkamer met 50% meer toeneemt en 
de ejectiefractie van de linkerkamer met 10% daalt ten opzichte van een normotensieve 
zwangerschap.
In Hoofdstuk 3 worden de voorspelde 10- en 30-jaar risicoscores voor hart- en 
vaatziekten in voormalige pre-eclampsie vrouwen beschreven, 5-10 jaar na de zwanger-
schap in vergelijking met vrouwen die een gezonde zwangerschap hebben gehad. Deze 
risicoscore is berekend aan de hand van de Framingham Risico Score. Voormalige 
pre-eclamptische vrouwen hebben als groep een vergelijkbaar berekende risicoscore, 
vergeleken met de controle groep, in tegenstelling tot eerder geobserveerde getallen in 
observationele studies. Dit roept de vraag op of de huidige risico-modellen voor het 
ontwikkelen van hart- en vaatziekten geschikt zijn voor deze specifieke jonge vrouwen. 
Wel blijkt dat voormalig pre-eclamptische vrouwen met hoge bloeddruk een tweevoudig 
verhoogd voorspeld risico hebben op het ontwikkelen van hart- en vaatziekten in de 
komende 10-30 jaar ten opzichte van voormalig pre-eclamptische vrouwen zonder hoge 
bloeddruk: de 10- en 30-jaar HVZ mediane risico scores, gebaseerd op de lipidenwaardes 
van de vrouwen, waren achtereenvolgens 3.1% versus 1.5% en 19.0% versus 8.0%.
In Hoofdstuk 4 wordt middels een prospectief cohort onderzoek de prevalentie 
aangetoond van asymptomatische structurele hartveranderingen (hartfalen stadium B) 
bij voormalige pre-eclamptische vrouwen, 1 en 4 jaar na de bevalling. Bij deze vrouwen 
observeerden we een prevalentie van 23% van hartfalen stadium B op beide meetmo-
menten. Dit suggereert een persisterende cardiale dysfunctie, maar op individueel niveau 
is er een verschuiving in vrouwen die herstellen van deze aandoening tussen de twee 
tijdstippen (meer dan 60%) en vrouwen die hartfalen stadium B alsnog ontwikkelden 
(ongeveer 20%). Bovendien was de prevalentie van ofwel diastolische of systolische 
dysfunctie verschillend op beide tijdstippen en blijkt de concentrische vormverandering 
van het hart de meest voorkomende vorm van hartfalen stadium B, 4 jaar na de bevalling.
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In Hoofdstuk 5 wordt de associatie tussen zowel hartfalen stadium B en endotheeldys-
functie bij voormalige pre-eclamptische vrouwen beschreven. In deze cross-sectionele 
studie wordt aangetoond dat voormalig pre-eclamptische vrouwen een acht keer hogere 
prevalentie van hartfalen stadium A hadden (risicofactoren voor hartfalen) en een drie 
keer hoger voorkomen van hartfalen stadium B in vergelijking met vrouwen die een 
gezonde zwangerschap hebben gehad. Bovendien hadden voormalige pre-eclamptische 
vrouwen 4 jaar na de bevalling, een slechtere endotheelfunctie, gemeten met de zoge-
naamde “flow mediated dilation technique” in vergelijking met de controle groep die 
enkel normotensieve zwangerschappen heeft doorgemaakt. In tegenstelling tot onze 
verwachtingen werd er geen relatie gevonden tussen hartfalen stadium A of hartfalen 
stadium B met endotheeldysfunctie, bepaald in de arm slagader.
In Hoofdstuk 6 wordt de associatie tussen concentrische vormverandering van het 
hart en plasmavolume, een maat die met name de aderlijke reserves van de bloedsomloop 
weerspiegeld, bij voormalige pre-eclampsie vrouwen beschreven. In dit longitudinaal co-
hort onderzoek zagen we dat 18% van de voormalige pre-eclamptische vrouwen concen-
trische vormveranderingen van het hart hebben, een paar jaar na de zwangerschap. Ook 
wordt in deze studie aangetoond, dat vrouwen met concentrische vormverandering van 
het hart vastgesteld op 4.8 jaar na de bevalling, vaker een gering plasmavolume hebben 
0.8 jaar na de probleemvolle zwangerschap. Middels een gecorrigeerde multivariabele 
analyse hebben we aangetoond, dat een gering circulerend volume 0.8 jaar na de beval-
ling onafhankelijk geassocieerd is met latere concentrische vormverandering van het 
hart, 4.8 jaar na de probleemvolle zwangerschap. Bovendien is elke toename in mmHg 
in drukbelasting ook geassocieerd met meer kans op het ontwikkelen van concentrische 
vormverandering van het hart in de jaren na de bevalling en daarmee ook de kans met 
hartfalen stadium B (OR 1.15, 95% CI 0.99-1.35, OR 1.24, 95% CI 0.98-1.58 en OR 1.20, 
95% CI 0.98-1.47, respectievelijk).
In Hoofdstuk 7 worden de resultaten uit dit proefschrift bediscussieerd en wordt er een 
uiteenzetting gegeven van de huidige literatuur omtrent hart- en vaatfunctie bij vrouwen 
met een doorgemaakte pre-eclampsie.
Samengevat leggen onze bevindingen de nadruk op de cardiovasculaire complicaties 
tijdens en na een zwangerschap gecompliceerd door pre-eclampsie. De studies in dit 
proefschrift leveren bewijs voor een hoge prevalentie van hartfalen stadium B en risi-
cofactoren voor hart- en vaatziekten bij voormalige pre-eclamptische vrouwen in het 
eerste decennium na de zwangerschap. Daarnaast toonden we aan dat in deze populatie 
een gering plasmavolume (volume aanbod) en hoge bloeddruk (drukbelasting aan het 
hart) geassocieerd zijn met hartfalen stadium B. Dit manuscript toont het belang aan van 
herhaaldelijke cardiovasculaire evaluatie met speciale aandacht voor bloeddruk en echo-
cardiografie. Gezien de verschuiving in risicofactoren en cardiale fenotype is van belang 
dat deze risico beoordeling niet eenmalig plaatsvindt, maar herhaald zou moeten worden.
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This thesis provides insight in cardiovascular (CV) function during and after preeclamp-
tic pregnancies and the increased risk for remote CV disease (CVD) later in life in these 
women.
Chapter 1 presents a general introduction with the objectives of this thesis.
Chapter 2 presents insight in the magnitude and course of change in systolic cardiac 
function during pregnancy. The course of change is assessed through meta-analysis and 
systematic review where we reviewed all studies on systolic function in normotensive 
pregnant women and women with a pregnancy complicated by a hypertensive disorder. 
During normotensive pregnancies, there is a significant rise in left ventricular end systolic 
volume and left ventricular ejection fraction (18% and 4%, respectively), while during 
hypertensive pregnancies left ventricular end systolic volume increases more with 50% 
and left ventricular ejection fraction decreases with 10% compared with a normotensive 
pregnancy.
Chapter 3 describes the predicted 10- and 30-year risk scores for CVD in former 
preeclamptic women, 5-10 years after their pregnancy compared with healthy parous 
controls. CVD risk is calculated based on the Framingham Risk Score. Formerly pre-
eclamptic women, as a group, had a comparable risk score compared to the control group 
in contrast to earlier observed numbers in observational studies. This raises the question 
if the current risk models for the development of cardiovascular disease are suitable for 
these specific young women. However, hypertensive former preeclamptic women have 
a twofold increased risk of developing CVD risk in the next 10-30 years compared to 
formerly preeclamptic women without hypertension: 10- and 30-year CVD median risks 
weighing subjects’ lipids were 3.1% versus 1.5% and 19.0% versus 8.0%, respectively.
Chapter 4 describes the prevalence of asymptomatic structural heart alterations (heart 
failure stage B) in former preeclamptic women at 1 and 4 years postpartum, in a pro-
spective cohort study. We observed a prevalence of 23% of heart failure stage B at both 
timepoints in these women. This suggests a persistent cardiac function, however, at an 
individual level, there is a shift in women who are recovering of this disease between the 
two timepoints (more than 60%) and women who developed heart failure stage B (about 
20%). Moreover, the prevalence of either diastolic or systolic dysfunction were different 
at both timepoints, where concentric remodeling was the most prevalent form of heart 
failure stage B at 4 years postpartum.
Chapter 5 describes the association with both heart failure stage B and endothelial 
dysfunction in former pre-eclamptic women. We showed in this cross-sectional cohort 
study that formerly preeclamptic women had an eight-fold higher prevalence of heart 
failure stage A (risk factors for heart failure) and a three-fold higher prevalence of heart 
failure stage B compared to healthy parous controls. Furthermore, at 4 years postpartum, 
formerly preeclamptic women had a lower endothelial function measured with the 
“flow-mediated dilation technique” compared to the control group who experienced only 
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normotensive pregnancies. In contrast to our expectations, no association was found 
between the prevalence of heart failure stage A or heart failure stage B and endothelial 
dysfunction measured with flow mediated dilation measured at brachial artery level.
Chapter 6 describes the association between concentric remodeling and plasma 
volume, a measurement which reflects in particular the venous reserves of the blood 
circulatory system, in former pre-eclamptic women. We observed in this longitudinal 
cohort study that 18% of former preeclamptic women have concentric remodeling a few 
years after pregnancy. Moreover, we showed that women with concentric remodeling 4.8 
years postpartum more often have a low plasma volume 0.8 years after their complicated 
pregnancy. An adjusted multivariable analysis shows that a low plasma volume 0.8 years 
postpartum was independently associated with later concentric remodeling at 4.8 years 
postpartum. Moreover, each mmHg rise in arterial blood pressure (systolic, diastolic 
and mean arterial pressure) is also associated with more risk of developing concentric 
remodeling in the years postpartum and with it heart failure stage B (OR 1.15, 95% CI 
0.99-1.35, OR 1.24, 95% CI 0.98-1.58 and OR 1.20, 95% CI 0.98-1.47, respectively).
Chapter 7 elaborates on the findings of this manuscript and gives an explanation of the 
currently available literature on CV function in formerly preeclamptic women
In summary, our findings underline the cardiovascular complications during and 
after a preeclamptic pregnancy. The studies in this thesis provides evidence for a high 
prevalence of heart failure stage B and CV risk factors in former preeclamptic patients in 
the first decade after pregnancy. Moreover, we show that these women have a diminished 
plasma volume (volume load) and high pressure load which are associated with heart 
failure stage B. It is important that former preeclamptic women undergo a CV screen-
ing and follow-up, with a special focus on blood pressure and echocardiography. As 
the prevalence of CV risk factors and cardiac phenotype change postpartum, these risk 
assessments should not only be offered once but repeated follow-up after a few years is 
necessary.
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Dit hoofdstuk beschrijft de waardecreatie, die verkregen kan worden uit de resultaten van 
de studies in dit proefschrift en hoe deze vertaald kunnen worden naar de klinische praktijk. 
Het omschrijft hoe deze kennis ten goede komt aan het maatschappelijk belang en in het 
bijzonder de vrouw die pre-eclampsie heeft gehad. 
InleIdIng
Hart- en vaatziekten (HVZ) zijn doodsoorzaak nummer één bij vrouwen1, 2. Dit heeft 
te maken met het atypische klachten patroon bij vrouwen, man-vrouw verschillen in 
onderliggende systeem biologie en de huidige diagnostische hulpmiddelen. Hierdoor 
wordt deze ziekte bij vrouwen vaak pas in een laat stadium herkend. In deze late stadia is 
het ziekteproces vaak moeilijk om te keren of te herstellen. Daarom is het belangrijk om 
in een vroege fase vrouwen op te kunnen sporen, die daadwerkelijk een verhoogd risico 
lopen op hart- en vaatziekten. Bij mensen gevoelig voor hart- en vaataandoeningen, start 
dit proces al vroeg in het leven en zou met de nodige aanpassingen in leefstijl (mediter-
raan dieet en beweging) of passende medicamenteuze preventiemiddelen, om ongunstige 
veranderingen in hart en vaten te voorkomen of verbeteren (cholesterolverlagende 
middelen of angiotensine converting enzyme (ACE)-remmers of angiotensine receptor 
blokkers (ARB’s)), tegengegaan kunnen worden.
Dit belangrijk agendapunt is door de enquête van de Nederlandse Hartstichting 
verkozen tot nummer 2 op de prioriteitenlijst voor wetenschappelijk onderzoek3. Behalve 
conventionele risicofactoren, die het risico op HVZ zowel bij vrouwen als mannen ver-
hogen, zijn er ook onderbelichte vrouwspecifieke risicofactoren1, 4. Een vrouwspecifieke 
risicofactor die van cruciaal belang is, vormt zwangerschapsvergiftiging (pre-eclampsie)4. 
Deze zwangerschapsaandoening wordt gekarakteriseerd door het ontwikkelen van hy-
pertensie en proteïnurie tijdens de zwangerschap5. Onderliggend is een op dat moment 
aanwezige vaatdysfunctie. Vrouwen die een vroege zwangerschapsvergiftiging hebben 
doorgemaakt, hebben een 7.7 keer verhoogd risico op het ontwikkelen van HVZ6.
Zwangerschapsvergiftiging is een vaatwandziekte, die meestal zichtbaar wordt in de 
tweede helft van de zwangerschap. Aangedane vrouwen hebben meer risico op een groei 
vertraagd kind, epileptische aanvallen en zelfs sterfte. Op de lange termijn hebben deze 
vrouwen een verhoogd risico op HVZ, ongeveer 15 jaar eerder dan hun leeftijdsgenoten, 
die een gezonde zwangerschap hebben doorgemaakt. Intermediaire ziektematen of 
risicofactoren, zoals subklinisch hartfalen en endotheeldysfunctie enerzijds en geringe 
circulatoire reserves (gering plasma volume), dislipidemie, glucose metabolisme stoornis-
sen en hoge bloeddruk (metabool syndroom) anderzijds, zouden sterk kunnen bijdragen 
aan betere determinatie van vrouwen daadwerkelijk at risk.
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De studies in dit proefschrift beschrijven het risico op hart- en vaatziekten bij deze 
specifieke groep vrouwen en de relatie tussen enerzijds pre-eclampsie en anderzijds sub-
klinisch hartfalen, endotheelfunctie en laag plasma volume. Volgens het model (Hoofd-
stuk 1 Figuur 1) stijgt na pre-eclampsie het risico op HVZ gradueel, om binnen enkele 
jaren (maar nog op relatief jonge leeftijd) de klinische grens te bereiken. Risicofactoren 
zouden deze progressie kunnen versnellen. Echter is het tot nu toe nog onbekend, in 
welke orde dat gebeurt en welke risicofactoren na pre-eclampsie zwaarder wegen dan 
andere. Het is dus van klinisch belang om een betere inventarisatie te hebben van de 
factoren, die een essentiële rol spelen in het krijgen van hart- en vaatziekten in deze 
specifieke jonge vrouwelijke populatie
Zwangerschap als stresstest
Zwangerschap is een unieke gezondheidstest voor hart en vaten. Pre-eclampsie wordt 
verder gekenmerkt door een ongezonde verdikking van de hartspier, die ook gezien 
wordt bij niet zwangere patiënten met jaren bestaande chronische hypertensie. Deze 
verdikking van de hartspier gaat bij vrouwen vaak vooraf aan hartfalen en leidt in veel 
gevallen tot een stugger hart, dat zich minder makkelijk laat vullen (diastole dysfunctie). 
Bij iets minder dan de helft van deze vrouwen blijven de ongunstige aanpassingen van het 
hart aan pre-eclampsie na de bevalling bestaan. Volgens de Amerikaanse cardiologische 
definitie vallen deze afwijkingen onder asymptomatisch hartfalen stadium B (HF-B)7. 
HF-B en milde diastole dysfunctie zijn veelal omkeerbare veranderingen, mits tijdig 
ontdekt. Wanneer HF met symptomen gepaard gaat, is deze niet meer omkeerbaar en 
kan men hooguit de klachten verminderen; een vermindering, die ondanks verbetering 
van de hartstructuur, niet tot verandering van de prognose leidt. Transitie van het asymp-
tomatische stadium B naar het symptomatische stadium C gaat gepaard met een 5x groter 
overlijdensrisico8. Daarom is vroegtijdige herkenning en voorkomen van progressie van 
asymptomatisch naar symptomatisch HF de enige logische strategie.
relevantIe
In 2018 was het aantal levende geboorten in Nederland 168.5259, uitgaande van een 
prevalentie van pre-eclampsie van 3-5%10, komt dit uit op een jaarlijks aantal geboorten 
van 5056 tot 8426 van vrouwen, die een gecompliceerde zwangerschap met pre-eclampsie 
doormaken. Jaarlijks komen er dus gemiddeld 6741 vrouwen bij de al reeds bestaande 
groep met vrouwen met pre-eclampsie in de voorgeschiedenis.
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Aangezien deze patiëntengroep van grote omvang is, is het belangrijk om vrouwen 
hierover te informeren. Vaak weten zij niet goed wat de cardiovasculaire consequenties 
zijn van het doormaken van pre-eclampsie en hebben zij veel vragen. Daarom is er een 
factsheet gemaakt met to the point resultaten van onder andere dit proefschrift, zodat de 
vrouwen die pre-eclampsie hebben meegemaakt op de hoogte worden gehouden over 
welke nieuwe bevindingen er tot nu toe zijn gedaan.
Naast het informeren van patiënten en hen van adviezen te voorzien van de noodzaak 
van een follow-up ná de zwangerschap, is het belangrijk dat huisartsen en gynaecologen 
een duidelijker besef hebben, dat deze patiëntengroep een grote kans heeft op hart- en 
vaatziekten en daarom dus in de gaten moet worden gehouden. Het gebeurt nog te vaak 
dat we vrouwen uit het oog verliezen, terwijl juist deze vrouwen baat zouden kunnen 
hebben bij passende follow-up, om daarmee hun HVZ risico te verminderen. Daarnaast 
laat dit proefschrift ook zien, dat een eenmalige follow-up niet voldoende is om hartfalen 
uit te sluiten en dat een aanvullende follow-up een aantal jaar later erg belangrijk is.
Naast de resultaten voor de patiënt, de arts en de wetenschap hebben mijn uitkomsten 
ook meegeholpen aan de tot stand brenging van de Queen of Hearts studie. Deze studie 
wordt gefinancierd door de Nederlandse Hartstichting en is een groot wetenschappelijk 
onderzoek naar de aanwezigheid van de risicofactoren van hart- en vaatziekten en bio-
markers voor subklinisch hartfalen bij vrouwen, die in het verleden pre-eclampsie heb-
ben doorgemaakt.
Door onderzoek naar vrouwspecifieke biomarkers voor hartfalen en geassocieerde risi-
coprofiel, kan er een gepersonaliseerd screeningsprogramma ontwikkeld worden op basis 
van een multimarker model, waarop preventieve therapieën kunnen worden afgestemd.
doelgroep
De doelstelling van dit proefschrift is onze kennis te vergroten in de cardiovasculaire 
determinanten, die het risico vergroten op het ontstaan van cardiovasculaire aandoenin-
gen in vrouwen met pre-eclampsie. De vrouwen, die wij hebben onderzocht, zijn jong en 
hebben geen herkenbare of klassieke cardiovasculaire symptomen. Deze vrouwen komen 
grotendeels uit de regio oost-midden Nederland, die gezien de demografie vergelijkbaar 
is met de rest van Nederland.
InnovatIe
De bevindingen van dit proefschrift tonen aan welke veranderingen er in het hart tijdens 
de zwangerschap plaatsvinden en welke aanhouden of verdwijnen tijdens de postpartum 
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periode. Het belicht belangrijk hartfalen stadium B, een stadium waarbij er al wel veran-
deringen in het hart zijn, maar nog geen symptomen. Één op de vier vrouwen heeft een 
aantal jaar na de gecompliceerde zwangerschap dit stadium van hartfalen al. Maar wat 
belangrijk is, is dat er ook een verschuiving is in prevalentie. Er zijn vrouwen die 1 jaar 
na de zwangerschap nog geen hartfalen stadium B hebben, maar dit wel na 4 jaar heb-
ben ontwikkeld. Dit onderstreept het belang dat er ook na een aantal jaar een follow-up 
echografie belangrijk is.
Door inzicht te krijgen in de factoren, zoals endotheelfunctie en plasma volume, die 
een rol spelen in de etiologie van hartfalen, zullen preventieprogramma’s daar beter op 
ingericht kunnen worden.
ImplementatIe, plannIng en realIsatIe
De eerder genoemde factsheet, waarop to the point resultaten vermeld zijn, is toepas-
baar op de individuele patiënt en wordt gepubliceerd bij de hart voor HELLP stichting. 
Deze stichting zet zich in voor meer begrip, (h)erkenning en acceptatie voor vrouwen, 
die pre-eclampsie en/of het HELLP syndroom hebben gehad. Door het publiceren van 
de factsheet zal ten eerste voor de patiënt zelf inzichtelijk worden gemaakt met welke 
onderzoeken we ons momenteel bezighouden, welke uitkomsten daaruit komen en welke 
klinische consequenties deze kunnen hebben. Daarnaast zorgt het ook weer voor een 
reactivatie in het bewustzijn van zowel patiënt als hulpverlener en maatschappij. Door 
scherper intermediaire ziekte-maten te bestuderen hopen we veel beter de zorg te verleg-
gen naar zij die het nodig hebben en de anderen juist in een vroeger stadium te kunnen 
geruststellen.
Verder geven de bevindingen van dit proefschrift aan, dat in de eerste decade na 
zwangerschap vrouwen niet eenmalig onderzocht moeten worden, maar in een ge-
structureerde follow-up terecht zouden moeten komen, waarbij om de paar jaar een 
uitgebreide cardiovasculaire screening verricht wordt. Vanuit deze structuur kunnen we 
in de zorg doelmatigheidsvragen beantwoorden, om zo de zorg voor deze groep veilig te 
personaliseren.
Tot slot is er op basis van de bevindingen een logische interventie trial in ontwikkeling, 
ter behandeling van subklinisch hartfalen.
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